Trading Analysis Report: JD¶

Analysis date: 2026-10-08
Rating: Overweight
Generated: 2026-10-09 07:57:39
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-opus-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 26.91 (USD) Price As Of: 2026-10-08

`JD` (JD.com, Inc.): Technical Report¶

Bottom line¶

JD is still in a downtrend on the daily, weekly and monthly charts. The stock fell about 23% from its 2026-08-10 close of $33.47 to its 2026-10-02 close of $25.78. There are signs the selling is wearing out: momentum stopped falling as fast even though price made a new low, the weekly TD Sequential count reached 9, volatility has narrowed, and price has bounced 4.4% in four sessions. None of that is a confirmed reversal yet. The next test is the $27.04 → $27.44 → $27.72 zone. Separately, a 50/200-day "death cross" (the 50-day average dropping below the 200-day) is almost certain within about two sessions because of how the averages are calculated. It reflects the decline that has already happened and doesn't add much new information.

Indicators chosen and why¶

The current pattern is a slow, low-volume decline followed by an early bounce. I picked eight indicators that each answer a different question:

Category	Indicator	Why it fits here
Trend (medium / long)	`close_50_sma`, `close_200_sma`	Show where price sits against its averages and how close a death cross is
Trend (multi-timeframe stop)	`supertrend`	Gives a concrete trend-flip level for daily, weekly and monthly charts
Momentum	`macd`	Checks whether momentum confirmed the 2026-10-02 low or diverged from it
Momentum	`rsi`	Shows how stretched the move is and confirms divergence (I skipped stochrsi to avoid overlap)
Volatility	`atr`	Stop distances and position sizing; also shows volatility narrowing
Volume	`obv`	Checks whether volume supports the bounce or the decline
Exhaustion	`td_9`	Counts how mature the decline is on each timeframe

The verified snapshot also supplied Bollinger Bands, the 10-day EMA, the MACD signal line and the MACD histogram. Every value the indicator tool returned matches the verified snapshot.

1. Price structure and context¶

12-month range (from the data): the high is $34.30 (2026-05-13 intraday) and the low is $23.66 (2026-03-05 intraday). At $26.91, JD sits about 30% of the way up that range.
The current decline: price peaked at a $33.47 close on 2026-08-10. On 2026-08-13 it gapped down from $31.61 to $29.30 (-7.3%) on 32.1M shares, about 5× the recent ~6M daily average. That looks like a reaction to news or earnings, but these tools can't confirm the cause. After that, September drifted lower on light volume (mostly 4–7M shares a day), which looks like steady selling rather than a panic.
The bigger pattern is a narrowing range, not a collapse. In 2026 the closing lows have been rising while the highs have been flat to slightly lower:
Lows: $24.53 (2026-03-04), $25.19 (2026-06-25), $25.78 (2026-10-02)
Highs: $33.77 (2026-05-13), $33.47 (2026-08-10)
The two earlier lows led to rallies of about +38% (Mar→May) and +33% (Jun→Aug).
That history doesn't predict the next move, but it explains why a stock stuck in a range keeps showing "oversold, then bounce" behavior.
The last two sessions: both 2026-10-07 and 2026-10-08 hit an intraday high of exactly $27.04. 2026-10-08 was an inside day (low $26.64 vs the prior day's $26.42) and closed in the top two-thirds of its range. Price is pausing at $27.04; it hasn't been rejected there.
Retracement levels (my calculation using the 33.47→25.78 swing):
23.6% = $27.59, which lines up with the upper Bollinger Band ($27.58) and the 2026-09-22 high ($27.72).
38.2% = $28.72, close to the 50/200-day average cluster ($28.49–28.64).

2. Moving averages¶

Price is below both the 50-day SMA ($28.64, 6.0% above price) and the 200-day SMA ($28.49, 5.5% above price).
The last close above the 50-day was 2026-08-25 ($29.36 vs $29.28).
The last close above the 200-day was 2026-08-28 ($28.74 vs $28.70).
The 50-day is falling quickly. It dropped from $29.63 (2026-09-16) to $28.64, about 0.10 per session. The closes now dropping out of its 50-day window are from late July and early August, at $32–33.50, so the decline will speed up.
The 200-day is falling slowly. It went from $28.86 (2026-08-11) to $28.49. That near-flat slope means the long-term picture is closer to a range around ~$28.5 than a strong downtrend.
Death cross projection (my arithmetic, not a tool output):
If JD stays near $26.91, the 50-day is about $28.53 vs the 200-day's $28.48 on 2026-10-09, so no cross yet.
By 2026-10-12 it would be about $28.41 vs $28.48, so the cross happens.
Delaying it would take an average close of about $29.05 or higher over the next two sessions (+8%).
Takeaway: the cross is baked in by the math. It describes the August–September decline, and in a stock that trades in a range, these crosses often arrive close to short-term lows. Don't treat it as a fresh sell signal by itself.
Short term: price is above the 10-day EMA ($26.66), so the very short-term trend has turned up.

3. SuperTrend (trend-following stop on three timeframes)¶

Timeframe	Direction	Stop	Distance from close
Weekly (primary)	DOWN	31.63	price is 14.9% below the stop
Monthly (big picture)	DOWN	41.83	price is 35.7% below the stop
Daily (entry timing)	DOWN	27.44	price is 1.9% below the stop, about 1.0 ATR

All three timeframes agree the trend is down. The useful trigger is the daily line: a daily close above $27.44 flips the daily trend to up. That is only about one average day's range away. Even then, the weekly trend stays down until $31.63, so a daily flip would mark a counter-trend rally inside a weekly downtrend, not a new uptrend.

4. Momentum: MACD and RSI¶

MACD: −0.46. The signal line is −0.59 and the histogram is +0.13, so the MACD line is above its signal line (a bullish crossover).
The lowest MACD reading of this decline was −0.81 on 2026-09-17. On 2026-10-02, price made a lower low ($25.78 vs $26.64), but MACD made a higher low (−0.66 vs −0.81). That is a bullish divergence: price fell further, but downside momentum got weaker.
MACD is still well below zero. The 12-day EMA remains under the 26-day, so this is a recovery inside bearish territory. A move above zero would confirm a trend change.
RSI: 46.64. It recovered from 30.43 on 2026-10-02. At the September lows it touched about 30–31 three times (31.33 on 09-09, 30.38 on 09-17, 30.43 on 10-02) and never closed below 30. That repeated floor at a lower price is a soft bullish divergence.
RSI hasn't been above 50 at any point in the window shown (2026-08-24 onward). Its high in that window is 47.95 (2026-10-07). A close with RSI above 50 would be the first momentum sign that the bounce is turning into more than a relief rally.

5. Volatility: ATR and Bollinger Bands¶

ATR: 0.52, about 1.9% of price. That is down about 30% from 0.74 on 2026-08-24, with a low of 0.49 on 2026-09-30. Volatility shrinking as price declines usually means sellers are running out of urgency, and it often comes before a bigger move in either direction.
Bollinger Bands: middle $26.77, upper $27.58, lower $25.97. The bands are 1.61 wide, about 6% of the middle line.
Price is just above the middle, about 58% of the way from the lower to the upper band. That implies a daily z-score of roughly +0.35, which is near fair value and not stretched.
The upper band ($27.58) sits right on the 23.6% retracement level, making it a strong resistance zone.

6. Volume: OBV (On-Balance Volume)¶

OBV went from −191.4M (2026-08-10) down to its lowest point, −308.5M on 2026-10-02.
−73.0M of that came in four sessions, 2026-08-11 to 2026-08-14.
Another −58.2M came from 2026-08-20 to 2026-10-02.
OBV made a new low together with price on 2026-10-02. That means there is no bullish divergence in volume: the momentum improvement in Section 4 is not yet backed by buying.
Since then OBV has recovered +14.6M to −293.9M. The bounce days traded 6.7–7.4M shares, only a little above the ~6M 20-day average (my calculation). That is buying interest, but not a strong buying surge. A breakout above $27.44 on less than about 8M shares should be treated as suspect.

7. Exhaustion: TD-9 (TD Sequential)¶

Timeframe	Count	Meaning
Weekly (primary)	+9, buy setup complete	Watch for a reversal
Monthly	−1 (sell setup)	Not meaningful yet
Daily	−2 (sell setup)	Two closes above the close four bars earlier, a short-term upturn

Important detail (my check against the daily closes): the 9^th weekly bar is the current, unfinished week. Its close so far ($26.91) is only $0.15 below the close of the week ending 2026-09-11 ($27.06), which is the comparison bar. If JD closes at or above $27.06 on Friday 2026-10-09, the weekly 9 technically fails and the count ends at 8. A typical TD buy 9 points to a bounce lasting 1–4 bars, and the bounce may already be under way. So the 9 supports the bullish case, but it is fragile until the week closes.

8. Key levels¶

Level	Source	Role
28.64 / 28.49	50-day / 200-day SMA	Main resistance cluster; the 38.2% retracement (28.72) is nearby
27.72	2026-09-22 high	Most recent swing high; breaking it ends the daily pattern of lower highs
27.58–27.59	Upper Bollinger Band / 23.6% retracement	Resistance zone
27.44	Daily SuperTrend stop	Daily trend-flip trigger
27.04–27.06	Intraday high on 10-07 and 10-08 / weekly TD comparison close	First test
26.77 / 26.66	Bollinger middle / 10-day EMA	Nearby support
26.42	2026-10-07 low	Short-term support for the bounce
25.97	Lower Bollinger Band	Support
25.71	2026-10-02 low (intraday)	Key swing low; losing it cancels the reversal case
25.19 / 24.55	2026-06-25 close / 2026-06-26 low	Next support levels below if 25.71 breaks

9. Scenarios and possible trades¶

A. Bounce turns into a breakout (the case for a reversal) - Trigger: a daily close above $27.44 (daily SuperTrend flips up), ideally above $27.72, on volume above about 7–8M shares, with RSI above 50. - Targets: $28.45–28.70 (the moving-average cluster and 38.2% retracement), then $29.3–29.4 (late-August closes). - Stop: below $26.42 (about 2 ATR below the trigger). - Note: this would still be a counter-trend trade while the weekly SuperTrend is down (stop at $31.63). Expect sellers in the $28.5 zone, where the death-crossed averages will sit.

B. Buy-the-dip into support (aggressive, mean-reversion) - Entry: around $26.66–26.77 (10-day EMA / Bollinger middle). - Stop: $25.65, just below the 2026-10-02 low. That risks about $1.05, or roughly 2 ATR. - Target: about $28.45, a reward-to-risk of roughly 1.6–1.7 to 1. - Case for it: the MACD divergence, RSI holding above 30 and the weekly TD 9. - Case against it: volume (OBV) hasn't confirmed.

C. Bounce fails (the case for the downtrend continuing) - Setup: rejection at $27.04–27.72, for example a daily close back below $26.42, or OBV turning down again on volume above 7M. - Short entry: in the $27.4–27.7 zone, stop above $27.95, target $25.97 then $25.71. That is roughly 3:1 reward-to-risk, but it trades against the momentum divergence. - Breakdown version: a daily close below $25.71 opens the way to $25.19 and then $24.55. That would also be the first lower low against the year's pattern of rising lows, which damages the bigger "narrowing range" case.

Position sizing: with ATR at 0.52, a 2-ATR stop is about $1.04 per share. For a 1% account risk, shares = (0.01 × account equity) ÷ 1.04.

10. Risks and caveats¶

The 2026-08-13 gap (−7.3% on about 5× normal volume) shows JD can jump sharply on news. JD.com usually reports quarterly results in mid-November; these tools don't confirm that date, so check it before holding a position through it.
The death cross will probably trigger automated or headline-driven selling around 2026-10-12, even though it is a lagging signal.
The weekly TD 9 depends on Friday's close staying below $27.06.
Averages, retracement levels, death-cross timing and volume averages marked as my calculations are arithmetic on the tool data, not direct tool outputs.
No discrepancies were found between the indicator tool and the verified snapshot.

Summary table¶

Area	Reading (verified / derived)	Signal	What to watch
Price	Close $26.91 (2026-10-08); +4.4% from the 10-02 low of $25.78; −23% from the 08-10 high of $33.47	Early bounce inside a downtrend	Inside day; $27.04 tested twice
50 / 200 SMA	$28.64 / $28.49; price 6.0% / 5.5% below	Bearish	Death cross projected around 2026-10-12 (lagging signal)
10 EMA	$26.66, price above	Short-term bullish	Support for the bounce
SuperTrend	Weekly DOWN 31.63 · Monthly DOWN 41.83 · Daily DOWN 27.44	Bearish on all three	Daily close above $27.44 flips the daily trend
MACD	−0.46 vs signal −0.59, histogram +0.13; low was −0.81 (09-17)	Bullish divergence, still below zero	Move above zero would confirm a trend change
RSI	46.64; lows held at about 30–31 three times	Recovering, below 50	Close with RSI above 50
ATR	0.52 (about 1.9% of price), down 30% from 0.74 (08-24)	Volatility narrowing	Use for stops (2 ATR ≈ $1.04)
Bollinger	25.97 / 26.77 / 27.58; z ≈ +0.35	Neutral, near the middle	Upper band 27.58 = 23.6% retracement
OBV	Low −308.5M (10-02), now −293.9M	No divergence; bounce only lightly backed by volume	Breakout needs about 8M+ shares
TD-9	Weekly +9 buy (provisional) · Monthly −1 · Daily −2	Downtrend looks exhausted	Friday close must stay below $27.06 to confirm the 9
2026 structure	Higher lows: 24.53 → 25.19 → 25.78; highs 33.77 / 33.47	Narrowing range	Losing $25.71 breaks the pattern
Bull trigger	Close above 27.44, then 27.72, on volume	Counter-trend long	Targets 28.45–28.70, then 29.3–29.4
Bear trigger	Rejection at 27.0–27.7, or close below 25.71	Downtrend continues	Targets 25.97 / 25.71, then 25.19 / 24.55
Overall	Downtrend intact; selling looks exhausted, not yet reversed	Neutral-to-bearish, with a bullish trigger close by	The 27.04–27.44 zone decides it over the next 1–2 sessions

Sentiment Analyst¶

Overall Sentiment: Mixed (Score: 5.3/10) Confidence: Low

JD Sentiment Report (2026-10-01 to 2026-10-08)¶

Bottom line: Sentiment on JD is Mixed, with a faint constructive tilt (score 5.3/10, low confidence). The company-specific news is mildly positive. A report says JD is poised to win EU approval for its ~$2.5bn Ceconomy deal, and Zacks flags relative strength. The sector backdrop is negative: Barron's links weakness in Chinese internet stocks to rising Treasury yields. Retail on StockTwits is close to evenly split, with 8 Bullish vs 6 Bearish tags out of 30 messages (57/43 among labeled posts). Reddit was disabled, so one of the three sources is missing.

1. Source-by-source breakdown¶

News (Yahoo Finance, 5 headlines; titles only, with no article bodies or publication timestamps) - JD.com poised to win EU approval for $2.5bn Ceconomy deal (Retail Insight Network): This is the most material company-specific event in the window. The wording ('poised to', 'report') means clearance should be treated as expected but not confirmed. Directionally positive, because it removes a regulatory overhang on JD's largest disclosed European push. - JD.com (JD) Advances While Market Declines (Zacks): Describes a session where JD outperformed a falling market. Mildly positive, but the date is not given and these Zacks daily recaps are formulaic. - JD.com (JD) Is a Trending Stock (Zacks): Signals elevated investor search and attention. Directionally neutral. - Alibaba Stock Falls. Treasury Yields Aren't Just a U.S. Problem (Barron's): Not JD-specific, but a clear sector read-through. Higher US yields are cited as a headwind for Chinese internet equities. Mildly bearish for JD. - Chinese retailers launch UK land grab (The Telegraph): Covers Chinese retailers expanding their UK footprint. The title does not name JD, so its relevance is inferred. It fits an international-expansion narrative, though the 'land grab' framing hints at possible political or media scrutiny. Neutral to mildly positive. - Net news read: mildly constructive on company events, mildly negative on macro and sector. The feed contains no earnings, guidance, or analyst rating changes.

StockTwits (30 most recent messages: 26 on 2026-10-08, 4 on 2026-10-07) - Tag split: 8 Bullish (27%), 6 Bearish (20%), 16 unlabeled (53%). - Among labeled posts the ratio is 57/43. That sits in the uncertainty zone, far from the >=90/10 level that would suggest over-extension. - The sample covers only about 27 hours, not the full 7-day window. - Bullish voices are concentrated. 3 of the 8 bullish tags come from one user, @Monn1985 ('Recovering now', '$30 soon', 'Maybe $100 this time'). That leaves effectively 6 unique bullish accounts. The more substantive bullish posts: - @MichaellaFinancial: a contrarian thesis that 'valuations are very attractive', with a possible rally after the US midterms. This is second-hand opinion. - @Pope_of_Profit: calls an entry, with resistance around $29.5. - @Congostockchat: discloses JD as 30% of the portfolio, with a self-reported 103.99% YTD return that cannot be verified. - @rocketinvesting: called a 'straight line run to mid $30' at 13:25Z, then rescinded it about 28 minutes later ('I rescind the strength statement'). This captures the intraday indecision. - Bearish voices (5 unique accounts; @TopPi posted twice) are mostly low-substance: - @villancico: emoji-laden 'Ultra super BEARISH' on $BABA $JD $KWEB. - @bruh5: 'puts are printing?' - @Shortyyyy: a bare ticker. - @tifa_lockhart: 'y'all got tricked by Burry'. This implies a Michael Burry-linked bull narrative that the data does not substantiate. - @TopPi makes the best-argued bear case: global markets are near all-time highs except China, China names keep falling 'while US is rising', and they are exposed if a broad market sell-off arrives. - Unlabeled posts lean modestly bullish in content: - @LurenTrader is still accumulating ('continue adding. One more week and I will be done'). - @GoodNewsBull (4 posts) argues 'Buy whats cheap & hold' and expects European selling of China names to reverse into the US close. - @prd001 flags an inverse head-and-shoulders on $BABA and suggests China may outperform. - @HedgeFollow notes JD trades 21.4% below Tiger Global's ~$33.70 average buy price. - @SuperGreenToday promotes Oct 30 2026 $25 calls with JD at $27.00. This is promotional and gets low weight. - Bear-leaning: @Alpha_Instinct09 ('china in depression... Red for months non stop'). - Noise: @Milanfinest's four posts carry no content beyond one frustrated emoji. - Data warning: @rocketinvesting flagged a StockTwits glitch that displayed a false $28.50 price, so some intraday enthusiasm may be driven by a data artefact. - Price levels mentioned in the feed: - Spot: about $27.00 on Oct 7 per @SuperGreenToday. HedgeFollow's -21.4% vs $33.70 implies about $26.5. - Resistance about $29.5, round-number target $30, stretch target mid-$30s. - Intraday on 2026-10-08: weak early relative to US indices (@TopPi, 14:06Z), followed by a recovery attempt (@Monn1985, 18:18Z, 'Recovering now').

Reddit (r/wallstreetbets, r/stocks, r/investing) - No data. Reddit was disabled by the sentiment_include_reddit config. Nothing can be said about measured (r/stocks), long-horizon (r/investing), or speculative (r/wallstreetbets) community sentiment on JD for this window.

2. Cross-source divergences and alignments¶

Divergence between the company story and retail focus. The JD-specific news items (Ceconomy approval, UK and European expansion) do not appear anywhere on StockTwits. Retail is trading JD as a China-beta proxy, cross-tagging $BABA, $KWEB, $PDD, $BIDU, $NIO, $TCEHY and $YINN. Either retail is under-discussing the European expansion, or it views that story as minor next to China macro.
Alignment on the macro headwind. Barron's yields-driven Alibaba decline matches StockTwits complaints that China names fall while US markets rise, and the 'red for months' framing.
Partial divergence on relative strength. Zacks reports JD advancing on a down-market day, while Oct 8 posts describe China lagging an up-market. Together with @Monn1985's comment about moving 'opposite direction to the US market', this suggests JD has traded with low or inverse correlation to US indices day to day. Retail is debating that pattern; it is not a settled trend.
Alignment on valuation. Zacks 'trending' attention, the Tiger Global cost-basis reference, and several 'cheap China' posts all fit a value-based contrarian frame. None of the sources supply actual valuation metrics such as P/E or EV/EBITDA.

3. Dominant narrative themes¶

China as cheap contrarian value vs. value trap. This is the most recurring theme: MichaellaFinancial, GoodNewsBull, HedgeFollow and LurenTrader on one side; TopPi, Alpha_Instinct09 and villancico on the other.
China underperformance vs. US and global markets, plus rate sensitivity. Driven by the Barron's yields piece and StockTwits complaints about relative weakness.
JD's European and international expansion. The Ceconomy deal and the UK retail push are covered by institutional news but ignored by retail.
Technical levels and short-dated options. Posts cite a $27 base, $29.5 resistance, a $30 target, Oct 30 $25 calls, and inverse head-and-shoulders chatter.
Smart-money references. Tiger Global's ~$33.70 average buy and a Burry mention are both unverified in this data and should not be over-weighted.

4. Catalysts and risks¶

Catalysts (upside): - Formal EU clearance and closing of the ~$2.5bn Ceconomy deal, reported as likely but not yet confirmed. - The US midterms (November 2026), cited by retail as a possible trigger for a sentiment shift on China equities. This is speculative. - A break above the ~$29.5 resistance or the $30 round number, which several posts are watching. - The Oct 30, 2026 option expiry, with call speculation around the $25 strike. - The next quarterly earnings report; its date is not in the data.

Risks (downside): - Rising Treasury yields pressuring Chinese internet stocks (Barron's). - A broad global equity correction hitting high-beta China names harder (TopPi's thesis). - Continued China macro weakness and the multi-month downtrend ('Red for months non stop'). - Execution, financing and margin risk from European expansion and the Ceconomy acquisition, plus possible political or regulatory scrutiny of Chinese retailers abroad. This is inferred from headline tone; the data gives no detail. - Signal quality: many StockTwits posts are emoji-only, promotional, or from one repeat poster, and a platform glitch showed a false price.

5. Summary of key sentiment signals¶

Signal	Direction	Source	Supporting evidence
Ceconomy deal nearing EU approval	Bullish	News (Retail Insight Network)	'JD.com poised to win EU approval for $2.5bn Ceconomy deal'; reported, not confirmed
Relative strength on down-market day	Mildly Bullish	News (Zacks)	'JD.com, Inc. (JD) Advances While Market Declines'; date not given
Elevated attention	Neutral	News (Zacks)	'JD.com, Inc. (JD) Is a Trending Stock'
Yields-driven pressure on China internet	Bearish	News (Barron's)	'Alibaba Stock Falls. Treasury Yields Aren't Just a U.S. Problem'
Chinese retailer UK expansion	Neutral / Mildly Bullish	News (Telegraph)	'Chinese retailers launch UK land grab'; JD not named in title
Retail tag split	Mixed	StockTwits	8 Bullish / 6 Bearish / 16 unlabeled of 30; 57/43 among labeled
Contrarian value / accumulation	Bullish	StockTwits	'valuations are very attractive'; 'continue adding'; 'Buy whats cheap & hold'; -21.4% vs Tiger Global ~$33.70
China lagging US / crash risk	Bearish	StockTwits	'all china Stocks are down while US is rising'; 'Red for months non stop'
Intraday indecision	Mixed	StockTwits	rocketinvesting's 'mid $30' call rescinded within ~28 minutes; 'Recovering now' later in session
Technical levels / options	Mildly Bullish	StockTwits	~$27 spot, resistance ~$29.5, '$30 soon', Oct 30 $25 calls
Reddit community read	Unavailable	Reddit	Disabled by config

Confidence: low. Reddit is missing entirely. The news is headline-only, with no dates or article bodies. The StockTwits sample is just 30 messages over about 27 hours, with heavy noise and concentration in single users. Treat this as one input alongside fundamentals and technicals for JD, not as a price call.

News Analyst¶

JD.com (`JD`) news and macro report, as of 2026-10-08¶

Bottom line¶

JD's own news is improving, but the global backdrop is getting worse. The main company item is that JD's ~$2.5bn takeover of Ceconomy (owner of MediaMarkt/Saturn) is reportedly close to EU approval. JD has also been rising on days the market fell. Against that, the Fed and the ECB both raised rates in mid-September, the US 10-year yield is at a cycle high of about 5.3%, oil is near $100, and the dollar is strengthening. All of these usually hurt US-listed Chinese stocks. Beijing's reported AI probe into Alibaba also brings back regulatory risk for the whole sector. The trade decision is left to the next agent.

1. JD company news¶

a) Ceconomy deal near EU approval¶

Early October (Retail Insight Network): JD is reportedly "poised to win EU approval" for the ~$2.5bn Ceconomy deal.
September (MT Newswires, Retail Insight Network): JD had to change its proposed concessions after rivals objected.
What this means: the regulatory risk looks largely resolved, pending the formal European Commission decision. That decision is the next catalyst and could support the stock in the short term.
Longer-term questions:
Ceconomy is a low-margin electronics retailer in Europe.
The ECB has raised rates to 2.5% and German 10-year yields have climbed to 3.18%, which weighs on European consumers.
Integration and capital-allocation risk will stay a debate for valuation.
A Telegraph piece on Chinese retailers expanding in the UK fits the same theme of moving into Western markets.

b) Analysts, positioning and attention¶

Arete downgraded JD to Neutral from Buy and cut its price target to $30 from $36 (September). This is the main recent negative from the sell side.
Barchart: "JD.com Stock May Look Ugly, But Options Traders Perceive an Opportunity." Options flow appears bullish even though the chart is weak.
Simply Wall St: "Could Still Be a Bargain on Earnings." The value case is getting attention.
Zacks: several "trending stock" and "investors heavily search" articles, so retail attention is high.

c) Recent relative strength¶

In early October Zacks ran two headlines of this kind: "JD Advances While Market Declines" and "JD Increases Despite Market Slip."
One late-September headline went the other way: "JD Fell More Than Broader Market."
Overall, the recent pattern is outperformance on down days. That fits money moving into cheap China stocks and/or positioning ahead of the Ceconomy approval.

d) Sector and regulatory news¶

Alibaba fell 4% on a reported Beijing AI probe, while Baidu eased and JD dipped (24/7 Wall St.). Chinese regulatory risk is back in the headlines.
JD has less AI and cloud exposure than Alibaba, so it may suffer less if this stays focused on AI. A JD-vs-Alibaba pair trade could be worth looking at.
Barron's: "Alibaba Stock Falls. Treasury Yields Aren't Just a U.S. Problem." This links rising US yields directly to pressure on Chinese internet stocks (see section 2).
Nike is cutting China online distributors to curb discounting (Quartz).
This points to ongoing price wars and brands pushing back against platform discounting.
It could mean less branded supply through third-party sellers, but also less discount pressure on gross margin.
JD's 7Fresh Kitchen "Chef Transformer" launch (GlobeNewswire) continues its push into fresh food and food delivery. That push has cost JD margin through subsidies.
Early September (24/7 Wall St.): "Alibaba Climbs 3%, PDD and JD Tick Up: Is China Technology Finding Buyers Again?" Buyers were returning to China tech before the rate shock.

2. Macro backdrop (FRED data)¶

a) Both the Fed and the ECB raised rates¶

Fed:
The effective fed funds rate rose from 3.63% to 3.88% on 2026-09-17, a 25bp hike at the September 15–16 meeting.
The Fed had cut from 4.09% (October 2025) to about 3.63% and then held from January to August 2026. This is a reversal from that cutting cycle.
ECB: the deposit rate went from 2.25% to 2.50% on 2026-09-16. It was 2.0% a year ago.
Central banks are tightening into an oil shock. That is bad for growth-sensitive and emerging-market stocks.

b) Inflation is the reason¶

Headline CPI (August): +3.35% year on year.
CPI jumped about 2.0% in three months from March to May (March +0.87% month on month, April +0.64%, May +0.47%), which looks like an energy shock.
It then dipped (June −0.42%) and picked up again (August +0.40%).
Core PCE (August): +3.01% year on year.
Recent momentum is softer: June +0.13%, July +0.13%, August +0.25%. That is roughly 2.0% annualized over three months and about 2.7% over six months.
Inference: the Fed hiked mainly because of headline/oil inflation and inflation-expectation risk, not a core flare-up. If oil fades, the case for more hikes weakens.
Unemployment: 4.2% (September), versus 4.5% in November 2025. The labor market is firm enough that the Fed can stay hawkish.

c) The selloff has moved to long-dated bonds¶

Metric	Recent move
10-year Treasury	5.28% (Oct 7); peak 5.31% (Oct 5); +53bp since Aug 31; +115bp year on year
2-year Treasury	4.77%; peaked 4.92% (Sep 28); roughly unchanged since the Fed hike
2s10s spread	+0.47%, up from +0.20% (Sep 21): long yields rising faster than short ones
Mortgage rates	"Highest level in nearly three years" (Yahoo)

Since the hike, the 10-year is up about 27bp while the 2-year is flat.
Inference: markets are not pricing many more Fed hikes. The pressure is in long-dated bonds, where investors are demanding a higher premium (likely concerns about inflation and fiscal policy).
That raises the discount rate for all stocks and has historically pushed money out of emerging markets and US-listed Chinese stocks.
Yahoo's "Chart of the Day" warned that "rapid bond yield moves have preceded nearly every major financial blowup."

d) The dollar is up but the yuan is holding¶

Broad dollar index: 117.9 (Sep 9) → 121.8 (Oct 1), about +3.3% in three weeks.
USD/CNY: 6.7038 (Oct 2), flat through the dollar rally and stronger than 6.7745 in June.
Inference: the yuan is strong against the dollar and holding up against other currencies, likely with central-bank support. JD earns in yuan and its shares trade in USD, so a strong yuan helps its reported USD earnings. This partly offsets the headwind from the stronger dollar.

e) Oil and geopolitics¶

WTI: $83.76 (Aug 10) → $107.02 peak (Sep 15) → $96.24 (Oct 6). Prices have been very volatile.
A headline on Oct 8 put oil at about $103 (likely Brent) after Trump said the US will not attack Iran before the midterm elections (Nov 3). That lowers near-term tail risk, but only until the election.
Impact on JD:
Higher fuel costs for its in-house logistics network.
Pressure on Chinese consumers, since China imports most of its oil.

f) Market sentiment¶

VIX: 15.08, in a 14–18 range despite the bond selloff and rate hikes. Stocks look complacent relative to bonds, so equity volatility could jump.
Comex gold: $4,131.80, a high level that points to steady demand for hedges.
Chip stocks fell despite Samsung's record profit guidance. Good news is being sold, which signals tired risk appetite.

3. How the macro picture affects JD¶

Factor	Direction	Notes
10-year yield at 5.3% and rising	❌ Negative	Higher discount rates; outflows from emerging markets and Chinese stocks (Barron's links this directly to Chinese internet stocks). JD's low valuation softens the impact somewhat.
Fed and ECB hikes	❌ Negative	Weaker global demand; the ECB hike also weighs on the Ceconomy outlook.
Dollar up ~3%	❌ Mildly negative	Typical headwind for emerging markets.
Yuan steady at ~6.70	✅ Positive	Helps JD's earnings when converted to USD; reduces currency risk.
Oil at $96–103	❌ Negative	Fuel costs for JD's logistics; pressure on Chinese consumers.
Beijing probe of Alibaba	⚠️ Mixed	Bad for the sector, but JD has less AI exposure and could do better than Alibaba.
Ceconomy approval near	✅ Positive (near term)	Removes an overhang; carries execution risk later.

4. Upcoming catalysts¶

Formal EU Commission decision on Ceconomy: expected soon, based on the "poised to win" reports.
US September CPI (mid-October): a hot number would push long yields up further and pressure Chinese stocks.
FOMC meeting, October 27–28 (my estimate from the usual calendar): markets will watch for signs of a second hike.
China Golden Week (Oct 1–7) spending data: an early read on Chinese consumer demand.
Singles' Day (11.11) presales, which normally start in late October: a test of the price war and margins.
JD Q3 earnings: usually mid-November. The date isn't confirmed by my tools.
US midterms (Nov 3): the Iran-strike risk returns after the vote.

5. Takeaways for the trading decision¶

Expect JD to keep outperforming the market but not to escape it. Recent outperformance on down days and the Ceconomy news give it stock-specific support, but higher yields are pressuring the whole China-tech group. A long position could be hedged with rates (for example, short long-dated Treasuries).
Consider long JD / short Alibaba. The Beijing probe is aimed at AI, where Alibaba is more exposed. JD also has its own catalyst in Ceconomy.
Use options rather than outright stock for event risk. Barchart reports bullish options flow. With the VIX at 15, volatility is relatively cheap ahead of the EU decision, 11.11 and Q3 earnings.
Downside markers: Arete's $30 target is the sell-side anchor. A move in the 10-year above ~5.3–5.4% or Brent back above $105 would likely bring broad selling of emerging-market and Chinese stocks.
Upside triggers: a formal EU approval, a soft US CPI print (core is already near 2% annualized over three months), and continued yuan strength.

Data gaps: - Prediction-market odds (Fed path, US–China tariffs) were withheld for this date. - The news feed returned only headlines, without article text. - No JD price data, August news (Q2 results) or China activity data were available. - No US–China tariff or trade headlines appeared in this week's feed.

Summary table¶

Category	Item	Data / evidence	Effect on `JD`	Signal
Company	Ceconomy ~$2.5bn deal	Reportedly "poised to win EU approval"; remedies revised after rival objections in September	Removes overhang; European expansion	✅ Positive (near term)
Company	Analyst rating	Arete cut to Neutral; target $30 (from $36)	Caps sentiment; reference level	❌ Negative
Company	Options and attention	Barchart: bullish options flow; Zacks "trending / heavily searched"	Possible move as investors reposition	⚠️ Constructive
Company	Relative price action	"Advances while market declines" and "increases despite market slip" (early October)	Money rotating into cheap China names	✅ Positive
Sector	Beijing AI probe	Alibaba −4%; JD dipped	Regulatory risk returns; JD less exposed	⚠️ Mixed (long JD / short Alibaba)
Sector	Nike cuts China online distributors	Brands pushing back on discounting	Less branded supply vs. less margin pressure	⚠️ Mixed
Sector	7Fresh / food delivery	"Chef Transformer" launch	Continued spending to grow; margin watch	⚠️ Neutral
Macro US	Fed policy	Effective rate 3.63% → 3.88% (Sep 17 hike)	Tighter global conditions	❌ Negative
Macro US	Inflation	CPI +3.35% yoy; core PCE +3.01% yoy, ~2.0% annualized over 3 months	Driven by oil; core easing	⚠️ Watch September CPI
Macro US	Labor	Unemployment 4.2%	Lets the Fed stay hawkish	⚠️ Neutral
Rates	10-year Treasury	5.28% (+53bp since Aug 31; +115bp yoy)	Discount-rate pressure; EM/China outflows	❌ Negative
Rates	2-year / curve	2-year 4.77%; 2s10s +0.47% (up from +0.20%)	Long-end selloff; risk of broader market stress	❌ Negative
FX	Broad dollar	117.9 → 121.4 (+~3%)	EM headwind	❌ Mildly negative
FX	USD/CNY	6.7038, stable/strong yuan	Helps JD's USD-reported earnings	✅ Positive
Commodities	Oil	WTI $96.24 (peak $107); Brent ~$103; no Iran strike before midterms	Logistics costs; Chinese consumers	❌ Negative
Europe	ECB	Deposit rate 2.50% (hike Sep 16); German 10-year 3.18%	Weaker European consumers → Ceconomy outlook	❌ Mildly negative
Sentiment	VIX / gold	VIX 15.08; gold $4,131.80	Stocks complacent vs. bonds; demand for hedges	⚠️ Volatility could jump
Calendar	Key events	EU decision; US CPI (mid-October); FOMC (Oct 27–28, estimated); 11.11; Q3 earnings (mid-November, unconfirmed); midterms Nov 3	Several events ahead	⚠️ Event-driven

Fundamentals Analyst¶

JD.com, Inc. (`JD`): Fundamental Research Report¶

As of 2026-10-08 · Consumer Cyclical / Internet Retail · NASDAQ (NMS)

0. What data was available¶

Item	Status
Annual income statement, balance sheet and cash flow (FY2011–FY2025)	✅ Available, from SEC EDGAR as filed. The latest is the FY2025 20-F.
Quarterly / interim 2026 data (Q1 and Q2 2026)	❌ Not available. JD is a foreign private issuer. It reports quarters on 6-K forms, and those aren't tagged in this data feed. The only interim data returned was 9-month 2018 and 2019.
Market cap, valuation multiples, 52-week range	❌ Withheld by the vendor, which has no point-in-time history for these
Insider transactions	❌ Withheld by the vendor, which has no filing dates
Gross profit and net income (after FY2016)	⚠️ Not tagged. I calculated gross profit as revenue minus cost of revenue, and estimated net income from EPS.

Unit note for other agents: the tool headers say "USD in millions," but every row is labeled CNY in raw units. For example, FY2025 revenue of 1,309,085,000,000 means RMB 1.309 trillion. All figures below are in RMB billions.

Past-week note: none of these tools returned any filing or event dated in the last week. The newest fundamental data is the full year to Dec-31-2025.

1. Summary¶

In FY2025, JD's revenue grew faster and its gross margin hit a record, but almost all of its operating profit disappeared because operating expenses jumped.

Revenue: RMB 1,309.1bn, up 13.0% year on year. That's the fastest growth since FY2021 (+27.6%) and well above FY2022–24 (+3.7% to +9.9%).
Gross margin: 16.04%, the highest in the 14-year record (FY2024: 15.87%; FY2021: 13.56%).
Operating income: fell 92.8%, from RMB 38.7bn to RMB 2.8bn. Operating margin dropped from 3.34% to 0.21%, the lowest since JD turned profitable in FY2019.
Diluted EPS: fell 52%, from RMB 13.43 to RMB 6.45 per ordinary share. One ADS equals two ordinary shares, so that's about RMB 12.90 per ADS, down from about 26.86. EPS fell much less than operating income because non-operating income (interest on a large cash pile, investment gains) propped up the bottom line. Underlying earnings quality is weaker than EPS suggests.
Operating cash flow: fell 67%, from RMB 58.1bn to RMB 19.0bn. Free cash flow fell 79% to about RMB 11.2bn.
Cash: rose to RMB 137.5bn (+26.9%). This came mostly from RMB 41.8bn of investing inflows (selling or maturing investments), not from operations.

The squeeze came from operating expenses, not gross margin. The data can't break expenses down by line. As outside context (not from these tools), the timing matches JD's heavy 2025 spending on new businesses, especially its food-delivery launch and the subsidies that came with it. Because this spending is mostly discretionary, the main swing factor for the stock is whether it shrinks in 2026.

2. Long-term revenue and profit history¶

FY	Revenue (RMB bn)	YoY	Gross margin*	Operating income (RMB bn)	Op. margin	Opex / revenue*	Diluted EPS (RMB/sh)
2012	41.4	–	8.4%	-1.95	-4.7%	13.1%	-2.18
2013	69.3	+67.6%	9.9%	-0.58	-0.8%	10.7%	-1.47
2014	115.0	+65.9%	11.6%	-5.80	-5.0%	16.7%	-5.35
2015	181.0	+57.4%	12.2%	-5.36	-3.0%	15.2%	-3.33
2016	258.3	+42.7%	13.7%	-1.25	-0.5%	14.2%	-1.36
2017	362.3	+40.3%	14.0%	-0.84	-0.2%	14.3%	-0.05
2018	462.0	+27.5%	14.3%	-2.62	-0.6%	14.8%	-0.87
2019	576.9	+24.9%	14.6%	9.00	1.56%	13.1%	4.11
2020	745.8	+29.3%	14.6%	12.34	1.65%	13.0%	15.84
2021	951.6	+27.6%	13.6%	4.14	0.44%	13.1%	-1.15
2022	1,046.2	+9.9%	14.1%	19.72	1.89%	12.2%	3.21
2023	1,084.7	+3.7%	14.7%	26.03	2.40%	12.3%	7.61
2024	1,158.8	+6.8%	15.9%	38.74	3.34%	12.5%	13.43
2025	1,309.1	+13.0%	16.0%	2.77	0.21%	15.8%	6.45

*Gross margin is (revenue − cost of revenue) / revenue. Opex is gross profit minus operating income, so it covers fulfillment, marketing, R&D and G&A combined.

What the table shows: 1. Revenue growth has compounded. Revenue grew about 30% a year from 2012 to 2025, about 14.6% a year from 2019 to 2025, and about 7.8% a year from 2022 to 2025. FY2025 broke a three-year slowdown. 2. Gross margin has risen steadily, from 8.4% to 16.0% over 13 years. Gross profit rose 14.2% in FY2025 (to RMB 210.0bn), faster than revenue. That points to a better mix (marketplace, advertising, services) and healthy core retail pricing. 3. Opex is the problem. Opex rose 42.8% (RMB 145.1bn → 207.3bn), while gross profit rose only RMB 26.2bn. The opex ratio of 15.8% is the highest since FY2014. 4. Rough size of the extra spending: if the opex ratio had stayed at FY2024's 12.5%, FY2025 operating income would have been about RMB 46bn instead of 2.8bn. That means about RMB 43bn of extra spending above the FY2024 run-rate. 5. Operating leverage: at FY2025 revenue, each 1 percentage point of opex ratio is worth about RMB 13bn of operating income, almost five times the whole FY2025 operating profit. Each 0.5 point of gross margin is worth about RMB 6.5bn. 6. EPS is noisy. FY2020 EPS (15.84) and FY2021 EPS (−1.15) moved far more than operating income, which is consistent with fair-value swings on JD's investment portfolio. Valuing JD on operating income is more reliable than valuing it on reported EPS.

A useful precedent (FY2018 → FY2019): JD has gone through an investment-driven margin squeeze before. - In the first nine months of 2018, it had an operating loss of RMB 1.68bn (−0.51% margin). - In the first nine months of 2019, operating income was RMB 8.47bn (2.08% margin) on revenue up 24.2%. Nine-month operating cash flow rose 67% (RMB 14.9bn → 24.8bn). - For the full year, operating income went from −RMB 2.6bn in FY2018 to +RMB 9.0bn in FY2019.

The precedent shows management will pull back spending and that margins can recover within about four quarters. It doesn't guarantee that will happen this time.

3. Cash flow¶

FY	Operating CF	Capex (tagged)	FCF (OCF − capex)	Investing CF	Financing CF	OCF / revenue
2019	24.8	2.6	22.2	-25.3	+2.6	4.3%
2020	42.5	3.4	39.2	-57.8	+71.1	5.7%
2021	42.3	5.6	36.7	-74.2	+19.5	4.4%
2022	57.8	5.5	52.3	-54.0	+1.2	5.5%
2023	59.5	4.0	55.5	-59.5	-5.8	5.5%
2024	58.1	5.4	52.7	-0.9	-21.0	5.0%
2025	19.0	7.8	11.2	+41.8	-26.7	1.5%

Key points: - Operating cash flow fell by two-thirds after holding near RMB 58bn for three years. OCF as a share of revenue dropped from 5.0% to 1.5%. JD's model normally turns profit into cash well because supplier payables fund its inventory. OCF was about 1.4 times net income in FY2024 and roughly 1.0 times in FY2025, so the cash advantage has narrowed. - Capex rose 46% (RMB 5.4bn → 7.8bn), consistent with investment in new businesses and logistics. The tagged capex line may not include land-use rights or construction in progress, so total capex could be higher. - Capital returns exceeded free cash flow. Financing outflows of RMB 26.7bn (consistent with JD's buybacks and annual dividend) were larger than FY2025 FCF of RMB 11.2bn. The gap of about RMB 15.5bn was covered by selling or maturing investments (investing inflow of +RMB 41.8bn). That works for a while given the balance sheet, but it isn't sustainable if OCF stays near RMB 19bn. - Cumulative FCF for FY2019–2025 was about RMB 270bn, so the long-run cash engine is real. FY2025 is a sharp break from the trend.

4. Balance sheet¶

FY-end	Total assets	Current assets	Cash & equiv.	Total liabilities	Current liabilities	Equity (attributable)†	Current ratio	Liabilities / assets
2021	496.5	299.7	70.8	249.7	221.6	208.9	1.35x	50.3%
2022	595.3	351.1	78.9	321.1	266.6	213.4	1.32x	53.9%
2023	629.0	307.8	71.9	332.6	265.7	231.9	1.16x	52.9%
2024	698.2	386.7	108.4	384.9	299.5	239.3	1.29x	55.1%
2025	695.2	374.4	137.5	401.4	306.1	225.0	1.22x	57.7%

†Total assets minus total liabilities was RMB 293.8bn at FY2025. The roughly RMB 68.7bn gap from the RMB 225.0bn equity figure is mainly non-controlling interests in listed subsidiaries such as JD Logistics and JD Health.

Key points: - Liquidity is strong. Cash of RMB 137.5bn covers 45% of current liabilities (36% a year earlier). Total investments are likely larger still: the FY2025 investing inflow suggests part of the cash rise came from moving money out of short-term investments. - Leverage is creeping up. Liabilities rose to 57.7% of assets from 52.9% in FY2023. Non-current liabilities rose 11.6% to RMB 95.3bn. Working capital fell from RMB 87.2bn to 68.3bn, and the current ratio from 1.29x to 1.22x. None of this is alarming for a retailer funded by its suppliers, but the direction is negative. - Equity attributable to shareholders fell 6.0% (RMB 239.3bn → 225.0bn) even though FY2025 was profitable. That implies capital returns and other equity reductions of over RMB 30bn. - Asset turnover improved to about 1.88x (from 1.75x), as revenue grew 13% on a flat asset base. - Estimated return on equity: assuming about 2.9–3.0bn diluted ordinary shares, FY2025 net income was about RMB 19bn, giving ROE of roughly 8%, down from about 17–18% in FY2024. Treat these as approximations.

5. Implications for traders¶

Bullish points: 1. The core business is healthy. Gross margin is at a record 16.0% and revenue growth sped up to 13%. The FY2025 collapse came from spending decisions, not from price wars hurting gross margin. 2. Profits are highly sensitive to spending. About RMB 43bn of spending above the FY2024 ratio is the lever. A 1–2 point normalization of the opex ratio would add RMB 13–26bn of operating income, five to nine times FY2025's total. That's the setup for a sharp earnings recovery if spending falls. 3. JD has done this before. The FY2018 → FY2019 swing (−RMB 2.6bn to +RMB 9.0bn) shows management is willing to cut back after an investment phase. 4. There's plenty of cash. RMB 137.5bn (plus probable additional investments) gives JD time to keep investing and keep returning capital.

Bearish points: 1. Core profit is close to zero. A 0.21% operating margin leaves no room for error. Reported EPS depends on non-operating income. 2. Cash generation has weakened sharply. OCF fell 67% and FCF 79%. Buybacks and dividends exceeded FCF by about RMB 15.5bn and were paid from the investment pile. 3. Leverage is drifting higher and equity is shrinking. Liabilities are up to 57.7% of assets and equity is down 6%. 4. The spending may be ongoing. If competitive pressure in new businesses persists, the elevated opex ratio could last well into 2026. Nothing in this dataset shows whether it improved in Q1 or Q2 2026.

What to watch next: - Q3 2026 results, which JD usually releases in mid-November. Focus on the opex ratio (above or below about 15.8%), new-business losses, gross margin holding near 16%, and OCF recovery. - The Q1 and Q2 2026 6-K results, which these tools couldn't access. Another agent should get them, because they decide whether the FY2025 squeeze peaked or deepened. - Valuation, price action and insider/buyback activity, which were also unavailable here and need another source.

Fundamental read (for the deciding agent): the full-year data is mixed to neutral. The core franchise is improving (revenue speed-up, record gross margin, strong balance sheet), but earnings and cash flow are badly depressed by voluntary investment. The case for the stock depends on how much spending falls in 2026. Without 2026 interim data, these tools can't show which way that is going. The risk/reward depends on the entry valuation, which I couldn't see here.

6. Key metrics summary¶

Category	Metric	FY2024	FY2025	Change	Signal
Growth	Revenue (RMB bn)	1,158.8	1,309.1	+13.0%	🟢 Fastest growth since FY2021
Profitability	Gross margin (derived)	15.87%	16.04%	+17 bp	🟢 Record high
Profitability	Operating income (RMB bn)	38.7	2.8	-92.8%	🔴 Near breakeven
Profitability	Operating margin	3.34%	0.21%	-313 bp	🔴 Lowest since FY2018
Costs	Opex / revenue (derived)	12.5%	15.8%	+331 bp	🔴 Highest since FY2014; spending-driven
Costs	Extra spending vs FY2024 ratio	–	~RMB 43bn	–	🟡 Recovery lever if spending falls
Earnings	Diluted EPS (RMB/ord. share)	13.43	6.45	-52.0%	🔴 Propped up by non-operating income
Cash flow	Operating cash flow (RMB bn)	58.1	19.0	-67.3%	🔴 Sharp drop
Cash flow	Capex (tagged, RMB bn)	5.4	7.8	+46.1%	🟡 Investment phase
Cash flow	Free cash flow (RMB bn)	52.7	11.2	-78.8%	🔴 Below capital returns
Cash flow	Financing outflow (RMB bn)	-21.0	-26.7	+27%	🟡 Exceeds FCF by ~RMB 15.5bn
Balance sheet	Cash & equivalents (RMB bn)	108.4	137.5	+26.9%	🟢 Strong, partly from selling investments
Balance sheet	Current ratio	1.29x	1.22x	-0.07x	🟡 Slightly weaker
Balance sheet	Liabilities / assets	55.1%	57.7%	+2.6 pp	🟡 Leverage creeping up
Balance sheet	Equity attributable (RMB bn)	239.3	225.0	-6.0%	🟡 Capital returns exceed earnings
Returns	Estimated ROE	~17–18%	~8%	about halved	🔴 Estimate only
Efficiency	Asset turnover	1.75x	1.88x	+0.13x	🟢 Improving
Precedent	FY2018 → FY2019 operating income	-2.6 → +9.0	–	–	🟢 Margins recovered within a year last time
Data gaps	Q1/Q2 2026 results, valuation, insiders	–	–	–	⚠️ Another agent should get these
Catalyst	Q3 2026 earnings	–	Expected mid-Nov 2026	–	👀 Opex ratio and OCF are the key checks

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Opening: JD. The Market Is Pricing a Spending Decision as a Broken Business

My thesis in one sentence: JD didn't lose its business in 2025. It chose to spend its profit. The market is treating a discretionary surge in spending of roughly RMB 43bn as permanent damage. It's doing that at a technical level where the selling is visibly running out. A mispriced earnings trough plus a chart setup with defined risk is what I want to own.

1. The core business is the strongest it has been¶

Set aside the operating line for a moment and look at what the business itself did in FY2025:

Revenue rose 13.0% to RMB 1,309bn. That's the fastest growth since 2021 and ends a three-year slowdown (+3.7% to +9.9%).
Gross margin hit 16.04%, a record in a 14-year dataset. It has risen almost every year from 8.4% in 2012.
Gross profit rose 14.2%, faster than revenue. The shift toward higher-margin marketplace, advertising and services revenue is working.
Asset turnover improved from 1.75x to 1.88x.

If JD were losing a price war, gross margin is where it would show. It didn't. Customers bought more, at better margins.

What broke was operating expense. Opex rose 42.8%, taking the opex-to-revenue ratio from 12.5% to 15.8%. That was a spending decision, and the timing matches the food-delivery launch subsidies. Spending decisions can be reversed.

2. Small cost cuts move profit a lot¶

Each 1 point of opex ratio is worth about RMB 13bn of operating income. That's almost 5x FY2025's entire operating profit.
Returning to the FY2024 opex ratio gives about RMB 46bn of operating income, versus RMB 2.8bn reported.
Recovering only half the gap gives about RMB 24bn, roughly 9x FY2025.

This doesn't require anything heroic. Management only has to repeat FY2018 to FY2019: - Operating income went from −RMB 2.6bn to +RMB 9.0bn in one year. - Nine-month operating cash flow rose 67%. - Revenue still grew 24% over the same period.

3. What you're paying (my arithmetic; the vendor withheld valuation data)¶

Metric	Estimate
ADS count (~2.95bn ordinary shares ÷ 2)	~1.47bn
Market cap at $26.91	~$40bn ≈ RMB 266bn
Cash and equivalents	RMB 137.5bn (~$20.5bn), about half the market cap
P/E on depressed FY2025 EPS (≈$1.92/ADS)	~14x
P/E on FY2024 EPS (≈$4.01/ADS)	~6.7x

For enterprise value, I add back about RMB 69bn of minority interests in JD Logistics and JD Health. I don't have debt or short-term investment figures, so they're excluded.

Cash treatment	EV / fully normalized operating income	EV / half-normalized operating income
Full credit for cash	~4.3x	~8x
Zero credit for cash (the bear's "it's all supplier float" view)	~7x	~14x

Even on the harshest assumptions, you pay a market-type multiple for trough earnings and get the recovery for nothing. Arete's downgrade, the bear's best sell-side evidence, still carries a $30 target. That's 11.5% above today's price.

4. Upcoming catalysts¶

Ceconomy EU approval. JD is reportedly "poised to win" it, which removes the overhang.
The $2.5bn price is about 12% of cash and about 6% of market cap, so it doesn't strain the balance sheet.
It gives JD an established European retail footprint (MediaMarkt/Saturn) for its supply chain.
Singles' Day presales, which normally start in late October.
Q3 results, usually mid-November. The first report showing an opex ratio below 15.8% is the re-rating trigger.
A firm yuan.
USD/CNY is 6.70, stronger than 6.77 in June, even though the dollar index rose about 3%.
That supports earnings translated into USD.
Market behavior.
"JD Advances While Market Declines" ran twice in early October.
Barchart reports bullish options flow, so someone is positioning.
Regulation. Beijing's AI probe is aimed at Alibaba. Among the big China internet names, JD has the least AI exposure.

5. The chart shows sellers running out of steam¶

The bear will point to a downtrend on every timeframe. Here's what sits underneath it:

Higher lows all year. Closing lows went 24.53 → 25.19 → 25.78. The two earlier lows led to rallies of +38% and +33%.
MACD bullish divergence. Price made a lower low (25.78 vs 26.64), but MACD made a higher low (−0.66 vs −0.81). The histogram is now positive.
RSI held at about 30 three times without closing below it.
ATR is down 30% since August. Sellers have lost their urgency.
The weekly TD Sequential count reached 9. It's provisional: a Friday close at or above $27.06 would technically cancel it, and I'd gladly take that outcome.
The death cross (around Oct 12) is pure arithmetic.
It happens because late July and early August closes of $32–33 are dropping out of the 50-day window.
The 200-day average is nearly flat at about $28.5. That describes a range, not a collapse.

6. Answering the bear's likely objections in advance¶

"Earnings are propped up by interest income." Agreed. That's why I value JD on a recovery in operating income, not on EPS. A core operating line near zero is the opportunity, not a gotcha.

"Cash flow collapsed and capital returns exceeded free cash flow." - True for one year: operating cash flow fell from RMB 58bn to 19bn, and RMB 26.7bn was returned against RMB 11.2bn of free cash flow. - But this company generated about RMB 270bn of cumulative free cash flow from 2019 to 2025 and holds RMB 137.5bn of cash. - Funding one investment year from the investment portfolio is the balance sheet doing its job, not a solvency problem. - The supplier-funded model is unchanged, so cash flow should recover as opex normalizes.

"A 5.3% 10-year yield kills China internet stocks." - Higher discount rates hurt companies whose value depends on cash flows far in the future. - A stock at about 7x prior-year earnings, with half its market cap in cash, is about as short-duration as equities get. - The 2-year yield hasn't moved since the Fed hike, and core PCE is running about 2% annualized over three months. The hike was driven by oil. - I concede that rates limit any re-rating in the near term. That's why my target is a return to the top of the range, not a 15x multiple.

"OBV hasn't confirmed the bounce." Correct. That's why I'm proposing a trade with a defined stop, not an all-in bet.

"The Aug 13 gap was probably a bad Q2, and we can't see 2026 interim results." - This is the bear's strongest point, and I accept it. We can't see what was in that report. - But the stock has already fallen 23% and sits about 30% of the way up its yearly range. - Two months of selling have priced that report in, and the MACD and RSI divergences say the remaining sellers are few.

7. How I'd trade it¶

Entry: a starter position at $26.66–26.91 (the 10-day EMA and middle Bollinger band). Add on a daily close above $27.44 on more than about 8M shares, which flips the daily SuperTrend.
Stop: $25.65, just below the Oct 2 swing low. If that breaks, the higher-low pattern is broken and I'm wrong. The risk is about $1.05–1.26 per share, around 2 ATR.
Targets:
$28.45–28.70 (the moving-average cluster and 38.2% retracement)
$30 (Arete's own target)
$33.47 (the range top)
Reward to risk: about 5:1 to the range top and about 2.5:1 to $30.
Sizing: risk 1% of equity, so shares = (0.01 × equity) ÷ ~1.1. Confirm the Q3 earnings date. Before the report, consider trimming or switching to calls, since a VIX of 15 makes options cheap.

Bottom line¶

To win this debate, the bear has to argue two things at once: - A company with record gross margins, accelerating revenue, RMB 137.5bn of cash and a proven record of cutting spending will keep spending an extra RMB 40bn or more a year indefinitely. - The market hasn't already priced that in after a 23% drop.

I think that's the much harder case to make.

My direct question to the bear: what 2026 opex ratio does $26.91 imply, and why is that the right number? Bull Analyst: # Bull Rebuttal: JD. Run the Bear's Model to the End and It Argues for Owning the Stock

The bear caught real mistakes in my opening and asked a fair question. I'll concede the mistakes first. Then I'll accept the bear's valuation framework and follow it through. It shows three things: the price assumes JD keeps most of a one-year spending surge, the market has already priced in the bad Q2, and the stock yields double digits on normal free cash flow.

1. What the bear got right¶

FY2019 wasn't a cost cut. Opex grew about 10% while revenue grew 25%. It shows management can slow spending growth, not that it cuts spending outright.
My 5:1 headline relied on the farthest target. From $26.91 with a $25.65 stop, the first target pays only about 1.2:1. I wouldn't put on the trade for that target alone.
A stop doesn't protect against a gap. August showed JD gaps. I'm resizing below.
The weekly TD 9 is weak evidence. I'm dropping it.
I can't name a disclosed 2026 opex ratio. Neither of us has the Q1 or Q2 filings. The bear can't name one above 15.8% either. We are both inferring from the Aug 13 gap.

None of these answers the central question: what does $26.91 assume, and is that assumption too pessimistic?

2. "About 14% is priced in": right on the math, wrong on the conclusion¶

I accept the bear's inputs: revenue of RMB 1,400bn, a 16.0% gross margin, and 8–10x pre-tax EV/EBIT. The extra step is to split opex the way the fundamentals report does. Think of it as a baseline at the FY2022–24 norm of about 12.5% of revenue, plus excess spending on top.

Scenario	Excess spending above the 12.5% norm (RMB bn)	Share of FY2025's excess still being spent
FY2025 actual (15.8%)	~44	100%
Priced at $26.91 (bear's 13.6–14.6%)	~15–29	~35–67%
Midpoint (14.4%)	~27	~61%
FY2024 norm (12.5%)	0	0%

So the bear's "normal recovery" means JD keeps spending RMB 15–29bn a year above its three-year norm in 2026. The bear then values that single year at a trough multiple and gives no credit for 2027 or beyond.

Here is what the bear's own numbers imply (my arithmetic): - Each point of opex ratio is worth RMB 14bn of operating income. At 8–10x, that is RMB 112–140bn of EV, or about $11–14 per ADS. - Recovering halfway to the norm (14.15%) implies about $28–33. - Recovering fully (12.5%) implies about $47–57. - The same sensitivity works in reverse. Every point that doesn't come back costs the same $11–14. That's why Section 8 sizes the position for a gap.

The Q2 markdown is already in these numbers. The drop from $33.47 to $26.91 is $6.56, which is about half a point of opex on the bear's sensitivity. The market didn't ignore the bad quarter. It priced it, and by a measurable amount.

3. The bear's downside case needs every assumption to go wrong at once¶

It needs revenue to slow while costs stay high. The bear has growth falling back to 7% "once subsidies ease," but also says cost cuts are too hard mid-fight. - The subsidies are the cost. - If they ease enough to pull growth back to 7%, most of the RMB 44bn excess goes away with them. - If they don't ease, growth stays nearer 13%, and the faster-growing revenue base lowers the ratio on its own. - The bear's short needs JD to cut subsidies enough to lose the growth but not enough to save the money.

The cut isn't heroic. The bear's RMB 22–32bn cut equals 36–52% of FY2025's RMB 62.2bn opex increase. That means reversing a third to half of one launch year's spending, not cutting into the core business.

The bear's accounting point actually supports my case. The bear is right that the price war is booked below gross profit. That means the damage sits in a single, discretionary line. The goods business above that line still posted a record margin. Whether customers stay once coupons shrink is the real unknown, and I grant that.

The recent "expansion" moves don't add to the subsidy spending. - Ceconomy is capital spent buying a profitable, if low-margin, retailer. It brings gross profit along with its opex. - The 7Fresh Kitchen launch is a product headline with no disclosed cost.

Singles' Day isn't a new headwind. It falls in every year's figures, including FY2022–24, when the opex ratio was 12.2–12.5%.

Beijing has signaled limits (this is outside our data feed, so weight it accordingly). In 2025, China's market regulator summoned the food-delivery platforms, JD included, at least twice over subsidy competition.

4. The Q2 question, using the bear's own method¶

I accept that the Aug 13 gap most likely reflects a disappointing Q2. But if we infer results from price moves in JD's usual reporting windows, we should apply that to all three windows. Our tools don't confirm these dates, which is the same caveat the bear applied to August.

Usual reporting window	What the price did	What it suggests (same standard of evidence)
Early March (FY2025 results)	Year's low, $24.53 close on Mar 4, followed by a +38% rally	The weak annual report coincided with the low
Mid-May (Q1)	Year's high, $33.77 close on May 13	Q1 was well received
Mid-August (Q2)	−7.3% gap on 5x normal volume	Q2 disappointed

That's one bad quarter out of three, not a uniform signal. Three more points: - The low after the bad quarter ($25.78) is above the earlier lows ($25.19 in June and $24.53 in March). Buyers stepped in at a higher price after Q2 than before it. - Arete saw Q2, downgraded, and still set its target at $30. The bear's best-informed source puts fair value 11.5% above today's price. - Since the Sep 17 Fed hike, the 10-year yield is up about 27bp and the dollar about 3%. Over that time JD has gone from $26.64 to $26.91, and it twice "advanced while the market declined" in early October. That isn't how a stock behaves when emerging-market outflows are draining it.

5. The balance-sheet critique is fair, but much smaller than claimed¶

Debt. Fair point: I deducted none. But my zero-credit-for-cash case already removes RMB 137.5bn. That's more than the entire RMB 95.3bn of non-current liabilities, which also include items that aren't debt. Short-term borrowings are unknown, and I'll treat that as an open question.

Leases. JD reports under US GAAP, where operating lease costs are already inside opex. Deducting lease liabilities from EV while using EBIT after rent would count the rent twice.

Supplier funding. The RMB 306bn of current liabilities is matched by RMB 374bn of current assets. Working capital is still a positive RMB 68bn.

The 2026 cash gap. The bear's RMB 32bn figure assumes operating cash flow doesn't recover at all for a full year. Even then, about RMB 105bn of cash remains.

Normal free cash flow is what the rates argument leaves out. - FY2022–24 free cash flow averaged RMB 53.5bn. Revenue grew only 3.7–9.9% in those years, so that cash didn't come from fast-growth supplier float. - That equals 16% of EV with zero credit for cash, and 27% with full credit. - If only half of it comes back, the yield is still 8–13.5%. - Every one of those numbers beats a 5.28% Treasury. On normal cash flow, JD competes with bonds and wins. - The stock trades at about 1.2x attributable book value, for a business that earned a 17–18% return on equity in FY2024.

The bear compared Arete's 11.5% upside to the 10-year yield but left out capital returns. By the bear's own figure, JD returned about RMB 27bn last year, roughly 10% of today's market cap. Even if cut back to trough free cash flow, that's still about 4%.

6. Macro, briefly¶

Oil is minor in the same way the yuan is. The bear called the yuan "noise" next to one opex point. The same logic applies to oil: fuel is a slice of fulfillment costs, while subsidies are the big driver. WTI is also $11 below its peak, and the Iran-strike risk is deferred until after Nov 3.
The market isn't pricing a second hike. The 2-year yield is flat. Core PCE is running about 2.0% annualized over three months, so the case for another hike rests on oil.
I concede that weak flows into China ADRs limit how much the multiple can expand. That's why my case relies on earnings recovering, not on a higher multiple.

7. The chart: concessions and one correction¶

Concessions. RSI moving between 30 and 50 is typical of a downtrend. MACD is still below zero. On-balance volume hasn't confirmed the bounce. That's exactly why I only add on confirmation.

Correction. "A third failed bounce" misreads the record. The last two bounces from this zone gained +38% and +33%. They were sold at the top of the range. That argues for buying in the bottom 30% of the range, which is where JD is now.

The bear's short has the same gap problem the bear found in my long. - Its stop is 25–55 cents above the entry. - It runs through a known upside headline (the Ceconomy approval) and earnings. - A 7% gap up from $27.50 means a loss of about $1.90, which is 3.5–7.7x the planned risk. - It is also a short taken against a bullish MACD divergence.

8. The revised trade¶

The time horizon is through Q3 and into the FY2026 results, not five weeks. Q3 (July–September) ends before Ceconomy can be consolidated, and JD reports new-business losses as a separate segment. So the bear's "muddied signal" concern applies to later reports, not to the one that matters now.

Step	Rule
Starter position (now, $26.66–26.91)	Size for a gap, not for the stop. Assume a −15% gap (twice August's), about $4 per share. Shares = (0.01 × equity) ÷ 4, roughly a quarter of my original size. Keep $25.65 as the exit level if trading is orderly.
Add on confirmation	Use the bear's own trigger: a daily close above $27.44 (ideally $27.72) on at least 8M shares, with RSI above 50. Stop below $26.42.
Holding through Q3	Keep earnings exposure through a call spread, where the most you can lose is the premium paid. Check `JD`'s own implied volatility first; the VIX at 15 is only a rough proxy.
Targets	Sell a third at $28.45–28.70, more at $30, and the rest toward $33.47.
Exit conditions	A daily close below $25.71, the year's first lower low: exit the stock. A Q3 report where the opex ratio isn't improving year on year and new-business losses aren't shrinking: exit everything.

On "I'd rather buy at $29 with proof": on the bear's own numbers, a Q3 that comes in even half a point better than priced is worth $5.50–7 a share, and the bear agrees JD gaps. Proof arrives as a gap up, not a pullback. Waiting for proof means paying for it.

Bottom line¶

Buy JD: start a small position sized for gap risk now, and add on confirmation.

At $26.91, the market assumes JD keeps roughly 60% of a one-year spending surge. It values that at a trough multiple, after already pricing in a bad Q2. JD doesn't need to get back to FY2024 margins. Getting halfway there is worth about $28–33 on the bear's own multiples. Normal free cash flow yields 16% of EV even with no credit for cash. The bear's valid points change how I hold the stock: smaller, sized for a gap, adding only on confirmation, and using defined risk through Q3. They don't change whether I hold it.

My question back to the bear: your own sensitivity values each point of opex at $11–14 a share, and your short needs 2026 opex at or above about 14.6%. That means JD keeps spending roughly RMB 29bn above its FY2022–24 norm, two-thirds of the launch-year excess, in the second year of the fight, while revenue growth slows to your 7%. Why would two-thirds of the spending stay once the growth it paid for is gone? Bull Analyst: # Bull Rebuttal: JD. The Price Doesn't Need JD's First-Ever Cut. It Needs a Repeat of FY2022.

The bear's 13-for-13 fact is correct. I re-derived opex for every year, and the absolute figure rose in all 13 year-over-year comparisons. But it answers a question the price isn't asking.

The bear's "absolute cut" requirement comes from pairing two inputs that contradict each other: - 7% revenue growth, which the bear justified in round one as "back to the 2022–24 trend once subsidies ease." - A flat budget, which assumes subsidies don't ease.

Pair the inputs consistently and $26.91 asks for nothing JD hasn't done after every prior profit trough.

All figures are my arithmetic on the reports. I use the bear's conventions: 8–10x pre-tax EV/EBIT, about 1.474bn ADS, RMB 6.70 per dollar, RMB 137.5bn cash and RMB 68.7bn minority interests. On full credit for cash, $1 per ADS ≈ RMB 9.9bn of market cap, and market cap = EV + RMB 68.5bn.

1. What I concede¶

Absolute opex has never fallen. Verified.
"Normal" free cash flow of RMB 53.5bn assumes the recovery. I withdraw it as independent evidence. The same goes for the 17–18% ROE; trailing operating ROE is under 1%.
Capital returns. Counting buybacks as yield on top of full credit for cash double-counts. Withdrawn.
Cash basis. My "halfway = $28–33" used full credit for cash, and I should have labeled it. Section 5 defends that choice instead of hiding it.
The new-mix normal opex ratio. Food delivery probably raises it above 12.5%. I'll use 13–13.5% for full recovery. That is worth $35–50, not $47–57.
Chart details. My Sep 17 anchor was a swing low, the post-Q2 higher low is thin, and the tape is mixed.

One correction: quarter size reflects gap risk, not low conviction. Sizing for a 15% overnight move is risk management for event-driven volatility.

2. "Name the year": the price doesn't need one¶

Here is how much opex can change at $26.91, depending on the revenue growth you assume:

FY2026 revenue growth	Allowed opex change, full credit for cash (8x / 10x)	Half credit (8x / 10x)
+7% (bear's input)	−3.8% / −1.4%	−8.0% / −4.8%
+10%	−0.8% / +1.6%	−4.9% / −1.7%
+13% (FY2025 repeated)	+2.3% / +4.7%	−1.9% / +1.4%

If JD keeps fighting and keeps FY2025's growth, the price allows opex to grow 2–5%. That matches JD's own 2022 (+2.3%) and 2023 (+4.5%) rates. No cut is needed.
Why growth wouldn't fall to 7% if the budget holds (my reasoning; the timing is outside our feed). JD's food-delivery push began in early 2025 and scaled through the year. A business that ramped during 2025 contributes a full year at its exit-rate level in 2026, even if it is only defended. The bear's "year two defends, it doesn't grow" ignores this annualization.
The bear's model holds gross margin flat at 16.0%. Gross margin rose in 11 of 13 years, including FY2025, the launch year. It was flat once and fell once (FY2021).
Each 0.1 point of gross margin is worth $1.1–1.4 per ADS at 8–10x.
Merely repeating FY2025's +0.17 points adds about $2.
If base rates settle this debate, they apply to gross margin too.

3. The right base rate: what JD did after each prior trough¶

The bear's 13-for-13 comes from years with no subsidy surge to unwind, so it has no direct precedent for the current situation. The relevant sample is the year after each prior low in operating margin:

After the trough	Opex ratio	Revenue growth	Opex growth	Gap	Ratio factor
FY2014 → FY2015	16.7% → 15.2%	+57.4%	+43.4%	14.0 pts	0.91
FY2018 → FY2019	14.8% → 13.1%	+24.9%	+9.5%	15.4 pts	0.885
FY2021 → FY2022	13.1% → 12.2%	+9.9%	+2.3%	7.6 pts	0.93
Priced at $26.91, full credit (10x / 8x)	15.8% → 14.6% / 14.2%			~8.5–11 pts	0.92 / 0.90
Half credit (10x / 8x)	→ 14.1% / 13.6%			~12–16 pts	0.89 / 0.86

On full credit, the price asks for the median of JD's own recoveries. The price needs a ratio factor of 0.90–0.92. The three precedents delivered 0.885–0.93.

FY2022 is the closest analogue. Growth was single-digit, and it followed a year of new-business losses. Repeat the whole year: - Revenue +9.9%, opex +2.3%, gross margin +0.5 points. - That gives EBIT of RMB 26.4bn, worth $28–34. - The bear's "leanest year" case ($16.6–19) uses 2022's cost growth but not its revenue growth or its gross-margin gain. It applies only half of the precedent.

FY2022 probably did contain an absolute cut. - Opex rose only RMB 2.9bn while revenue grew 9.9%. - Unless less than about 23% of JD's opex moves with volume, everything else fell in absolute terms. - JD runs its own warehouses and couriers, and fulfillment has historically been its largest opex line (outside our feed). - If half of opex scales with volume, the rest fell about 5%. - So JD has cut discretionary spending before. The cut was hidden inside a rising total.

4. Scenarios where spending and revenue move together¶

Scenario	Revenue	Gross margin	Opex	EBIT (RMB bn)	Value at 8–10x, full credit	Half credit
Retreat: cut to new-mix normal (~13.3%)	+7%	16.0%	−10%	37.5	$37–45	$30–38
Repeat FY2022 in full	+9.9%	16.6%	+2.3%	26.4	$28–34	$21–27
Escalate: costs grow like 2023	+13%	16.0%	+4.5%	20.1	$23–27	$16–20
Bear's mismatched case: flat spending, growth reverts	+7%	16.0%	flat	16.8	$20.5–24	$13.5–17

In every scenario where revenue moves with spending, the downside is the escalate case: −14% to +1%. The bear's −24% to −38% figures come only from the mismatched case, where RMB ~40bn of subsidies buy zero extra growth. Management chose to start this spending, so it can choose to stop.
My weights: retreat 25%, FY2022 repeat 40%, escalate 25%, mismatched case 10%.
On standard EV (full credit for cash), the weighted value is about $31, or +16%.
On the bear's half-credit floor it is about $24.
That gap is the whole disagreement, so the cash question deserves a direct answer.

5. Why full credit for cash is the right answer¶

The bear's half credit is a liquidation test. - Current liabilities exceed non-cash current assets by about RMB 69bn. Denying credit for that much cash assumes every supplier is paid off and none are replaced. - You can't value JD as an ongoing business (EBIT × multiple) and as a liquidation (payables called) at the same time.

The multiple is calibrated for full credit. - The 8–10x range is a market convention built on standard EVs, which give full credit for cash and treat payables as operating items. - Using that multiple on a non-standard EV understates value.

The supplier float grows in all of the bear's own scenarios. - Current liabilities rose from RMB 221.6bn to 306.1bn over FY2021–25. They were flat only in 2023. - Every bear scenario has revenue growing at least 7%, so the float is a source of cash, not a use of it.

If you deny credit for the cash, credit its income instead. - Float that is "needed for operations" earns interest as part of operations. - At an assumed 2% yield, the disallowed half earns about RMB 1.4bn, or about $1.3 per ADS. The half-credit case also gives no value to JD's non-current investments.

What the floor actually implies. If you still hold the bear's floor, a FY2022 repeat is worth about today's price and the upside depends on retreat. That makes the stock fairly priced with an upside tail. It isn't a case for avoiding a small position sized for gap risk.

6. Smaller points¶

Depreciation. Capex rose by RMB 2.4bn. Depreciated over five years, and even doubled for untagged items, that adds RMB 0.5–1bn a year, or 0.04–0.07 points of opex ratio. That is immaterial next to the 1.2–2.2 points in question.
The summonses. Annual data averages the quarters before and after them. Neither of us can see the path within the year, and that is exactly what Q3 2026 will show.
The reporting windows. Apply your method to positioning rather than to the reports themselves:

Window	Where `JD` went into it	What followed
Early March (FY2025: operating income −93%)	After a crash, at the year's low	+38%
Mid-May (Q1)	At the year's high, $33.77	−25%
Mid-August (Q2)	Near the range top	−23%
Mid-November (Q3)	About 30% up the range, after a 23% drop	?

The weakest set of numbers in the dataset produced the best rally, because the stock went into it already beaten down. The reports weren't verdicts so much as tests of positioning. Q3's setup looks more like March than like May or August. With only three data points, I weight this lightly.

7. The trade, with a Q3 test the bear can hold me to¶

Step	Rule
Starter	Quarter size, sized for a 15% gap: shares = (0.01 × equity) ÷ 4, at $26.66–26.91. A call spread is an acceptable substitute.
Add	Daily close above $27.44 (ideally $27.72) on 8M+ shares, with RSI above 50.
Through Q3	Move exposure into a call spread so the maximum loss is defined. Check `JD`'s own implied volatility. Full-size holders can reasonably use the bear's put spread.
Q3 pass/fail	Revenue growth beats opex growth by 8 points or more (the gap $26.91 needs). Opex ratio below 15.8%. Gross margin at 16% or higher. Operating cash flow up year on year.
Exit	Daily close below $25.71, or Q3 fails the test above.

On the cost of waiting: - The bear's buy trigger, absolute opex down year on year, is my retreat scenario, worth $37–45. - When that prints, the stock won't be sitting at $29. Waiting costs more than the bear's $1–6, because the bear's table leaves out the case the bear says would make it a buyer. - And if Q3 fails, my gap-sized starter loses a fraction of 1% of equity.

Bottom line¶

Buy JD with a small starter sized for gap risk, and add on confirmation. - The bear's "first-ever cut" requirement only appears when 7% growth (subsidies easing) is paired with a flat budget (subsidies not easing). - Pair the inputs consistently, and $26.91 needs either FY2025's growth with 2022–23 cost discipline, or a partial retreat. Both match the median of JD's own recoveries. - The downside in consistent scenarios is low-teens percent. The upside runs to the high-20s and 30s, and the retreat case reaches the 40s.

My question back to the bear: your flat-budget case has JD spending RMB 207bn, the same as the launch year, while revenue growth halves to the 7% you justified by "once subsidies ease." Which is it? - If subsidies continue, what revenue growth do you assume? If it's above about 10%, how does the flat budget remain a downside case? - If subsidies ease, why is opex flat? Bull Analyst: # Bull Rebuttal: JD. You Won the 2026 Argument. The Price Isn't a 2026 Bet.

You asked what probability I put on the opex ratio falling less than a point this year. My answer is 40%. Add that to our scenario table and my $31 becomes about $27, which is your number. I concede it.

Look at what that table does, though. Every row takes one year's EBIT and multiplies it by 8–10x, and a multiple treats that year as permanent. Your "Defend in 2026" row is really "Defend forever." Your FY2022 row is really "a 14.7% opex ratio forever." My table made the same mistake; it just hid it better.

Price the war as something that lasts a number of years and then ends. Then $26.91 requires JD's opex ratio to settle near 14.5% permanently. That is two points above where it ran for the three years before the war. Neither earlier spike in JD's record did that.

All figures are my arithmetic on our agreed basis: - Full credit for cash, 8–10x pre-tax EV/EBIT, about 1.474bn ADS, RMB 6.70 per dollar. - Value per ADS = (EBIT × multiple + RMB 68.8bn) ÷ 9.876. - I use your inputs throughout: +7% revenue and a 16.2% gross margin, your +0.17-point pace. - New this round: a 25% tax rate, and the discount rate each multiple implies (9.4% at 8x, 7.5% at 10x).

1. Your question, answered¶

40% is the weight of my "long war" (25%) and "permanent war" (15%) cases in Section 6. In both, the 2026 ratio falls less than a point.
On the one-year method, here is your table reweighted to put 40% in that bucket:

Scenario	Weight
Retreat	25%
FY2022 repeat	35%
Defend	28%
FY2024 in full	8%
FY2023 in full	4%
Weighted value	≈$27.2

By that method, the stock is fairly priced. If the method were right, I'd wait with you.

2. Other concessions¶

"Escalate" was mislabeled. Its 8.5-point gap was wider than FY2022's. It was a middle case labeled as a downside case.
Gross margin. FY2022's +0.5 points was a rebound. I'm using your +0.17 pace everywhere this round.
Your gap base rate is right. At growth under 20%, JD's best revenue-over-opex gap is 7.6 points. 2026 will probably move more slowly than the one-year method requires.
The March risk is real. The drop can come before the rally. I'm adopting your $24.5–25.2 bid zone (Section 7).
One pushback. Your FY2023 and FY2024 rows combine continuing subsidies with growth below 7%. That's the pairing you withdrew last round. I still include a permanent-war tail anyway, using your Defend row valued exactly as you valued it.

3. Same path, two prices¶

Multiplying EBIT by 8 means assuming that EBIT every year, permanently. That's correct for a business in a steady state. For a business partway through a subsidy war, it treats the subsidy as a permanent cost.

Read your table as permanent states: - FY2022 row: a 14.7% opex ratio forever. - Defend: 15.3% forever. - FY2024 in full: 16.1% forever.

On either of our weightings, that puts 75–80% of the probability on JD running 2.2 or more points above its FY2024 cost structure permanently. That isn't a forecast about how fast 2026 goes. It's a forecast that the war never ends.

Here's what the method does to a single path. Take your slowest precedent, the FY2014 spike. Scale its unwind to today's excess, and let it settle at 13.5%, a full point above pre-war, which is consistent with my earlier concession on the new business mix:

	2026	2027	2028	2029	2030+
Opex ratio	14.9%	14.2%	14.3%	14.6%	13.5%

2026 falls only 0.9 points. That puts this path in your "less than a point" bucket, and it fails my 8-point Q3 test.
Capitalize 2026 (the one-year method): $22–26.
Value it as a path (Section 4): $34–42.

It's the same company with the same costs. The $12–16 difference comes entirely from assuming 2026 lasts forever.

4. Valuing the business and the burn separately¶

Value = what JD is worth at its long-run cost structure, minus the after-tax cost of the excess spending ("the burn") until it gets there.

Inputs: - Revenue of RMB 1,400.7bn, then held flat. No credit for growth. - Gross margin of 16.2%. - Long-run EBIT valued at 8–10x pre-tax. - Burn = FY2025's 15.8% opex ratio minus the long-run ratio, applied to FY2025 revenue. It runs at full launch-year intensity with no taper, is taxed at 25%, and is discounted at the rate implied by the multiple.

Long-run opex ratio	No further burn	+2 years full burn	+4 years full burn
13.0%	$43–52	$38–47	$34–43
13.5%	$38–45	$34–41	$30–38
14.0%	$32–38	$29–35	$26–32
14.5%	$26–31	$24–29	$22–27

Pre-war actual: 12.2–12.5% (FY2022–24).

Where $26.91 sits in this table: - With no further burn, it implies a permanent ratio of about 14.5% (8x) to 14.8% (10x). That's roughly RMB 30bn a year above FY2024's cost structure, forever. - At 8x with a 14% long-run ratio, it implies four more years of full launch-intensity burn with no taper. - Stacking three bear inputs at once also gets you to today's price: - a 7x multiple, a 10.7% after-tax earnings yield that's 5.4 points over the 10-year; - a 13.5% long-run ratio; - four years of burn with no taper.

Together these give $26.6.

5. Where the ratio settles¶

What the precedents show: - Both earlier spikes in the record, FY2014's 16.7% and FY2018's 14.8%, ended in the same place: 13.1% in FY2019. The ratio then fell further, to 12.2–12.5% over FY2022–24. - "Never returned to its pre-spike level" compares against FY2013's 10.7%, which was a one-year low between FY2012's 13.1% and the FY2014 spike. Measured against FY2012, the ratio came all the way back. - Faster growth helped those unwinds happen quickly. So I use them only for where the ratio settled, not how fast it got there.

A permanent ~14.5% requires one of two things: - Food delivery becomes a permanent loss center of about RMB 30bn a year. That's a management choice. You conceded that "if JD walks away from food delivery, earnings will snap back hard." - Competition permanently raises core retail's costs. That would show up in the JD Retail segment margin, which Q3 reports. It's my thesis exit (Section 7).

"Why would year three bring cuts when year two didn't?" It doesn't have to. At 8x, JD can keep spending at full launch intensity for four more years, settle at 13.5%, and still be worth $30–38.

6. Weighted scenarios, with a stress test¶

Scenario	2026 ratio	Long-run ratio	Path	Value (8–10x)	Weight
Retreat	~13.5%	13.5%	Burn ends in 2026	$38–45	25%
Taper (your FY2022 row, continued)	14.7%	13.5%	Excess halves each year	$36–43	35%
Long war (harsher than your Defend)	15.8%	14.0%	Full burn, no taper, 4 years	$26–32	25%
Permanent war (your Defend, valued your way)	15.3%	15.3%	Never ends	$18–21	15%
Weighted				≈$34 (+28%)

Your FY2022 row alone moves from $24–28 to $36–43 once the excess keeps shrinking instead of freezing at its 2026 level.
Stress test:
add 0.5 points to every long-run ratio;
make the permanent tail FY2025's 15.8% forever;
mark Ceconomy at zero (−$1.70 per ADS).

Result: about $27. Today's price is my stress case.

7. The trade, revised¶

You've won the near-term argument, so I'm not buying for the Q3 print. I'm buying because of what the burn actually costs, and setting up to buy more if Q3 disappoints.

Step	Rule
Entry	Same quarter-size total, sized for a 15% gap. Half now at $26.66–26.91. Half on a resting bid at $24.6–25.2, your zone.
Stop (changed)	A weekly close below $24.40, under March's $24.53 close and June's $24.55 low. My old $25.71 stop sat just above the zone where we both want to buy, so it would force selling exactly there.
Through Q3	Hold the event exposure in a call spread expiring after the print. Check `JD`'s own implied volatility first. Full-size holders: your $26/$22 put spread is sensible.
Add to full size	Q3 passes the 8-point test with operating cash flow up, even after a gap. The taper case alone is worth $36–43.
Thesis exit (changed)	Exit on any of: new-business segment losses above Q3 2025's; JD Retail segment margin down year on year; guidance for sustained or higher food-delivery spending into 2027.
Trims	$28.45–28.70, $30 and $33.47. Value sits above all three.

I'm flagging two rule changes rather than burying them: - The stop moved, for the reason in the table. - The Q3 exit changed. Last round, failing the 8-point test meant exiting everything. Now it closes only the call spread. - The 8-point test measures how fast 2026 goes, and speed only matters under the one-year method. - The new exit tests what the price actually depends on: whether the war is becoming permanent.

Bottom line¶

2026 is probably slow. I concede that: a 40% chance the ratio falls less than a point, and about $27 on the one-year method.
The one-year method prices the war as permanent. Three-quarters of your table's weight assumes JD runs 2.2 or more points above its FY2024 cost structure forever.
Valued as a path, $26.91 needs one of three things:
a permanent ratio of about 14.5%;
a 14% ratio reached after four years of untapered burn;
a 7x multiple stacked on four years of burn.

Both earlier spikes settled at 13.1%. - Base case is about $34 (+28%). The stress case is about today's price.

Buy JD: - Take a quarter-size position, half now and half in your bid zone. - Add on a Q3 pass. - Exit on evidence the war is permanent.

My question back to you: what is your long-run opex ratio, and how many years of burn does it take to get there? At 8x, $26.91 needs about 14.5% forever. That's roughly RMB 30bn a year above JD's FY2024 cost structure, permanently. Both earlier spikes settled at 13.1%. Why would this be the first one to become permanent, and what would JD's management have to believe to keep paying for it? Bull Analyst: # Bull Rebuttal: JD. $26.91 Needs You to Win Two Arguments at Once

You made two good corrections. Operating margin is the cleaner unit, because neither of us can see where food-delivery costs land. 10x on a zero-growth model does imply a 7.5% cost of equity, which is too thin for this stock. I'll adopt both and center on 8x.

With those changes, your $26.3 rests on two assumptions stacked on top of each other:

JD keeps none of its gross-margin gain. You hold gross margin at the 16.2% record but take operating margin from FY2019–24, when gross margin averaged 14.6%. That quietly sets the long-run opex ratio at 14.3%, which is higher than every year from FY2019 to FY2024 (12.2–13.1%).
JD never grows again. Revenue stays at RMB 1,400.7bn forever.

Relax either one, at your 9.4% cost of equity and your scenario weights, and the stock is worth $29–32. Today's price sits in the one corner where you win both.

All figures are my arithmetic on the basis we both now use: - Full credit for cash, about 1.474bn ADS, RMB 6.70 per dollar, 16.2% gross margin, 25% tax. - Burn runs at FY2025 intensity and is discounted at 9.4%. - Value per ADS = (EBIT × multiple + RMB 68.8bn − PV of burn) ÷ 9.876.

1. What I concede¶

Operating margin is the right unit. I'll use it from here on.
10x on zero growth is too generous. For any zero-growth valuation I center on 8x, which implies a 9.4% cost of equity, 4.1 points over the 10-year Treasury. I use 10x only with explicit growth (Section 3).
FY2024 is a high-water mark. My line about "two points above pre-war" measured against the record year, and that framing was loaded.
My exits moved, and your bid zone was offered as an alternative, not an addition. I've fixed both in Section 5, with no averaging down.
"New-business losses above Q3 2025's" was a trigger that could almost never fire. I've replaced it.

2. Your first question: my destination isn't `JD`'s best year¶

My destination is your average plus half of the gross-margin gain you're already assuming.

You've mixed two time periods. Your 1.9% operating margin is FY2019–24's average gross margin (14.6%) minus its average opex ratio (12.7%). Then you apply it on top of a 16.2% gross margin. The question that matters is how much of the 1.6-point gross-margin gain survives into peacetime:

What happens to the gross-margin gain (14.6% → 16.2%)	Long-run opex ratio	Operating margin	Opex above FY2024's ratio, per year
All kept (FY2019–24 average opex)	12.7%	3.5%	~RMB 3bn
Half kept (mine)	13.5%	2.7%	~RMB 14bn
None kept (yours)	14.3%	1.9%	~RMB 25bn
FY2024 actual	12.5%	3.34% (on a 15.9% gross margin)	0

JD's record says gross-margin gains reach operating margin unless there's a spending spike. - Gross margin rose in 11 of 13 years. Operating margin rose in 8 of those 11. - The three exceptions are FY2014, FY2018 and FY2025, which are exactly the three opex spikes. - Outside a spike, JD has never had a year where gross margin rose and operating margin didn't. - In FY2022–24, its last peacetime run, gross margin rose 1.8 points and operating margin rose 1.45. About 80% was kept. I assume 50%. You assume none.

Spikes have left no permanent damage, measured against where they started.

Spike	Before	Spike year	After	Permanent residue
FY2014 (opex)	13.1% (FY2012)	16.7%	13.1% (FY2019)	None
FY2018 (opex)	14.3% (FY2017)	14.8%	13.1% (FY2019)	None; ended below where it started
FY2021 (operating margin)	1.65% (FY2020)	0.44%	1.89% (FY2022, at +9.9% growth)	None; ended above where it started, in one year
FY2025 (opex)	12.5% (FY2024)	15.8%	?	Mine: 1.0 pt (~30% of the spike). Yours: 1.8 pts (~55%)

"Both spikes settled at 1.56%" describes a level reached on a 14.6% gross margin. The actual pattern is that the margin after each spike ended above the margin before it. FY2019's 1.56% beat both earlier pre-spike margins (−0.2% and −0.6%).
Your median also counts FY2021, a spike year. You called FY2022's gross margin a "rebound" from FY2021's drop. A year you treat as abnormal for gross margin can't be normal for operating margin. Excluding it, the median of JD's profitable years is 1.89% and the mean is 2.17%. At 8x with no further burn, the price implies 1.76%.

Slow recovery is already charged through the burn. You're right that the FY2014 unwind ran on scale, and that the opex ratio rarely falls fast at single-digit growth. That's why the path model charges two to four years of launch-intensity burn. The one low-growth year that followed a margin hit (FY2021 → FY2022) recovered past its starting margin in a single year. If you charge a slow recovery through the burn and then again through a permanently worse destination, you've counted it twice.

We now agree that peace costs more than FY2024 did. We disagree by RMB 11bn a year. Your argument that the core business is under threat is an inference, and the data line where a threat would show up first, gross margin, hit a record. Q3's JD Retail segment margin tests it directly. It's your buy trigger and now my exit trigger, so we've agreed on what settles it.

3. Your second question: 10x is your 9.4% cost of equity plus 2% growth¶

The math: 0.75 ÷ (9.4% − 2%) ≈ 10.2x pre-tax. I'm not asking for a lower discount rate. I'm asking for 2% growth.

Why 2% is conservative - It's below every year in JD's 14-year record. The lowest was +3.7% (FY2023), and FY2022–25 compounded at 7.8%. - Your model has a company that just grew 13% never selling another yuan more in nominal terms.

How much opex growth costs: a proportional amount. - A constant-margin perpetuity already has opex growing with revenue. Rising absolute opex in 13 of 13 years is what a stable ratio looks like. - From FY2019 to FY2024, revenue doubled (RMB 577bn → 1,159bn) while the opex ratio stayed between 12.2% and 13.1%. - That growth came without a subsidy war: +9.9%, +3.7% and +6.8% in FY2022–24. - I assume no operating leverage from growth at all.

How much capital growth costs: little. - Current liabilities exceed non-cash current assets by about RMB 69bn, so working capital funds itself. - Tagged capex is about 0.6% of revenue. It may understate true capex, so I'm taking no credit for float growth.

Your table, with growth added and nothing else changed:

Scenario	Weight	Your destination	8x, zero growth (yours)	9.4% cost of equity + 2% growth
Retreat	25%	2.4%	$34.2	$41.6
Taper	35%	1.9%	$27.9	$33.7
Long war	25%	1.56%	$21.0	$25.8
Permanent war	15%	~0.9%	$18.1	$21.1
Weighted			$26.3 (−2%)	$31.8 (+18%)

At 1% growth, about a quarter of JD's worst year, your table gives $28.7.
Your destinations only get back to $26.91 at about 0.25% perpetual growth.
Mark Ceconomy at zero (−$1.70) and the 2% column still gives $30.1, or +12%.

4. The whole debate in one table¶

	8x, zero growth	9.4% cost of equity + 2% growth (≈10.2x)
Your destinations (none of the gain kept)	$26.3 (−2%)	$31.8 (+18%)
Midpoint destinations	$28.7 (+7%)	$35.0 (+30%)
My destinations (half kept)	$31.1 (+16%)	$38.3 (+42%)

Five of six cells sit above today's price, and four are at +16% or more.
The price only works where you win both arguments: no gross-margin gain kept, and no growth ever.
I'm not claiming $38. My claim is that you need both of those assumptions at once, and JD's record supports neither.

5. The trade, with rules I won't move again¶

The exits moved because the thesis moved from a chart setup to a valuation of the recovery path. That's a real reason, but it meant the old stops no longer fit the argument. Here is one fixed set. If I move them again, count it as a concession.

Step	Rule
Starter (now)	Half of the gap-sized quarter position at $26.66–26.91: shares = (0.005 × equity) ÷ 4. A 15% gap costs 0.5% of equity.
No averaging down	The second half is added only on Q3 evidence, never on price weakness. Your $24.5–25.2 zone stays your alternative entry, not my add.
Price stop	Weekly close below $24.40, under the March and June lows, means exit everything.
Q3 exit (either one)	JD Retail segment margin down year on year, or new-business losses not lower year on year. Exit everything, not just a hedge.
Q3 add (all three)	New-business losses down 25% or more year on year, JD Retail margin up year on year, and operating cash flow up year on year. Add the second half, even after a gap.
Anything in between	Hold the starter and don't add.

Why these thresholds? - They map onto the scenarios. Taper halves the excess spending (losses −50%); long war keeps it flat (0%). 25% is the line between them. - If losses aren't falling, long war on my destinations is worth about $26, today's price. There's no edge left, so I leave.

Practical notes - Segment data isn't in our feed, so confirm JD reports it and confirm the Q3 date. - Today's TD 9 count and the Oct 12 death cross don't change any of these rules. - For full-size holders, your $26/$22 put spread is reasonable.

Bottom line¶

Buy JD: a half-size starter now, add only on Q3 evidence, and exit on a Q3 failure or a weekly close below $24.40.

I've accepted your units and your discount rate. That means operating margin, 8x for zero growth, and a 9.4% cost of equity.
Your $26.3 needs two things together:
JD keeps none of its 1.6-point gross-margin gain, even though it kept about 80% in its last peacetime run and every gain outside a spike reached operating margin (8 for 8).
JD never grows again, even though its worst year was +3.7%.
Drop either assumption and your own table says $29–32. Drop both and it's $38.

My question back to you: which of the two will you defend? - (a) No gross-margin gain survives. Then name the non-spike year in which JD's gross margin rose and its operating margin didn't. - (b) Zero growth forever. Then name the year JD grew less than 2%.

If you keep both, the price is fair. If you drop either, your own numbers say buy.

Bear Researcher¶

Bear Analyst: # Bear Response: JD. The Bull Is Paying for a Recovery That's Already in the Price

The bull's case rests on one assumption: that FY2025's surge in operating expenses reverses quickly. Every supporting number comes from a fiscal year that ended nine months ago, and the only 2026 evidence we have points the other way. The current price already assumes a recovery like FY2019's. The proposed trade also runs into the busiest event calendar of the year with a stop that is more likely to gap than fill.

I'll start with the bull's question, because the answer undoes most of the argument.

1. What opex ratio does $26.91 imply? About 14%, which is the bull's own precedent, already paid for¶

My assumptions: - FY2026 revenue of about RMB 1,400bn, up 7%, which is back to the 2022–24 trend once subsidies ease. - Gross margin held at its record 16.0%. - A pre-tax EV/EBIT multiple of 8–10x, reasonable for a China ADR with a VIE structure when the US 10-year pays 5.3%.

EV basis (no debt, using the bull's convention)	EV (RMB bn)	Operating income needed at 10x / 8x	Implied 2026 opex ratio
The bull's: full credit for cash	~198	~20 / ~25	14.2–14.6%
Half credit for cash	~266	~27 / ~33	13.6–14.1%

$26.91 already prices in an opex ratio of roughly 13.6–14.6%. That's 1.2 to 2.2 points of improvement from 15.8%.
The bull's own precedent, FY2018 to FY2019, delivered 1.7 points. Even at a generous 12x, the price still assumes about a full point (around RMB 13bn) of recovery.
The market is not pricing a broken business. It is pricing a normal recovery. The bull's upside needs a full return to 12.5% and a re-rating, and the bull has already conceded that rates cap the re-rating.
On actual trailing results, JD is expensive. RMB 2.8bn of operating income against an EV of RMB 198–266bn is about 70–95x EV/EBIT.

2. The "spending decision" is a price war, booked below gross profit¶

The bull says that if JD were losing a price war, gross margin is where it would show. That's the wrong line. JD books fulfillment and marketing as operating expenses below gross profit. Rider costs, delivery costs and consumer coupons in a food-delivery war all land in opex. The price war did show up: it is the 42.8% jump in opex.

Here is what the faster revenue growth cost:

FY2024 → FY2025	Change (RMB bn)
Revenue	+150.3
Gross profit	+26.2
Operating expenses	+62.2
Operating income	−36.0

Every RMB 100 of added revenue cost about RMB 24 of operating profit.
The 13% growth the bull calls "the strongest it has been" was bought with subsidies.
You can't keep the subsidized revenue and drop the cost that produced it. Remove the subsidies and growth falls back toward the 3.7–9.9% of FY2022–24.

3. The 2018 → 2019 playbook doesn't carry over¶

It's worth checking how the bull's key precedent actually worked.

FY2019 needed no cost cuts.
Revenue grew 24.9%, and opex still grew about 10% in absolute terms (roughly RMB 68.7bn to 75.2bn).
The ratio fell only because revenue outran costs.
FY2026 has no such tailwind. Growth without subsidies is mid-single digits, so the ratio can only fall through real cuts.
Getting back to 12.5% means cutting RMB 22–32bn of absolute opex (−11% to −16%), depending on whether revenue grows 13% or 7%.
Even repeating 2019's 1.7 points requires cutting about RMB 10bn.
Those cuts would come mid-fight against Meituan, the established leader, and Alibaba. Cutting means giving back market share that JD just spent RMB 40bn+ to win.

Management's recent actions also point to expansion, not retrenchment: - Launching 7Fresh Kitchen "Chef Transformer", a further push into fresh food and food delivery. - Buying Ceconomy for about $2.5bn. - Being part of the "Chinese retailers launch UK land grab" story.

4. The only 2026 evidence points the other way¶

The bull calls the Aug 13 gap the bear's strongest point, then dismisses it as priced in. Here's the record:

The gap came in JD's usual Q2 reporting window. The tools can't confirm the cause, but the stock fell −7.3% on 32.1M shares, about 5x normal volume.
It kept falling for seven more weeks, another −12% to $25.78. The market didn't price the news in on the day; it kept repricing for weeks afterward.
Arete then downgraded JD to Neutral and cut its target from $36 to $30. Arete has seen the Q2 numbers. We haven't.

The bull uses Arete's $30 as an upside target but ignores the rating attached to it. A Neutral rating with 11.5% upside means "fairly valued." That 11.5% is only about 6 points more than the 5.28% risk-free 10-year yield, in exchange for China ADR, regulatory and earnings risk.

If Q2 had shown opex falling, why the gap on 5x volume, seven weeks of further decline, and a downgrade from a firm that had been rating it Buy?

5. The valuation treats assets and liabilities unevenly¶

Earnings quality - Operating income was RMB 2.8bn against roughly RMB 19bn of net income. - By my rough math, well over 80% of the bottom line came from interest and investment income. - That income shrinks as the cash is spent.

The cash isn't spare - Current liabilities are RMB 306bn, mostly owed to suppliers. - Working capital is only RMB 68bn, down 22% in a year. - Cash rose mainly because JD liquidated RMB 41.8bn of investments. That moved money between accounts; it didn't create new money.

Debt is left out - The bull credits every yuan of cash but deducts nothing for borrowings or lease liabilities. - Those sit inside RMB 95bn of non-current liabilities, which grew 11.6% last year. - So the bull's "harshest" valuation scenario isn't actually harsh.

The balance sheet is moving the wrong way - Shareholders' equity fell 6%. - Liabilities rose to 57.7% of assets. - The current ratio slipped from 1.29x to 1.22x. - Operating cash flow dropped from about 1.4x net income to about 1.0x, so the benefit of being funded by suppliers is narrowing.

The 2026 cash gap - Repeat FY2025's free cash flow (about RMB 11bn) and capital returns (about RMB 27bn), then add Ceconomy (about RMB 17bn). - That leaves a gap of about RMB 32bn, roughly a quarter of the cash pile. - If buybacks are what gets cut, the stock loses one of its few steady buyers.

None of this threatens solvency. The point is that "half the market cap in cash" overstates what shareholders actually own.

6. The macro backdrop has changed since the last two bounces¶

The +38% and +33% rallies both happened before September 17. Since then: - The Fed hiked, taking the effective rate to 3.88%. - The ECB hiked to 2.50%. - The US 10-year yield rose 53bp in five weeks, to 5.28%. - The dollar rose about 3.3%. - WTI is around $96, after peaking at $107.

"Short duration" misreads how rates hurt China ADRs. The damage comes through money leaving emerging-market and US-listed China stocks, not through discount math. Barron's tied Alibaba's drop directly to Treasury yields.

"The 2-year yield hasn't moved" actually hurts the bull's case. - It means the selloff is in long-dated bonds, driven by fiscal and inflation worries rather than Fed expectations. - A dovish Fed won't fix that. - Yahoo warns that rapid yield moves have preceded "nearly every major financial blowup." - Meanwhile the VIX is at 15. If stock-market volatility catches up with bond-market volatility, high-beta China ADRs fall first.

Oil hits the exact line the bull needs to fall. JD runs its own logistics fleet, so fuel goes straight into fulfillment costs. Oil also squeezes Chinese consumers, since China imports most of its oil.

The yuan doesn't matter much here. A 1% currency move on RMB 3bn of operating income is noise compared with one opex point worth about RMB 13bn.

Regulatory risk isn't confined to Alibaba. JD also fell on the Alibaba AI-probe headline.

7. The chart shows a bounce inside a downtrend, with nothing confirming it¶

SuperTrend is down on daily, weekly ($31.63) and monthly ($41.83) charts.
RSI hasn't closed above 50 since at least Aug 24. Its peak was 47.95. Swinging between 30 and 50 is what RSI typically does in a downtrend, so holding 30 three times is normal behavior, not a reversal signal.
MACD is still at −0.46. Bullish crossovers below zero during downtrends often fail.
On-balance volume hit a new low with price on Oct 2, and the bull concedes this. The selling came on 32M shares; the bounce came on 6.7–7.4M.
Price stopped at $27.04 two days in a row. Resistance is stacked above:
$27.04, $27.44, $27.58 and $27.72.
Then the moving averages at $28.49–28.72.
Then everyone who bought at $28–33 in August, including Tiger Global at a reported cost of about $33.70.
The weekly TD 9 isn't evidence. The bull says they would "gladly take" it failing. A signal that's bullish whether it completes or cancels tells us nothing. Its typical 1–4 bar bounce may also be finished already, after +4.4% in four sessions.
Lower volatility doesn't mean sellers are tired. The technical report says compression "often comes before a bigger move in either direction," and the calendar below is full of triggers.
The range top is where recovery hopes have been sold, not a target. The market pushed the stock to about $33.5 on May 13 and again on Aug 10, and sold it both times.

8. The trade's 5:1 depends on its least likely target¶

The bull's entry ($26.66–26.91) and stop ($25.65) are the technical report's Scenario B. The report rated that setup at 1.6–1.7:1 to $28.45 and flagged the lack of volume confirmation. The bull kept the entry and stop and swapped in a more distant target.

Target from $26.91 (risk $1.26)	Reward to risk	What it requires
$28.45–28.70	1.2–1.4:1	Breaking through five resistance levels and a fresh death cross
$30	2.5:1	Matching the target of an analyst who just downgraded the stock
$33.47	5.2:1	A +24% gain in about five weeks, through the weekly SuperTrend, with the 10-year at 5.3%

The bull plans to trim before Q3, so the real window is about five weeks. It contains: - Today: the weekly close decides the TD 9. - About Oct 12: the death cross, which can trigger automated and headline-driven selling. - Mid-October: US September CPI. - Oct 27–28: FOMC, with a risk of a second hike. - Late October: Singles' Day presales, the peak subsidy period, which pressures the opex ratio the bull needs to fall. - Nov 3: US midterms, after which the Iran-strike risk returns. - Mid-November: Q3 results.

A stop 6 cents below a swing low that every chartist can see won't protect against a 7% gap, and JD showed in August that it gaps. The bull's "defined risk" isn't actually defined.

9. The catalysts are weaker than they look¶

Ceconomy - It's "poised to win" approval, so approval is largely expected and could trigger selling on the news. - The deal concessions were revised after rivals objected. - JD is buying a low-margin European retailer just as the ECB hikes. - Once Ceconomy is consolidated, it will also muddy the opex-ratio signal the bull is waiting to see.

Singles' Day is when subsidies peak, not when they end. Nike pulling back from discount-heavy China online channels shows how intense the price war is.

Sentiment gives no edge: - The split among labeled posts is 57% bull / 43% bear. - Three of the eight bullish tags come from one user. - Someone is promoting the $25 calls. - A glitch showed a false $28.50 price.

10. What I concede, and what would change my mind¶

What I concede: - The balance sheet is safe. - The gross margin is excellent. - If JD walks away from food delivery, earnings will snap back hard. - The pattern of higher lows is intact for now.

I don't need to prove JD overspends "indefinitely." I only need three things to hold: - Normalization is slower and smaller than the bull assumes. - The price already reflects a reasonable recovery. - The next five weeks are stacked against a long position.

I'd turn constructive on: - A Q3 report with the opex ratio clearly below 15.8% and operating cash flow recovering. - A daily close above $27.72 on more than 8M shares, with RSI above 50. - The 10-year falling back below about 5%.

I'd rather buy JD at $29 with proof than at $26.91 on hope. The cost of waiting is a few dollars of upside. The cost of being wrong is a third failed bounce in a stock that has twice been sold at the top of its range.

Bottom line¶

Don't own JD through this cluster of events. - Holders: hedge through Q3. - Tactical traders: consider a short in the $27.4–27.7 resistance zone, with a stop above $27.95 and targets of $25.97 and then $25.71 (about 3:1). - If $25.71 breaks: that is the year's first lower low, which opens the way to $25.19 and then $24.55.

My question back to the bull: name one 2026 data point showing JD's opex ratio below 15.8%. If there isn't one, the thesis is a forecast about how management will behave. That is exactly what the market has already priced. The Q2 reaction, the Arete downgrade and the 7Fresh launch all argue against it. Bear Analyst: # Bear Rebuttal: JD. "Two-Thirds of the Excess" Is Just Last Year's Budget

This is the bull's strongest round so far. It accepted my valuation inputs and asked a precise question. If I answer that question in yuan rather than in "shares of excess," most of the debate resolves. The price doesn't assume JD keeps spending heavily. It assumes JD cuts its absolute cost base, which it hasn't done once in 14 years of data.

All figures below are my arithmetic on the reports, using the bull's accepted inputs: - FY2026 revenue RMB 1,400bn (+7%), gross margin 16.0%, 8–10x pre-tax EV/EBIT. - About 1.474bn ADS, RMB 6.70 per dollar. - RMB 137.5bn cash and RMB 68.7bn minority interests.

1. Where the bull is right¶

Leases. Under US GAAP, operating lease cost already sits inside opex. Deducting lease liabilities from EV would count the rent twice. I withdraw that point. Borrowings are still unknown, and I'll stop relying on them.
My short had the same gap risk I flagged in your long. I'm replacing it with a defined-risk structure (Section 7).
Singles' Day is seasonal and is in every year's baseline. I withdraw it as an opex argument.
Oil is minor next to subsidies. Agreed.
Pairing 7% growth with sticky spending needs an explanation. It gets one below.

2. Your question, answered in yuan¶

The 12.5% baseline grows with revenue. At 7% growth, about a quarter of the "excess" disappears even if JD doesn't cut a single yuan. In absolute terms:

What $26.91 implies	Opex ratio	FY2026 opex (RMB bn)	Change vs FY2025's 207.3
Full credit for cash, 10x	14.6%	~204	−1.4%
Full credit for cash, 8x	14.2%	~199	−3.8%
Half credit for cash, 10x / 8x	14.1% / 13.6%	~197 / ~191	−4.8% / −8.0%
Flat budget, for reference	14.8%	207.3	0%, which is ~74% of your "excess" kept

So "why would two-thirds of the spending stay?" really asks "why wouldn't JD trim its budget by more than 1.4%?" The history answers it:

FY	Opex (RMB bn, derived)	Opex change	Revenue change
2019	75.2	+9.5%	+24.9%
2020	~97	+29%	+29.3%
2021	~125	+29%	+27.6%
2022	~128	+2.3%	+9.9%
2023	~133	+4.5%	+3.7%
2024	145.1	+8.8%	+6.8%
2025	207.3	+42.8%	+13.0%

What the table shows: - Absolute opex rose in all 13 year-over-year comparisons in the dataset (FY2012–25). - Both "recoveries" you cite, 2019 and 2022, came from spending growing slower than revenue. Neither came from cuts. - The leanest year on record was +2.3%. Today's price already requires JD to beat its most frugal year by roughly 4–10 points of opex growth.

Why the budget stays even as growth slows: 1. Second-year spending defends; it doesn't grow. - FY2025's +13% was a one-time jump from adding a new category. - Holding that higher level takes continued spending, but it doesn't repeat the growth rate. - Slowing growth on a flat budget isn't a contradiction. It's what year two of a subsidy war looks like. - You conceded the key unknown yourself: "whether customers stay once coupons shrink." 2. There are three players. A unilateral cut hands share to Meituan, the leader, and to Alibaba. Entering the fight was discretionary. Leaving it isn't, unless you're willing to give up what you paid for. 3. Some of the spending is no longer subsidy. - Capex rose 46%, and tagged capex may understate the true figure. That depreciation flows into opex for years. - My reasoning, not reported data: food delivery costs more to serve per order than retail. Unless JD exits the business, the normal ratio for the new mix sits above 12.5%. 4. Management is adding, not subtracting: the 7Fresh Kitchen launch and the Ceconomy deal. 5. Regulatory summons (outside our data): if they happened, they happened in 2025. Opex still rose 42.8% that year.

Your dilemma has a third branch. You argue that if subsidies don't ease, revenue grows nearer 13% and "lowers the ratio on its own." - In FY2025, opex grew 3.3x faster than revenue. - A ratio that falls on its own needs growth nobody pays for, and you've just argued that kind of growth doesn't exist. - Your full-recovery case has the mirror-image problem. It keeps RMB 1,400bn of revenue while removing three-quarters of the subsidies that helped produce it. That's keeping the growth and saving the cost, the same inconsistency you charged me with.

3. Your valuation changed its cash assumption mid-argument¶

When answering my debt point, you used zero credit for cash.
When computing upside, "halfway = $28–33" uses full credit.
On half credit (my second EV row, which you accepted), the halfway case is $21–26, below today's price.

Here is every scenario on your most favorable basis, full credit for cash:

FY2026 opex vs FY2025	Opex ratio	EBIT (RMB bn)	Value per ADS at 8–10x
+2.3% (repeat of `JD`'s leanest year)	15.2%	11.9	$16.6–19.0
Flat budget	14.8%	16.7	$20.5–23.9
−1.4% to −3.8%	14.2–14.6%	20–25	$26.91 (today)
−4.4% (your "halfway")	14.15%	25.9	$28.0–33.2
−15.6% (full recovery)	12.5%	49.0	$46.7–56.6

What the table shows: - Upside to your halfway case is $1–6. Downside to a flat budget is $3–6. Downside to a repeat of JD's most disciplined year is $8–10. - Full recovery is a real tail, and I've said so. But it needs a double-digit cut in the middle of a fight. Your own quarter-size position suggests you don't treat it as the base case either.

8–10x pre-tax isn't a trough multiple. - After a 25% tax, it equals 10.7–13.3x earnings, an earnings yield of 7.5–9.4%. - Against a 5.28% 10-year yield, that's a 2–4 point premium for a VIE-structure ADR in the middle of a regulatory headline cycle. - If anything, the multiple is generous. A lower multiple would mean the price requires even deeper cuts. - "Credit for 2027" requires explaining why year three brings cuts when year two didn't.

Q2 moved expectations toward my case. On the same basis: - At $33.47, the stock implied an absolute cut of about 5–8%. - After Q2, the market marked that down to about 1.5–4%. - The real 2026 data pointed toward "cuts aren't coming," and the price still assumes some.

4. Applying your method to all three reporting windows¶

Window	Event	What followed
Early March	FY2025 report; stock already crashed to $24.53	+38% rally
Mid-May (Q1)	Year's high close of $33.77 on May 13	−25% to $25.19 by Jun 25
Mid-Aug (Q2)	−7.3% gap on 5x normal volume	−23% from the $33.47 peak to $25.78

What the table shows: - The only window followed by a rally came after the stock had already fallen into it. - Both windows that delivered 2026 quarterly numbers marked the top and were followed by drops of 23–25%. "Q1 was well received" held for about a day. - In 2026, the rallies have been hope and the reports have been the verdicts. Both verdicts were negative.

The other price evidence is weaker than it looks: - The "higher low" after Q2 is 2.3% above June's low and a week old. - Your Sep 17 starting point is the day of a swing low. A lower low followed before today. - The tape is mixed. The sentiment report also logs "JD Fell More Than Broader Market" in late September and China lagging an up market on Oct 8.

5. Free-cash-flow yield and book value repeat the same bet¶

The RMB 53.5bn of "normal" free cash flow was earned at a 12.5% opex ratio. Calling it normal assumes the conclusion. It isn't independent evidence.
Trailing free cash flow of RMB 11.2bn is 3.3% of EV with zero credit for cash and 5.7% with full credit. That's roughly the 5.28% Treasury yield, with China ADR risk on top. Tagged capex may also understate the true figure.
Capital returns of RMB 26.7bn against RMB 11.2bn of free cash flow were paid by liquidating investments. That's handing back the same cash you've already credited in EV. It should be counted once, not twice.
The 17–18% ROE you cite was earned at a 12.5% opex ratio.
Today, operating income after a notional 25% tax is about RMB 2bn on RMB 225bn of equity.
That's under 1%, before subtracting the minority holders' share.
The ~8% headline ROE is mostly interest income, earned on cash that Ceconomy and buybacks are spending.

6. The trade: we agree on what proof looks like¶

Your revised trade is my trade plus a starter position: - Quarter size. - My confirmation trigger. - Defined risk through Q3. - An exit if opex doesn't improve.

"Proof arrives as a gap up"? So does disproof, as a gap down. Both 2026 quarterly reports were followed by drops of 23–25%. The cost of waiting compares like this: - If Q3 shows absolute cuts, the halfway case is $28–33, and I pay $1–6 more by waiting. - If it doesn't, a flat budget is worth $20.5–23.9, and your starter loses $3–6.

That's an even trade at best, with 13 out of 13 years of history favoring my side.

Who	Action
New money	Don't start a position before Q3. Confirm the report date.
Holders	Hedge with a put spread of about $26/$22 expiring after Q3. The $22 strike sits at the flat-budget value. Alternatively, collar against calls near $30, Arete's target. Check `JD`'s own implied volatility first.
Tactical bears	Use the same put spread instead of shorting the stock. If you do short stock at $27.4–27.7, size it for a 15% gap up (about $4 a share), the same rule you applied to yourself.
Breakdown	A daily close below $25.71 is the year's first lower low. Next levels are $25.19, then $24.55.
Near term	Today's weekly close decides the TD 9 count. The death cross arrives around Oct 12.

What would make me a buyer, even after a gap up: - Q3 shows absolute opex down year on year, with new-business losses shrinking and operating cash flow recovering. A ratio improvement alone isn't enough, because against launch-year comparisons that's a low bar. A real absolute cut would break a 13-year pattern, and I'd pay up for it. - On the chart, a close above $27.72 on more than 8M shares, with RSI above 50. - On rates, the 10-year back below about 5%.

Bottom line¶

Avoid JD until Q3. At $26.91, the price already assumes JD cuts its absolute operating budget by 1.4–8%. In 14 years of data it has never cut it at all. Its leanest year was +2.3%, which on your own most favorable basis implies $17–19.

Your halfway case only clears today's price if you give full credit to cash that is being spent. Both 2026 quarterly reports were followed by declines of about a quarter.

My question back to the bull: name the year. Today's price needs a 1.4–8% cut, your halfway case needs 4.4%, and your full recovery needs 15.6%. Why will FY2026 be the first year JD cuts its absolute budget? That's year two of a three-way fight, with 7Fresh Kitchen launching and Ceconomy closing. Bear Analyst: # Bear Rebuttal: JD. Your "Escalate" Case Is More Disciplined Than JD's Best Low-Growth Year

You caught me pairing a flat budget with 7% growth, and your annualization point is fair. I'll fix it.

Fixing it consistently exposes the same flaw, in reverse, in your table. All four of your scenarios have the opex ratio falling at least a full point. The one you call "escalate" is more disciplined than FY2022, your own best analogue.

Correct that and one gross-margin input. Keep your weights and full credit for cash. The expected value is then about $27.7, or +3%, five weeks before a print that settles the question.

All figures are my arithmetic on the reports, on your basis: - Full credit for cash, 8–10x pre-tax EV/EBIT. - About 1.474bn ADS, RMB 6.70 per dollar. - Value per ADS = (EBIT × multiple + RMB 68.8bn) ÷ RMB 9.876bn.

1. What I concede¶

Flat budget with 7% growth was a mismatched pair. If subsidies continue, the business that ramped in 2025 annualizes and revenue grows faster than 7%. I withdraw it as my downside case.
"First-ever absolute cut" depended on 7% growth. At 13% growth, the price allows opex to rise. The test that holds at every growth rate is the gap between revenue growth and opex growth (Section 3).
Full credit for cash. It's the convention behind the multiple we're both using. I'll use it throughout, and half credit becomes a stress test only. The half-credit case also ignored JD's non-current investments.
JD can cut. FY2022 likely included a cut to discretionary spending inside a rising total.
Depreciation from new capex is immaterial.
Gross margin usually rises. I keep it rising in every scenario below except your retreat case, which I use as you wrote it.
Quarter size for a 15% gap is sound risk management.

2. "Which is it?" Both branches, each paired consistently¶

If subsidies continue, revenue grows faster than 7%, and so does opex. Annualization works on both lines. - A food-delivery business that ramped through 2025 brings a full year of riders and per-order subsidies into 2026, along with a full year of orders. - If exit-rate revenue was above the FY2025 average, exit-rate opex was too.

Here's what your +13% case asks of the cost line: - Last year: each extra RMB 100 of revenue came with RMB 41 of extra opex (62.2 ÷ 150.3). - Your case: RMB 170bn of new revenue arrives with only RMB 5–10bn of new opex, or RMB 3–6 per 100. - History: that matches JD's two best years ever (FY2022: 3.1; FY2019: 5.7). Those increments came from core retail. Food-delivery revenue needs a rider for every order (my reasoning, not reported data). - Keeping subsidized growth while dropping its cost is the mismatch you charged me with.

If subsidies ease, opex falls and revenue slows. Growth could drop below 7% if coupon-driven customers leave, which you've conceded is the real unknown.

So the consistent "subsidies continue" case isn't a flat budget. It's Defend: - Revenue +11%, opex +7%. - The ratio still falls 0.6 points from operating leverage. - Worth $18–21.

Defend is generous. In FY2023 and FY2024, JD's last two ordinary years, opex grew faster than revenue.

3. The gap the price needs, against `JD`'s record¶

Your "ratio factor" table mixes years with very different growth rates. On full credit, $26.91 needs revenue growth to beat opex growth by 8.3–10.8 points, at every growth rate in your table.

FY	Revenue growth	Opex growth	Gap (pts)
2019	+24.9%	+9.5%	+15.4
2020	+29.3%	≈+28%	≈+1
2021	+27.6%	≈+29%	≈−2
2022	+9.9%	+2.3%	+7.6
2023	+3.7%	+4.5%	−0.8
2024	+6.8%	+8.8%	−2.0
2025	+13.0%	+42.8%	−29.8
Priced at $26.91			+8.3 to +10.8

The wide gaps all came with fast growth. Across all 13 year-over-year comparisons, JD opened a gap of 8.3 points or more four times (FY2013, 2015, 2016, 2019). Each time revenue grew roughly 25% or more, which pushes the ratio down almost automatically.
The low-growth record falls short. In the four years JD grew less than 15%, its best gap was FY2022's 7.6. That's just short of the price at 10x and well short at 8x.
Your "median of recoveries" mostly reflects high growth. Two of the three are 57%- and 25%-growth years. The one recovery at today's growth rates doesn't clear the bar.
The only precedent for a multi-point opex spike points to a slow recovery. In FY2014 the ratio jumped from 10.7% to 16.7%. It took five years to get back near 13% and never returned to its pre-spike level. Some of 2014 was probably IPO-year non-cash charges, so I weight it lightly.

4. Your scenario table, corrected¶

First, your "escalate" uses 2023's cost growth with 2025's revenue growth. - That's half a precedent, the exact charge you made against my "leanest year" case. - Its 8.5-point gap is wider than FY2022's 7.6, so your downside is more disciplined than your base case. - All four of your scenarios put the ratio at 14.8% or lower. You assign zero weight to the ratio falling by less than a point.

Second, FY2022's +0.5-point gross-margin gain was a rebound. - It followed FY2021's one-point drop and didn't even regain FY2020's level. - Today gross margin is at a record and rose only 0.17 points last year. - At last year's pace, "repeat FY2022" is worth $24–28. That's today's price. - At your four-year average (+0.6), your $28–34 holds. That one input accounts for all of the upside in your base case.

Scenario	Revenue	Opex	Gross margin	Opex ratio	EBIT (RMB bn)	Value
Retreat (as you wrote it)	+7%	−10%	16.0%	13.3%	37.5	$37–45
Repeat FY2022, at 2025's gross-margin pace	+9.9%	+2.3%	16.2%	14.7%	21.1	$24–28
Defend (subsidies continue, costs annualize)	+11%	+7%	16.2%	15.3%	13.7	$18–21
Repeat FY2024 in full	+6.8%	+8.8%	17.2%	16.1%	15.1	$19–22
Repeat FY2023 in full	+3.7%	+4.5%	16.6%	16.0%	9.3	$14.5–16.5

I'm not disputing that retreat exists, only its weight. If subsidized customers leave and growth drops to 3%, retreat is worth $30–36, which is still the upside tail.

Probability-weighted values: - Your weights (25/40/25/10): put Defend in your "escalate" slot and FY2024-in-full in the mismatched slot. Result: about $27.7, +3%. - My weights: retreat 20, FY2022 35, Defend 30, FY2024 10, FY2023 5. Result: about $26, −3%. - On half credit for cash, every value drops about $7.

Both weightings say the stock is fairly priced within ±3%. That expected gap is smaller than one year of the 10-year's 5.28% yield, and it comes five weeks before a print that decides which row we're in.

5. Full credit for cash, with two caveats¶

The supplier float doesn't grow automatically at low growth. - In FY2023 (+3.7% revenue), current liabilities were flat (266.6 → 265.7) and cash fell from 78.9 to 71.9. - In FY2025, current liabilities rose RMB 6.6bn, yet operating cash flow fell 67%. - In your retreat case, subsidized volume shrinks, so the float is more likely to stall than grow.

Ceconomy will spend part of the cash we're both crediting. - About RMB 17bn leaves in 2026 for a low-margin European retailer, just as the ECB is hiking. - Full credit assumes the deal is worth what JD pays. Neither of us has Ceconomy's numbers.

6. Your March analogy points at your own stop¶

In March, the stock fell into the report and bottomed at $24.53 before rallying. If Q3 repeats that pattern, the drop comes first: −9% from here, through your $25.71 exit.
Positioning isn't washed out.
March was the year's low after a crash.
Today the stock is 30% up its range, with bullish options flow and retail leaning 57/43 bull.
Someone is promoting $25 calls, and Tiger Global sits underwater at about $33.70.
So your analogy argues for a bid near $24.5–25.2, not a starter at $26.91 with a stop above that zone.

7. The Q3 test and the cost of waiting¶

I accept your pass/fail test, with two notes. - Your 8-point pass mark is above FY2022's 7.6, so you're asking Q3 to beat JD's best low-growth year. - In your favor: Q3 2025 was a launch-year base, so one quarter passes more easily than a full year. That's why including operating cash flow recovery in the test was right.

What waiting costs:

Q3 outcome	What happens if I wait
Pass, pointing to retreat	Your value is $37–45. Buying after a 15% gap, around $31, still leaves $6–14 with the main question answered. Waiting costs me about $4 of the move.
Fail	Defend and repeat-FY2024 values are $18–22. Waiting avoids that drop entirely.

Your starter risks about 1% of equity on a 15% gap in either direction. That's sound sizing, but on the corrected numbers it's a coin flip with no edge.

The real difference between our plans is one quarter-size position held for five weeks. I'd rather not hold it through CPI, the FOMC, the death cross and the print.

8. What to do¶

Who	Action
New money	Wait for Q3 and apply your pass/fail test. Confirm the report date.
If you must own it before Q3	Bid $24.5–25.2, where the March and June lows sit, not $26.91.
Holders	A $26/$22 put spread through Q3, or a collar against calls near $30. Check `JD`'s own implied volatility first.
Tactical bears	Defined-risk put spreads only. No naked shorts into the Ceconomy decision.
Breakdown	A daily close below $25.71 opens $25.19, then $24.55.
Calendar	Today's weekly close (TD 9), death cross around Oct 12, US CPI mid-October, FOMC Oct 27–28, Singles' Day presales, Nov 3 midterms, Q3 mid-November.

What would make me a buyer: - Q3 passes your test with operating cash flow up year on year. - A close above $27.72 on 8M+ shares with RSI above 50. - The 10-year back below about 5%.

Bottom line¶

Avoid JD until Q3. - The flat-budget pairing was mine to fix, and I've fixed it. Paired consistently, subsidies that continue raise opex along with revenue, and that Defend case is worth $18–21. - The price needs revenue to outgrow opex by 8.3–10.8 points. JD has never done that at revenue growth under 20%. Its best low-growth year, FY2022, managed 7.6. - Your +16% rests on two stacked assumptions: - Cost discipline better than any low-growth year, labeled as the downside. - A gross-margin gain three times last year's. - Correct both, on your own weights and your own cash basis, and the expected return is +3%.

My question back to the bull: all four of your scenarios have the opex ratio falling at least a full point, and your "escalate" case is tighter than FY2022. In 13 years, JD has never opened an 8-point revenue-over-opex gap at growth under 20%. - What probability do you put on the ratio falling less than a point in year two of a three-way fight? - If it's above zero, why isn't it in your table, and what does adding it do to your $31? Bear Analyst: # Bear Rebuttal: JD. Your "Pre-War Normal" Is JD's Best Year Ever

You're right about the method. Multiplying one year of EBIT by a multiple treats that year's subsidy spending as permanent, and my Defend and FY2024 rows did exactly that. I'll use your path framework from here on.

The path model, though, moves the whole debate onto one number: where the margin settles. Convert your opex ratios into operating margin and "$26.91 needs the war to last forever" becomes a much milder claim.

At 8x with no further burn, the price implies a 1.76% operating margin forever. JD's median operating margin across its six profitable years is 1.77%. The price doesn't assume a permanent war. It assumes JD earns what it has typically earned. Your upside assumes it earns what it has earned once.

All figures are my arithmetic on your stated basis: - Full credit for cash, about 1.474bn ADS, RMB 6.70 per dollar. - Revenue of RMB 1,400.7bn held flat, 16.2% gross margin, 25% tax. - Burn runs at FY2025 intensity and is discounted at the rate each multiple implies. - Value per ADS = (EBIT × multiple + RMB 68.8bn − PV of burn) ÷ 9.876.

1. What I concede¶

Method. Capitalizing a year that includes burn treats the burn as permanent. My Defend ($18–21) and FY2024 rows were permanent-war valuations presented as 2026 forecasts. I withdraw them as a method and keep permanent war only as a tail case, valued as one.
Your 40%. I accept it, along with your one-year reweighting to about $27.2.
My FY2023 and FY2024 "in full" rows paired continuing subsidies with growth under 7%. They're gone.
FY2014 baseline. Measuring the recovery against FY2012 rather than FY2013's one-year low is fair.
Your stop. The old $25.71 sat just above the bid zone I proposed, so moving it is consistent with that entry.

2. Your question: a 1.9% margin, after two more years of burn¶

My long-run destination is a 1.9% operating margin. At your 16.2% gross margin, that's a 14.3% opex ratio, reached after two more years at roughly launch-year intensity. It's JD's average across FY2019–24, its six profitable years. On your burn method it's worth $25.9 at 8x and $31.2 at 10x.

Why two years: - You put 40% on 2026 falling less than a point. - 2026 is year two of a three-way fight. - 2027 is the first year a retreat would show up in full-year numbers.

Why I use operating margin rather than the opex ratio: - We can't see the accounting split. Segment data isn't in our feed, so we don't know where food-delivery revenue and rider costs land between cost of revenue and opex. Operating margin is the only line where that split doesn't matter. - It doesn't change your arithmetic. Your model holds gross margin fixed, so a destination in opex is a destination in margin. Margin just puts it on a scale we can compare with JD's history.

JD's operating margin history

FY	Revenue growth	Gross margin	Opex ratio	Operating margin
2019	+24.9%	14.6%	13.1%	1.56%
2020	+29.3%	14.6%	13.0%	1.65%
2021	+27.6%	13.6%	13.1%	0.44%
2022	+9.9%	14.1%	12.2%	1.89%
2023	+3.7%	14.7%	12.3%	2.40%
2024	+6.8%	15.9%	12.5%	3.34%
2025	+13.0%	16.0%	15.8%	0.21%
FY2019–24				Mean 1.88%, median 1.77%

Long-run operating margin implied by $26.91, on your framework

Further burn at launch intensity	8x	10x
None	1.76% (14.4% opex)	1.41% (14.8%)
2 years	2.00% (14.2%)	1.55% (14.65%)
4 years	2.29% (13.9%)	1.72% (14.5%)
Your destinations	13.5% opex = 2.7%	14.0% opex = 2.2%

What the two tables show: - The price implies 1.4–2.3%. That's the band between FY2019 and FY2023, JD's ordinary profitable years. - Your 13.5% destination is a 2.7% margin. JD has beaten that once in 14 years. Your retreat and taper cases, 60% of your weight, both settle there. - "Two points above pre-war" measures against FY2024. That year beat JD's next-best year by almost a full point.

3. Why the destination isn't 13.5%¶

1. Your precedents settled at a 1.56% margin. - In FY2019, the 13.1% opex ratio sat on a 14.6% gross margin. - Apply 13.1% to today's 16.2% and you get 3.1%, close to FY2024's record. - That takes the precedents' cost level and adds the 1.6 points of gross margin earned since, assuming none of it is competed away. - FY2025 is the counterexample: gross margin rose to a record while the opex ratio jumped 3.3 points in the same year. - My long-war destination is exactly where both earlier spikes landed, measured in margin.

2. The "where" depended on the "how." You use the precedents only for where the ratio settled. It got there through scale: - From FY2014 to FY2019, revenue grew 5.0x (RMB 115bn to 577bn) while absolute opex grew 3.9x (RMB 19.2bn to 75.2bn). - In JD's four years of growth under 15%, the opex ratio fell once: FY2022, by 0.9 points. It then rose 0.1 and 0.2. - Between FY2022 and FY2024, operating margin rose 1.45 points. All of it came from gross margin (+1.8 points); the opex ratio rose 0.3. - Your destinations need the ratio to fall 1.8–2.3 points at single-digit growth. JD's whole low-growth record is −0.6 points over three years.

3. FY2024 may be what the war is about. This is inference, not reported data. - A company doesn't spend RMB 40bn+ to enter a three-way fight in its best-margin year unless it believes its core business is threatened. - If so, FY2024's 3.34% was the margin competitors came after, not a normal level JD returns to once the fight ends. - That also answers your last question. Management doesn't have to believe it should keep paying RMB 30bn a year forever. It only has to believe the old margin can't be defended without spending more than before. Launching 7Fresh Kitchen and buying Ceconomy are what that belief looks like in practice. - I don't need the war to be permanent. I need the peace to cost more than FY2024's did.

4. Your table, with one input changed¶

Same four paths, same weights, same 8–10x, same burn method. The only change: each destination is anchored to a year JD actually reported.

Scenario	Weight	Your destination	Mine (anchor)	Your value	Mine, 8x / 10x
Retreat	25%	13.5% (2.7%)	13.8% (2.4%, FY2023, JD's second-best year)	$38–45	$34.2 / $41.0
Taper	35%	13.5% (2.7%)	14.3% (1.9%, FY2019–24 average)	$36–43	$27.9 / $33.2
Long war (4 years full burn)	25%	14.0% (2.2%)	14.6% (1.56%, where both earlier spikes settled)	$26–32	$21.0 / $25.2
Permanent war	15%	15.3%	15.3%	$18–21	$18.1 / $21.0
Weighted				≈$34 (+28%)	$26.3 / $31.3; midpoint ≈$28.8 (+7%)

On your multiples and your weights, the upside falls from +28% to +7%. My retreat anchor is still JD's second-best year ever.
Your stress test was about $28.7 before the Ceconomy write-down. My base case is $28.8. Your "stress" case is simply JD's actual history.

5. The 10x end needs a 7.5% cost of equity¶

Your model holds revenue flat forever, so the multiple is effectively the discount rate.

Pre-tax multiple, zero growth	Implied cost of equity	Premium over the 5.28% 10-year	Weighted value (my destinations)
7x	10.7%	5.4 pts	$23.7 (−12%)
8x	9.4%	4.1 pts	$26.3 (−2%)
10x	7.5%	2.2 pts	$31.3 (+16%)

10x means a 2.2-point premium over Treasuries. That would apply to a VIE-structure ADR that just reported a 0.21% margin, in a sector under a regulatory probe, with the 10-year up 115bp in a year.
Zeroing out growth changed what 10x means. I accepted 8–10x when we were applying it to near-term EBIT, where some growth was implied. With growth set to zero, the top of that range is a 7.5% cost of equity.
If you want 10x, add growth explicitly. But at JD, growth has come with higher absolute opex in all 13 years of data, and that is the whole debate.
You called 7x a "bear input." A 5.4-point premium for this risk is middle of the road, not harsh. I center on 8x.

6. The trade: your exits keep moving¶

Round 1: "If [$25.65] breaks, the higher-low pattern is broken and I'm wrong."
Round 3: a failed Q3 test meant exiting everything.
Now: half the position bids below the level you called invalidation, and a failed Q3 closes only the call spread.

I offered the $24.5–25.2 bid as an alternative to $26.91, not an addition. Doing both means averaging down through the year's first lower low.

Your new exit triggers: - New-business losses above Q3 2025's. That was a launch-year quarter, probably near peak spending (inference; quarterly segment data isn't in our feed). This fires only if results get worse than the worst quarter. - Guidance for sustained spending into 2027. This fires only if management volunteers bad news. - JD Retail segment margin down year on year. This is a real test, and I'm adopting it.

Two of the three are unlikely to fire within five weeks, whatever Q3 shows. Quarter size keeps the position from being reckless, but it isn't an edge. Expected value is −2% at 8x and +7% at the 8–10x midpoint, which is about half of the single 15% gap you're sizing for.

7. What to do¶

Who	Action
New money	Wait for Q3, and confirm the report date.
If you must own it before Q3	Bid $24.5–25.2 instead of $26.91, sized for a 15% gap.
Holders	Buy a $26/$22 put spread through Q3, or collar against calls near $30. Check `JD`'s own implied volatility first.
Tactical bears	Use defined-risk put spreads only. No naked shorts into the Ceconomy decision.
Breakdown	A daily close below $25.71 opens $25.19, then $24.55.
Calendar	Today's weekly close decides the TD 9 (needs to stay below $27.06). Death cross around Oct 12, US CPI mid-October, FOMC Oct 27–28, Singles' Day presales, Nov 3 midterms, Q3 mid-November.

What would make me a buyer: evidence the destination sits above JD's average. - JD Retail segment margin up year on year. That's your exit, turned around. - New-business losses down both quarter on quarter and year on year, with consolidated margin on track to exceed about 2.4%. - Operating cash flow up year on year. - On the chart, a close above $27.72 on more than 8M shares, with RSI above 50. - The 10-year yield back below about 5%.

Bottom line¶

Avoid JD until Q3. - I concede the method. Valuing the business as a path rather than a single year is right. - The path moves everything onto the destination. On your framework, $26.91 implies a 1.4–2.3% long-run operating margin. That spans FY2019 to FY2023, JD's ordinary profitable years, and 1.76% at 8x matches its 1.77% median. - Your +28% needs a 2.7% margin. JD has beaten that once, in the year just before it started this war. Anchor your own scenarios to years JD actually reported, and the result is $26.3 at 8x and $31.3 at 10x. Your stress case is JD's real history. - The upper end needs a 7.5% cost of equity for a China VIE-structure ADR at a 5.28% Treasury yield.

My question back to the bull: - Your upside rests on a 2.7% long-run operating margin. In its low-growth years, JD's margin gains came from gross margin, and the opex ratio has never fallen for more than one year at a time. Why is the right destination JD's best year rather than its average? - If you want the 10x end, what perpetual growth rate are you assuming, and how much opex does that growth cost? Bear Analyst: # Bear Rebuttal: JD. I'll Drop Both of Yours. Your $38 Still Rests on Two Inputs You Never Varied.

You asked which of two assumptions I'll defend. I'll defend neither. - My 1.9% destination put an operating margin from the 14.6% gross-margin era on top of a 16.2% gross margin. You were right about that. - Zero growth can't be defended for a company whose worst year was +3.7%.

This round I use your destinations, your burn paths, your weights and your 2% growth, all unchanged.

Your $38.3 still holds two inputs at your values, and your table never varies them: - © A discount rate that fits a US large cap. 9.4% with growth is a 4.1-point premium over a 5.28% Treasury. That is roughly what an average S&P 500 company needs, and you're applying it to a China VIE-structure ADR. - (d) Peace that never ends. Your perpetuity begins after this war and assumes no other war ever follows. JD has had a margin spike about every 3.7 years since FY2014.

Correct both, using JD's own record and today's yield curve, and your own destinations are worth $26.4–28.8, with a midpoint of about $27.6 (+3%). That's fair value, not a buy.

Basis and inputs: - All figures are my arithmetic, on our shared basis: - full credit for cash; - about 1.474bn ADS at RMB 6.70 per dollar; - RMB 1,400.7bn of revenue; - 16.2% gross margin and 25% tax. - Value per ADS = (EBIT × multiple + RMB 68.8bn − PV of burn) ÷ 9.876. - Multiple = 0.75 ÷ (cost of equity − growth). Burn is discounted at the cost of equity. - Your inputs, unchanged: - destinations: retreat and taper 2.7%, long war 2.2%, permanent war about 1%; - your burn paths; - weights of 25/35/25/15. - These inputs reproduce your $31.1 and $38.3 exactly, so every difference below comes from the two changes.

1. What I concede¶

Mixing eras. My 1.9% applied an old-era operating margin to the new gross margin. I withdraw it as a peacetime destination.
Zero growth. I withdraw it. 2% is conservative, and with supplier float the working capital funds itself.
Your destinations. This round I accept that half of the gross-margin gain survives into peacetime. I'm also dropping my inference that "FY2024's margin is what the war is about." The spike record makes the case without it.
Counting a slow recovery twice. That's fair against my old destinations, and it's part of why I'm now using yours.
Your fixed trade rules. No averaging down, and an exit if JD Retail's margin falls year on year. Both are sound, and I'll hold you to them.

2. Your two questions¶

(a) "Name the non-spike year in which gross margin rose and operating margin didn't." - No one can, and the reason is definitional. Operating margin is gross margin minus the opex ratio. - A year in which gross margin rose but operating margin didn't is a year in which opex grew faster than gross margin. That is exactly how you define a spike. - So "8 for 8 outside spikes" is really 8 of 11, with the 3 failures defined out of the count. - The statistic that isn't circular: in 3 of JD's 11 gross-margin gains (FY2014, FY2018, FY2025), opex absorbed the entire gain in the same year. FY2021 also lost margin on both lines. - That doesn't refute your peacetime destination. It refutes treating peacetime as permanent.

(b) "Name the year JD grew less than 2%." - There isn't one, so I drop zero growth. - The extra $7 per share comes from somewhere else: adding 2% growth to a discount rate that was calculated assuming zero growth (Section 4).

3. Assumption (d): your perpetuity has no next war¶

Spike year	Operating margin	Average of neighboring years	Shortfall	Your label
FY2014	−5.0%	−1.9%	3.1 pts	Opex spike (IPO year; I exclude it)
FY2018	−0.6%	+0.7%	1.3 pts	Opex spike
FY2021	0.44%	1.77%	1.3 pts	"A year of new-business losses"
FY2025	0.21%	3.34% (FY2024)	3.1 pts	Food delivery

What the record shows: - The gaps between spikes were 4, 3 and 4 years. - Peace has never lasted more than three years: FY2015–17, FY2019–20 and FY2022–24. - Your spike table is right that each spike recovered fully. My charge assumes the same: no permanent damage, just another spike later.

The annual cost of recurring spikes: - A typical spike (1.3 points for one year) every 3.7 years costs 0.35 points a year. - The average spike excluding FY2014 (1.9 points), starting about four years from now, works out to roughly 0.37 points in present value at 11%. So the charge effectively begins after this war ends, and it doesn't overlap your burn. - Spikes the size of 2025's would cost about 0.6 points. - I use 0.35 points, worth about $4.10 per ADS at 8.3x. I apply it to the retreat, taper and long-war scenarios. Permanent war already is war, so it gets none. - I count every spike as lasting one year. FY2014–15 ran two years, and FY2025–26 may too.

On FY2021: you removed it from my median because it was a spike year. - That's correct for estimating a peacetime level. It's wrong for a perpetuity. - FY2019–24 contained one spike in six years, while JD's full record shows one every 3.7 years. If anything, my old average undercounted spikes.

On whether another spike is likely: - JD has made four big pushes into new businesses in twelve years. - It launched 7Fresh Kitchen this month, and Ceconomy is closing. - If future spikes buy future margin gains, model both effects. Right now your perpetuity keeps the gains that past spikes bought and charges for none of the future spikes.

4. Assumption ©: 9.4% was arithmetic, not an estimate¶

How we got to 9.4%: - Round 2: I proposed 8–10x as a market multiple for a China VIE ADR, applied to growing EBIT. Growth was already built into that range. - Round 4: you converted it into 9.4% and 7.5% discount rates assuming zero growth. - Round 5: I accepted that conversion in order to argue that 10x was too rich. That was my mistake as much as yours. I let arithmetic stand in for an estimate of the discount rate. - Round 6: you kept 9.4%, added growth, and arrived at 10.2x. That's above the top of the range we started from. - Calculated properly, 8x equals an 11.4% cost of equity with 2% growth. My "center on 8x" always meant that.

What the discount rate should be. I'm assuming a typical US equity risk premium of 4–5%; that figure isn't in our data. - A 9.4% rate gives this stock about the premium of an average US large cap. That leaves nothing extra for: - the VIE and ADR structure; - Beijing's regulators (this week's Alibaba AI probe pulled JD down too); - an operating margin that fell from 3.34% to 0.21% in one year; - two 2026 earnings reports, each followed by a 23–25% decline. - Last round I called a 10.7% rate "middle of the road." With your 2% growth, 11% gives 8.3x and 12% gives 7.5x. - The yield curve: - The 10-year is up 115bp in a year. - The gap between the 2-year and 10-year yields widened from 0.20 to 0.47 points, so the selloff is concentrated in long-dated bonds. A perpetuity is priced off that end of the curve. - Barron's ties China internet stocks directly to those yields. - Nothing in this market suggests the premium on China ADRs is shrinking.

5. Your table, with © and (d) added¶

Cost of equity (2% growth)	Premium over the 10-year	Multiple	Your destinations, permanent peace	Plus `JD`'s spike record (−0.35 pts)
9.4% (yours)	4.1 pts	10.2x	$38.3 (+42%)	$34.0 (+26%)
11%	5.7 pts	8.3x	$32.3 (+20%)	$28.8 (+7%)
12%	6.7 pts	7.5x	$29.6 (+10%)	$26.4 (−2%)

The two bottom-right cells are my case: $26.4–28.8.
The symmetry is real. You need to win one of © or (d) to get double-digit upside. I need to win both to get fair value. My two inputs come from JD's own 12-year record and a level I called middle of the road last round. Yours come from a calculation I shouldn't have accepted and the assumption that FY2025 was JD's last spike.
If Ceconomy is marked at zero, every cell falls by $1.70.

6. What $26.91 is actually betting on¶

Here are your scenarios at an 11% cost of equity, with the spike charge:

Scenario	Weight	Value
Retreat	25%	$34.7
Taper	35%	$32.8
Long war	25%	$23.3
Permanent war	15%	$18.6

No scenario is worth $27. The stock trades in the gap between two clusters: about $33.6 if the war is winding down and about $21.5 if it isn't.
What the price implies. The break-even probability that the war is winding down is 45% at an 11% cost of equity and 64% at 12%.
Your 60% falls inside that band. The price already agrees with your forecast.
What's left between us is only the discount rate.
Lower entry prices change this. At $24.5–25.2, the break-even probability drops to about 28%. That entry has an edge. $26.91 doesn't.

7. Your Q3 test can be passed in the long-war world¶

JD Retail margin, year on year: this is a genuine test, and I'm adopting it.
New-business losses against Q3 2025:
Q3 2025 was probably near the peak of launch spending. That's an inference, since quarterly segment data isn't in our feed.
Your long-war scenario runs at FY2025's average burn. Measured against a peak quarter, that could still show losses down 25% year on year.
In that case your add signal would fire in a world worth $23.3.
The fix: require losses to be down year on year and down from Q2 2026, or alternatively at least 25% below FY2025's quarterly average.
Under taper, losses fall every quarter. Under long war, they stay flat.
That is the distinction the price depends on.
Operating cash flow up year on year: this is being measured against a year when it fell 67%. It can confirm the story, but it can't tell the scenarios apart.
Your half-size starter: I won't call it reckless. I'll call it unpaid. The expected gain is about +3% at the midpoint, against a single-day gap risk of ±15%.

8. What to do¶

Who	Action
New money	Wait for Q3, and confirm the report date. Apply the tightened test in Section 7.
If you must own it before Q3	Bid $24.5–25.2, where the price needs about a 28% chance the war is winding down rather than 45–64%. Size for a 15% gap.
Holders	Buy a $26/$22 put spread through Q3, or a collar against calls near $30. Check `JD`'s own implied volatility first.
Tactical bears	Use defined-risk structures only. The upside cluster is $33.6, and the Ceconomy decision is pending.
Breakdown	A daily close below $25.71 opens $25.19, then $24.55.
Calendar	Today's weekly close (TD 9 holds only below $27.06); death cross around Oct 12; US CPI mid-October; FOMC Oct 27–28; Singles' Day presales; Nov 3 midterms; Q3 in mid-November (date unconfirmed); EU decision on Ceconomy.

What would make me a buyer: - Q3: JD Retail margin up year on year, new-business losses down both year on year and from Q2, and operating cash flow up. - Price: a drop into $24.5–25.2 with no break in the fundamentals. - Chart: a close above $27.72 on more than 8M shares, with RSI above 50. - Rates: the 10-year back below about 5%.

Bottom line¶

Don't open a position in JD before Q3. It's fairly priced, not cheap. - I concede (a) and (b), and I'm using your destinations, growth, burn paths and weights. - Your $38.3 also requires © a discount rate suited to a US large cap and (d) no future war. Correct both and your own numbers give $26.4–28.8. - The price already implies a 45–64% chance the war is winding down. Your 60% is inside that band. - Q3 shows which cluster we're in. Buy after it, or bid $24.5–25.2 before it.

My questions back to you: - © What premium over a 5.28% Treasury does a China VIE-structure ADR need? Yours is 4.1 points, about what an average US large cap needs. What's the case that the VIE structure, Beijing's regulators and a 3-point margin swing in a single year are worth nothing? - (d) Name four consecutive years since FY2014 in which JD had no margin spike. Your perpetuity assumes FY2025 was the last one.

If you can answer (d), I'll drop the spike charge. If you can't, your own destinations say the price is fair.

Research Manager¶

Recommendation: Overweight

Rationale: This was a good debate, and the two sides ended much closer together than they started. I land on a cautious Overweight: the bull won the argument about value, the bear won the argument about timing, and the plan reflects both.

Where the bull won: - The bull's sharpest point was that multiplying one year's EBIT by a multiple treats a subsidy war as permanent. The bear conceded it. - The bear also conceded that half of JD's 1.6-point gross-margin gain (now a record 16.04%) can reasonably survive into peacetime. JD's last peacetime run kept about 80% of a similar gain. - The bear dropped zero growth too. JD's worst year in 14 was +3.7%, so 2% perpetual growth is conservative. - Those concessions moved the bear from 'avoid, $17-19 downside' to 'fairly priced at $26.4-28.8'. Even the bear's best case now says the stock is fair, not expensive.

Where the bear won: - The discount rate. A 9.4% cost of equity gives a China VIE-structure ADR roughly a US large-cap premium over a 5.28% 10-year yield. That is too thin, and I use about 11%. - Recurring spending spikes. JD has had a margin spike roughly every 3.7 years (FY2014, FY2018, FY2021, FY2025). A perpetuity that assumes FY2025 was the last one is generous. - I give that spike charge only partial weight. Past spikes also bought the gross-margin gains the bull is now crediting, which the bear acknowledged. - On those inputs, fair value is about $29-31, roughly +8-13%, with a full range of about $26.4-32.3.

The outcome is two-sided: - At an 11% cost of equity, every scenario sits either near $33.6 (the spending war winds down) or near $21.5 (it doesn't). Nothing is worth $27. - The price breaks even at about a 45% chance of winding down. I put that chance at about 50-55%. - For winding down: record gross margin, past regulatory summonses over subsidies, and the fact that JD's margin recovered after every prior spike. - Against: a weak Q2, two 2026 earnings windows each followed by 23-25% declines, Arete's downgrade to Neutral with a $30 target, and management still expanding (7Fresh Kitchen, Ceconomy). - That is a real but thin edge at $26.91. At $24.5-25.2 the breakeven drops to about 28%, and the edge becomes clear.

The bear also wins the near term: - Trend is down on daily, weekly and monthly charts, and RSI has stayed capped below 50. - On-balance volume made a new low on Oct 2, and resistance sits at $27.04-27.72 and $28.5-28.7. - The 10-year yield is up 115bp in a year. - The calendar is crowded: a death cross around Oct 12, CPI, the Oct 27-28 FOMC, the Nov 3 midterms, the EU decision on Ceconomy, and Q3 in mid-November.

So direction is constructive, but conviction and timing don't support a Buy. The plan uses small, staged entries, adds only on evidence or a better price, and has hard exits if Q3 shows the spending war is becoming permanent.

Data we don't have: 2026 quarterly filings, segment data, borrowings and short-term investments, JD's own implied volatility, Ceconomy's financials, and a confirmed Q3 date.

Strategic Actions: Sizing is relative to a standard full allocation (100%). Total exposure before Q3 is capped at 50%. Separately, size stock held into any event so that a 15% overnight gap (about $4 per ADS) costs no more than about 0.5% of portfolio equity. Use whichever cap is smaller.

1) Starter, now. Buy 25% of standard allocation with limits at $26.66-26.91. Don't chase into the $27.04-27.44 resistance.

2) Second tranche, 25%. It fills on whichever comes first: - (a) a resting limit at $24.60-25.20, the March and June lows, as long as no adverse fundamental news has hit; or - (b) a daily close above $27.72 on at least 8M shares with RSI above 50. Use only one of these; never exceed 50% before Q3. Don't add on any other weakness.

3) Hard stop. Exit all stock on a weekly close below $24.40. A stop won't protect against overnight gaps, which is why the gap-risk cap above applies.

4) Into Q3: - Confirm the report date, and confirm that JD discloses segment data (JD Retail margin and new-business losses). - Before the print, hedge stock held into it with roughly a $26/$22 put spread expiring after Q3, or move part of it into a call spread. - Check JD's own implied volatility first; the VIX at 15 is only a proxy.

5) Q3 add rule. Add to 100%, even after a gap up, only if all three hold: - JD Retail segment margin is up year on year; - new-business losses are down year on year and also down from Q2 2026 (or at least 25% below FY2025's quarterly average); - operating cash flow is up year on year. Go to up to about 125% only if, in addition, the 10-year yield is back below about 5% and price holds above $28.70.

6) Q3 exit rule. Exit everything if any of these happen: - JD Retail margin falls year on year; - new-business losses are not lower year on year; - management guides to sustained or higher food-delivery spending into 2027. If results fall in between, hold the position and don't add.

7) Profit-taking. - Before Q3: if $28.45-28.70 is reached without volume confirmation, trim a third. - After a Q3 pass: hold the core position toward $30 (Arete's target) and $33.5 (the range top, roughly the wind-down value), and scale out above $33.5.

8) Events. - Don't trade the Oct 12 death cross or today's weekly TD 9 count mechanically. - Watch CPI, the Oct 27-28 FOMC, Singles' Day presales and the Nov 3 midterms. - Value Ceconomy conservatively: about -$1.70 per ADS if it proves worthless. - Use no naked shorts or uncapped option risk.

III. Trading Team Plan¶

Trader¶

Action: Buy

Reasoning: The research plan's Overweight rests on a fair value of about $29-31 at an 11% cost of equity, with a slight edge (about 50-55% odds against a roughly 45% breakeven) that the subsidy war winds down, so the direction is constructive. The near-term technicals argue for small size: all three SuperTrend timeframes point down, OBV made a new low on Oct 2 with no volume confirmation of the bounce, a death cross is due around Oct 12, and there is overhead resistance at $27.04-27.44 and $28.5-28.7. Exhaustion signals support a staged entry: MACD shows bullish divergence (-0.66 vs -0.81 at its low), RSI held about 30 three times, the weekly TD 9 is provisional, and the 2026 lows keep rising (24.53, then 25.19, then 25.78). The plan is a 25% starter at the 10-day EMA / Bollinger middle ($26.66-26.77) without chasing into resistance, a second 25% tranche either on a resting limit at $24.60-25.20 or after a confirmed close above $27.72 on 8M+ shares with RSI above 50, exposure capped at 50% before Q3, and a put-spread hedge into the mid-November print, whose date is not yet confirmed.

Entry Price: 26.75

Stop Loss: 24.4

Position Sizing: Starter 25% of a standard full allocation now via limit orders at $26.66-26.91. Add a second 25% only on (a) a fill at $24.60-25.20 with no adverse news or (b) a daily close above $27.72 on 8M+ shares with RSI above 50; never exceed 50% before Q3. Also cap size so that a 15% overnight gap (about $4 per ADS) costs no more than about 0.5% of portfolio equity, and use whichever cap is smaller. The hard exit is a weekly close below $24.40. Hedge into Q3 with roughly a $26/$22 put spread. Scale to 100% only if Q3 passes all three tests: JD Retail margin up YoY, new-business losses down, and operating cash flow up.

FINAL TRANSACTION PROPOSAL: BUY

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Since neither of you has spoken yet, I'll lay out the case for this Buy and answer the objections I expect from both of you.

Start with what the market is pricing. JD is a business that grew revenue 13% last year to RMB 1.31 trillion, its fastest growth since FY2021, with a record 16.04% gross margin. Its operating income still collapsed 93%, from RMB 38.7bn to RMB 2.8bn. The reason is a jump in operating expenses from 12.5% to 15.8% of revenue. That is about RMB 43bn of spending above the FY2024 run-rate, which lines up with the food-delivery subsidy push. Nothing is broken in the core franchise; the profit was spent. The fundamentals report puts the operating leverage plainly: every 1 point of opex ratio is worth about RMB 13bn of operating income. A 1–2 point normalization is five to nine times last year's entire operating profit.

Now the price. By my own back-of-envelope math, FY2024 diluted EPS of about RMB 26.86 per ADS is roughly $4.00 at today's 6.70 yuan. At $26.91, JD trades around 6.7 times what it earned the year before this spending spree, and around 14 times a trough year propped up by spending choices. Treat those as estimates, since the vendor withheld valuation data. Still, that gap is what this trade is about. JD has done this before. In FY2018 it ran an operating loss of RMB 2.6bn while investing heavily, and in FY2019 it posted plus RMB 9.0bn of operating income, with margins recovering within about four quarters. If management repeats that pattern, the stock is not worth $26.

To my conservative colleague, who I expect will open with "all three SuperTrends point down, OBV made a new low, and a death cross is coming." All true. But you don't get a $26 entry on a stock with a 30% earnings-recovery story while the trend is up. The weekly SuperTrend doesn't flip until $31.63. Waiting for that means buying above the low end of our fair-value range and giving up most of the edge. The death cross is arithmetic from the August–September decline. The technical report says that delaying it would take two closes averaging about $29.05. It tells us nothing new, and in a ranging stock these crosses often land near short-term lows.

The OBV point cuts both ways. September's decline happened on 4–7M shares a day. There was no capitulation, but there was no heavy institutional dumping either. Meanwhile momentum has turned: - MACD made a higher low (−0.66 vs −0.81) while price made a lower low. - RSI held about 30 three separate times and never closed below it. - ATR has compressed 30%. - The weekly TD count hit 9.

Most importantly, the 2026 closing lows keep rising: 24.53, then 25.19, then 25.78. The previous two lows produced rallies of 38% and 33%. I'm not claiming history repeats. I'm saying the burden of proof is on the bears to break $25.71, and they haven't.

You'll also point to the 10-year at 5.3%, the Fed and ECB hikes, oil near $100, and the Alibaba AI probe. I take the macro seriously, but look at how JD has actually traded through it. It has drawn headlines like "JD Advances While Market Declines" and "JD Increases Despite Market Slip," and it holds up on down days. Several things help it here: - The yuan has held at 6.70 through a 3% dollar rally, which directly supports JD's USD-reported earnings. - Core PCE is running about 2% annualized over three months, so the hike looks oil-driven. If oil keeps easing from its $107 peak, the case for more hikes weakens. - The Alibaba probe targets AI, where JD has far less exposure. If anything, it argues for JD as the cleaner China-internet long.

On the sell side, Arete's downgrade is the bear's best ammunition. But Arete cut its target to $30. Even the downgrade sits about 12% above our entry. When the bearish call is above your cost basis, the risk is lopsided.

On the collapse in cash flow: yes, operating cash flow fell 67% and free cash flow 79%, and capital returns exceeded free cash flow by about RMB 15.5bn. That is the same spending lever showing up in cash. Cut the subsidies and the cash comes back. In the meantime, RMB 137.5bn of cash gives management plenty of time.

To my neutral colleague, I expect your pitch will be "just wait for the close above $27.72 on volume." The plan already includes that as the trigger for the second tranche, so we capture confirmation if it comes. But passing on the starter at $26.75 to buy at $27.72 or higher gives away about 3.6% of basis. Against a $29–31 fair value, that is roughly a third to a half of the upside to the low end. Price is sitting above the 10-day EMA, on an inside day, after testing $27.04 twice without rejection. That is a constructive pause.

You might also say the weekly TD 9 is fragile because a Friday close at or above $27.06 voids it. Think about what that would mean: the 9 fails because the stock rallied. For a long position, I'll take that failure every time.

Here's why I'm comfortable leaning in. The trade is built so the position is smallest when uncertainty is highest and largest when the thesis is confirmed. The downside is bounded: - The starter is 25% of a full allocation. - The hard exit is a weekly close below $24.40. That level sits just under the March and June lows, so if it breaks, the rising-low structure is dead and we're wrong, cleanly. - If the stop is hit, the loss is about 8.8% on a quarter-size position, roughly 2.2% of a full allocation. - The gap cap limits a 15% overnight gap to about 0.5% of portfolio equity, and the $26/$22 put spread roughly covers that gap zone into the Q3 print. That date is still unconfirmed, so verify it before the hedge expiry is chosen.

The upside is the reverse. If Q3 shows JD Retail margins up, new-business losses down, and operating cash flow recovering, we scale to 100% just as the earnings snapback becomes visible. The targets then become the range highs at $33.47–33.77, not just fair value. Break-even odds are about 45%, the research puts ours at 50–55%, and the payoff widens exactly when we add size. That combination is what positive expected value looks like.

There are also near-term catalysts the cautious camp tends to discount: - Formal EU clearance of the $2.5bn Ceconomy deal, reported as "poised" but not yet confirmed. - Singles' Day presales starting in late October, a direct read on whether the price war is cooling. - Barchart-reported bullish options flow despite the ugly chart.

Sentiment is a mixed 57/43 split on StockTwits. That's far from crowded and gives the trade plenty of room to run if the story turns.

If I'd push anywhere, it's on execution, not caution. Put the hedge on early rather than late, while broad equity volatility looks complacent with the VIX near 15, though JD's own implied vol needs checking before we assume it's cheap. And if anyone wants more upside before Q3, a small defined-risk call spread toward the low $30s could express the range-high thesis, with its delta counted inside the 50% cap rather than on top of it.

What would hurt us is being so timid that we own nothing at $26.75 and then chase at $30 after the Q3 numbers prove the thesis. Buy the starter now, keep the stop disciplined, and let the scale-up rules do the rest. Aggressive Analyst: Aggressive Analyst: I'll start with what I'm conceding. Two of the criticisms are correct, and fixing them makes this trade stronger, not smaller.

The resting limit at $24.60 to $25.20 goes. I called $25.71 the line the bears have to cross, and a rule that buys more after they cross it contradicts me. The weekly-close stop at $24.40 goes too. The March intraday low of $23.66 shows how far this stock can travel midweek, and a stop that only fires on Friday can't deliver the 8.8% loss I quoted. I'll take a daily close below $25.71, with the neutral's one-time re-entry. If we're stopped out and the stock closes back above $25.71 within three sessions without closing below $25.19, we rebuild once, with a stop on a daily close below $25.19. This stock broke its lows intraday and recovered in both March and June, so one re-entry is worth having.

Here's where I part ways with both of you. The conservative tightened the stop and cut the size at the same time, and the neutral settled at 20%. The neutral's own rule is that risk equals size times distance. From $26.75 to $25.71 is $1.04, about 3.9%. That's two ATRs, the same stop the technical report uses for its own buy-the-dip setup. On a 25% starter it risks about 1% of a full allocation, or about 1.25% with slippage on a bad close. Even if we're stopped, re-enter and get stopped again, the total is roughly 1.6 to 1.9%. Every one of those numbers is below the 2.2% the original plan risked on a single stop. We've already halved the risk. Cutting size again adds little safety and gives up real exposure, so the starter stays at 25%.

That also answers the conservative's best quantitative point, that the edge was smaller than the uncertainty in our estimate. Under the old stop that was fair: risking 8.8% to make 8.4% needs better odds than we can claim. Under the new stop, risking 3.9% to make 8.4% to $29 breaks even at about 32%, and to $30 at about 25%. The neutral is right that a tighter stop gets hit by noise more often, so we shouldn't reuse 50 to 55% unchanged. Suppose noise drags the real hit rate down to 40%. We still clear breakeven by eight to fifteen points, and the re-entry rule wins back some of those noise stops. The payoff the conservative objected to no longer exists.

On the stale fundamentals, I agree: read the Q1 and Q2 filings this weekend. I'll accept a veto. If the opex ratio and new-business losses kept rising from Q1 to Q2, we stand aside. The neutral is right that the test has to be about direction, not about the full-year 15.8% level. The 7Fresh launch and Nike's distributor cuts can be read either way, and the Q2 expense line will settle it.

But remember those filings are public, and the market has had them for weeks. Reading them guards against a mistake. It doesn't take away an edge. And look at what this stock did this year with bad numbers already known. A December-year-end foreign issuer has to file its 20-F by the end of April, so by May the full FY2025 collapse was public. The stock still rallied from a $24.53 close in March to $33.77 in May. The market has already paid $33 for this franchise knowing how bad FY2025 was. Our $30 to $33.77 targets aren't a bet on the monthly SuperTrend at $41.83 or a return to 2021. They're levels the stock closed at on August 10. So on the conservative's line that business recovery and stock recovery are different bets: this year they haven't been.

On valuation, the conservative applied my FY2019 precedent to the wrong number. FY2019's 1.56% operating margin came with a 14.6% gross margin, while today's gross margin is 16.04%. The precedent is about how fast management cut spending. In FY2019 the opex ratio fell 1.7 points, from 14.8% to 13.1%. Apply that same 1.7-point cut to FY2025 and the opex ratio goes to about 14.1%, operating margin to about 1.9%, and operating income to roughly RMB 25 billion, not 20. That's still well short of FY2024's 38.7, and it only assumes JD repeats something it has already done once. Using the neutral's method, very roughly, that's RMB 21 to 24 per ADS depending on how hard you cut the interest income, or about $3.10 to $3.60. At today's price, that's seven to nine times year-one recovery earnings. Normalization isn't a return to the peak, and the trade doesn't need it to be.

The 8% ROE has the same problem: it's measured at the trough. FY2024 was 17 to 18%, and our $29 to $31 fair value already discounts at 11%. For scale, using the report's 2.9 to 3.0 billion shares, the market cap is roughly $39 to 40 billion. Year-end cash was RMB 137.5 billion, about $20.5 billion. Not all of that is spare, since a supplier-funded retailer needs a lot of it, but it's roughly half the market cap.

On Arete, I'm not calling a Neutral a hidden Buy. A Neutral at $30 means the analyst expects roughly market returns from $30. Even the cautious anchor sits 12% above our entry.

On whether the growth was bought, I can't refute it with this data. Gross profit grew 14.2%, faster than revenue, at a record margin, which argues against outright price-cutting. But if the subsidies sit in marketing, the conservative has a point. So I'll take the neutral's fourth test: revenue has to hold up as spending falls.

On Ceconomy, RMB 17 billion is a year and a half of last year's free cash flow. It's also about 12% of year-end cash and a third of FY2024's free cash flow. I agree it removes an overhang rather than adding earnings, and if the breakout comes on the approval headline, I'll require a second close above $27.72.

On the technicals, the conservative's list is MACD below zero, RSI never above 50, OBV at a new low and light volume on the bounce. Those are confirmation conditions, and every one is already in the second-tranche trigger: a close above $27.72 on 8 million shares with RSI above 50. Requiring them for the starter just means paying $27.72 or more for the same position. Three rising lows aren't a law, and I'm not claiming the 38% and 33% rallies repeat; a move to $30 is 12%. The neutral is right that the TD count runs on weekly bars and isn't complete until today's close, so I'll stop leaning on it.

And conservative, you can't call the StockTwits feed noise and then cite Tiger Global's $33.70 cost basis, which came from a HedgeFollow post in that same feed and is flagged as unverified. Even taken at face value, that's supply at the range high, not at our targets.

On Monday's death cross, our limits sit below Thursday's close. If automated selling hits, it fills us cheaper. If it doesn't, we don't chase.

On macro, I concede the analysis. The pressure is in the long end, the 2-year hasn't moved since the hike, and the "advances while market declines" headlines were undated boilerplate. But a long-end selloff punishes long-duration assets whose value sits in distant cash flows. A company at seven to nine times year-one recovery earnings, with cash worth half its market cap, is about as short-duration as China internet gets.

The right response to yield risk is the neutral's beta hedge, not a smaller position. I'd short KWEB rather than Alibaba, because a BABA short ties us to how the AI probe resolves, and a relief rally there would hit the hedge at the worst moment. The tripwires should freeze adds, not trigger selling. The 10-year is twelve basis points from 5.4% and Brent is two dollars from $105. Those levels will fire on noise, and the daily stop and the put spread already handle real damage.

I also don't accept counting five events as all downside. Singles' Day presales and the EU decision can go either way, and the presales are our most direct read on whether the price war is cooling.

The pre-Q3 cap is the real disagreement. The neutral got the logic right: the danger is unhedged size through a binary event. Follow that logic through. Say we hold 50% after the confirmation add, at an average cost near $27.25, fully covered by the $26/$22 spread at a $1.00 premium ceiling. If Q3 disappoints and the stock gaps 20% to about $21.40:

We lose $5.85 a share on the stock, the spread pays $4.00, and the premium cost $1.00, for a net loss of about $2.85.
That's roughly 10.5% on the position, or about 5.2% of a full allocation.
The conservative's unhedged 25% at $26.75 loses about 5.0% in the same gap.

So the worst cases match down to the low $21s. At the $33.47 range high, the hedged half makes about 9.6% of a full allocation after premium, against 6.3% for the unhedged quarter. That's the same downside and about one and a half times the upside. So I'd keep the cap at 50%, reached only through the confirmation trigger and only with the hedge on.

There's an honest caveat. Below $22 the bigger position loses faster, so the 20% gap rule on any unhedged portion still applies, and we use whichever cap is smaller. If the spread prices above the ceiling, we fall back to the neutral's tiers: 40% if lower strikes keep us hedged, otherwise 25%.

On chasing: the conservative says buying at $28 or $30 after Q3 beats $26.75 now. That assumes we get to buy at $28. When a one-to-two point drop in the opex ratio is worth five to nine times last year's entire operating profit, a good print doesn't drift up through $28.50. It gaps. This stock moved 7.3% in one session in August. A good Q3 could open near $30, which is the whole distance to the low end of fair value. The starter is how we own that gap. And we're not ignoring the conservative's logic: three quarters of the full position still waits for the information.

After Q3, I'll take the neutral's four tests, sequential as well as year on year. I disagree on the pace. Sitting at 60% until the weekly SuperTrend flips at $31.63 means buying the last 40% near the range high, into exactly the supply the conservative described. If all four tests pass, go to 75% on the print. Go to full size on a weekly close above the $28.50 to $28.70 moving-average cluster, which is still about 17% below the range high we're targeting.

So here's where I land:

Read the filings this weekend. If spending was still rising from Q1 to Q2, stand aside.
Otherwise, place a 25% starter Monday as limits at $26.66 to $26.77, with a daily-close stop below $25.71 and one re-entry. Delete the averaging-down order.
Add to 50% only on the confirmation close. The put spread must be on, under a $1.00 ceiling, with expiry at least a week past a confirmed Q3 date. If the breakout comes on the Ceconomy headline, require a second close. After the add, trail the stop to a daily close below $26.42.
Size any unhedged portion for a 20% gap, count existing China exposure against the cap, and consider a small KWEB short.
Use the macro levels to freeze adds, not to sell.
Skip the call spread until the event premium comes out after Q3.
After Q3: 75% if all four tests pass, full size on a weekly close above $28.70, and a full exit if the tests fail.

That's still a Buy, and still the aggressive version. It now carries less risk per dollar of upside than the plan I started with. Aggressive Analyst: Aggressive Analyst: Both of you landed real hits last round, so I'll concede those first. Then I'll show you that your own math points somewhere more aggressive than either of your plans.

Conservative, your random-walk point is right. In a stock with no drift, the chance of reaching $29 before a close below $25.71 is about 32 percent, which is exactly the breakeven I kept quoting. My 32 percent proved nothing. You also caught me comparing a hedged 50 percent against an unhedged 25 percent you never proposed. Your reporting-window timing undoes my line that the market paid $33 knowing FY2025 was bad. It paid $33 for Q1 and gave it back on Q2. And the KWEB short is gone. Shorting Meituan and Alibaba alongside a bet that the subsidy war ends means shorting our own catalyst, and I can't size it anyway.

Neutral, your tranche math ends my 50 percent cap. Your rough cases are $31 if the print is good and $23 if it's bad. In those cases the confirmation tranche at $27.72 makes about 8 percent and loses about 10. That's a coin flip that costs a dollar more to enter, and the $26 strike doesn't start paying until the tranche is down $1.72. Its breakeven is around 54 percent, right at the top of our odds. I argued for that add for three rounds, and it was the wrong tranche.

Now follow that logic all the way through. The edge sits at the cheap entry, with the long strike 75 cents below it. The conservative wants 20 now and 10 at the worse price. The neutral wants 25 now and 10 at the worse price. I want all of the pre-Q3 exposure at the good price. On a full filing pass, that means a 35 percent starter at $26.66 to $26.77, fully covered by the $26/$22 spread, and no confirmation add.

Run it through the neutral's own table. In a 20 percent gap to about $21.40, the starter loses $5.35 a share, the spread pays $4.00, and the premium cost $1.00. That's a net loss of $2.35, or 8.8 percent of the position, which is about 3.1 percent of a full allocation. At the $33.47 range high, it makes $5.72 a share after premium, about 21 percent of the position, or roughly 7.5 percent of a full allocation. The neutral's 25 plus 10 is 3.4 down and 7 up. The conservative's 20 plus 10 is 3.0 down and 6.0 up. For a tenth of a point more gap risk than the conservative, we get a quarter more upside, and we beat the neutral's plan on both sides. That isn't ignoring risk. It's the best upside per unit of downside of the three plans.

It also answers the conservative's best line, that a hedge doesn't make size free because risk moves above the long strike, below the short strike, and into the premium. That's true, and it's exactly why the add was bad: it had $1.72 of unhedged room above the strike. At a $26.75 entry, that room is 75 cents. In the neutral's most likely bad outcome, a 10 to 15 percent miss, the hedged starter loses only about 6.5 percent because the spread does nearly all the work. Size belongs where the hedge actually works.

Now the argument that our edge is smaller than our error. For the five weeks before the print, I agree. The neutral showed the spread isn't a sunk cost: it's worth about $1.30 if we're stopped early and about 40 cents at $29. So breakeven stays near 31 to 32 percent, and that window is close to a fair bet. Fine, then nobody should rely on the window. The edge is in the print, and there the objection fails. Using the same rough cases, the hedged starter makes about 12 percent or loses about 6.5. It breaks even at roughly 35 percent, and our estimate is 50 to 55. We can be fifteen to twenty points too optimistic and still get paid. The add was the one place where our error mattered, and it's gone.

Here's what the window costs at 35 percent. A stop at $25.71 loses $1.04 on the stock while the spread gains about 30 cents, so about 1 percent of a full allocation. If we're stopped, re-enter, and get stopped again at $25.19, with the spread held throughout as the neutral proposed, the total is roughly 1.5 to 1.8 percent. That's still under the 2.2 percent the original plan risked on a single stop. I'll take both of the conservative's re-entry filters: no re-entry after a breakdown on 8 million or more shares, none within a week of the print, and none without the hedge. I'll also take the neutral's rule to keep the spread through the three sessions. With no add, there's nothing to trail. The starter keeps its $25.71 stop so it survives to the print it was bought for.

The filings have to earn that size, and on the test I'm with the neutral. Q1 2026 against Q1 2025 compares against a quarter from before the war really started, so it fails even if spending has peaked. Q2 against Q2 has the 618 festival in both and both sit inside the spending period. That handles the seasonality concern better than the conservative's version does. JD doesn't guide formally, and every release says it will keep investing, so only an explicit statement that spending will rise should veto the trade.

So a full pass gets the 35 percent starter. That means Q2's opex ratio and new-business losses are both below Q2 2025, and new-business losses fell from Q1 to Q2. A partial pass gets 15 percent with no add. If nothing passes, we stand aside. The hedge is a second gate. If the $26/$22 spread prices above a dollar, the starter drops to 25 percent, and only at that size do we look at lower strikes, because the whole case for concentrating rests on a strike near entry. If Monday's limits don't fill because the stock runs, I don't chase. The confirmation close becomes a fallback entry at 20 percent, with its own spread struck about a dollar below entry and the same premium ceiling as a share of price. If the move comes on a Ceconomy headline, we wait for a second close.

On valuation, conservative, the FY2022 precedent is the wrong comparison. Look at the table. FY2021's squeeze was a gross-margin event: gross margin fell a full point, from 14.6 to 13.6, while the opex ratio stayed at 13.1, the same as in 2019 and 2020. The 0.9-point cut in FY2022 pushed opex below its own norm. Today the ratio is 15.8, about 2.7 points above that norm and 3.3 above FY2024. Unwinding a spending binge is a different exercise from trimming a normal cost base. Your point about slower revenue growth is fair. So is the point that Meituan and Alibaba get a vote, which is why the filings set the size. But 15 billion is a pessimistic floor, and even there the neutral's rough method puts JD at nine to eleven times recovery earnings.

On the reporting-window timing, I've conceded the claim, but look at what it shows. JD rallied 38 percent between the March and May reports, then gapped 7 percent on the August one and slid another 12. These events move this stock by double digits in both directions. That says nothing about direction, but it says a lot about size, and with a put spread capping the downside near entry, a big move works for us. On Arete, conservative, you said yourself that targets follow the price down. They also follow estimates back up, and a one-point drop in the opex ratio would change those estimates a lot.

On cash, I'll take the neutral's split: it's a solvency cushion, not a shareholder cushion. In a war of attrition, it still counts for something that JD can't be forced into a bad decision. And I'll stop citing FY2024 free cash flow. That was cherry-picking.

After Q3, the neutral's point about the SuperTrend helps me. A SuperTrend in a downtrend only moves lower, so the conservative's 1.5-point cost of waiting for $31.63 is overstated. As for having only one quarter of data, by the mid-November print we'll also have Singles' Day presales, which start in late October. They're the most direct real-time read on whether the Q4 price war is cooling, so we'll have Q3 plus a live read on Q4.

So, if all four tests pass both sequentially and year on year, and the presales don't show discounting getting worse, we go to 75 percent on the print. If the presales show the price war heating up, that step is 60 percent. Full size comes on two consecutive weekly closes above $28.70, or on a weekly SuperTrend flip wherever it has moved to, whichever comes first. Requiring two weekly closes means at least two weeks after the print, so the steps can't all happen in one week. Mixed results take us back to starter size with the daily stop. Failed tests mean we exit.

On macro, I accept that any single tripwire freezes adds. A 10-year above 5.4 percent and a VIX above 20 in the same week cuts anything unhedged. I also accept the 25 percent gap stress against the 0.5 percent of equity rule. By the neutral's math, it only binds when a full JD allocation plus existing China internet holdings is around a tenth of equity, and for those portfolios it should bind. Count existing China exposure against the cap. No call spread until the event premium comes out after Q3.

So my final position on JD is still Buy, and still the aggressive version:

Grade the filings this weekend.
On a full pass, place a 35 percent starter Monday at $26.66 to $26.77, with the $26/$22 spread bought the same day under a one-dollar ceiling and an expiry at least a week past a confirmed Q3 date.
Drop to 25 percent if the hedge prices above the ceiling, and to 15 percent on a partial pass.
Use a daily-close stop at $25.71, with one filtered re-entry and the spread held through it.
Make no add at a worse price, except the 20 percent fallback if the starter never fills.
After the print, step up to 75 percent and then to full size, gated by the four tests and the presales read.

Nearly every change I've made this round cut risk. The one place I'm still pushing is where your own numbers put the reward: hedged size at $26.75, going into a print that can move this stock by double digits. Aggressive Analyst: Aggressive Analyst: I'll start with two concessions. Conservative, comparing my unconditional 35 percent against your conditional maximums was the wrong comparison, and the neutral was right to call it out. The 20 percent fallback was also just the confirmation tranche under a new name. It needed about 44 percent odds at $31 and nearly 60 at $30, so it goes. There will be no breakout entry of any kind before the print.

Size is the last real disagreement, and I think the conservative's case rests on a mistake. You said that once the window is a fair bet, a 35 percent starter is just more variance than 25 with no more expected return. That's true of the five weeks before the print, and only of them. We don't hold this position for the window. We hold through it because we can't own the print without it. This stock gapped 7.3 percent on its last report and rallied 38 percent between the March and May reports, so buying the day before isn't an option. The window is the price of admission, and it costs the 35^th share exactly what it costs the 25^th. Taken to its end, your argument says hold nothing until the print, not 25 percent. You're keeping a 25 percent starter, so you don't believe that. The real question is how much of a positive-expected-value print we buy. As for 35 doing 40 percent more damage in the bad path, it also makes 40 percent more in the good one. As you said yourself, the ratio doesn't change with size. So what should set size is the edge per share, and we can measure that on Monday.

The neutral's quote-based sizing is right, and I want to take it one step further. Conservative, your breakeven table collapses into one number. Take the entry price, subtract the $26 strike, and add the premium. Call that the all-in. With a $30 good case, breakeven is simply the all-in divided by four, because $4 is the distance from the strike to $30. At $26.75 and a dollar premium, the all-in is $1.75 and breakeven is 43.75 percent, which is your 44. At 85 cents it's $1.60 and 40 percent. At $1.50 it's 37.5. At $2.00 it's a coin flip. That one number covers both the premium and the fill, which matters once the limits are working on more than one day.

Now price the edge. At the midpoint of our 50 to 55 percent, the print is worth about 35 cents a share at a $1.75 all-in. At $1.50 it's worth about 60 cents, nearly double, with less at risk. Neutral, your own scale moved from 25 to 30 percent for about four points of breakeven. I'm asking for one more step on that same scale:

35 percent when the all-in is $1.50 or less, which means a fill near $26.66 and a spread around 84 cents.
30 percent at $1.60 or less.
25 percent at $1.75 or less.
Above $1.75, sell the $32 call. If that still doesn't bring the all-in down to $1.75, go to half of 25.
Above $2.00, no trade until after the print, because a coin flip leaves us nothing to buy.

Sizing in proportion to the edge would put the top tier nearer 45, and I'm asking for 35, and only when Monday's numbers deliver it. That's my answer to the error-bar point. The rule declines the trade where our odds can't carry it, and it only sizes up where we can be twelve to seventeen points too optimistic and still get paid. Conservative, that's the margin you said we needed.

I'll plan on $30 as the good case. That's conservative from my side, because a good print puts the starter on the ladder toward $33.47. But the neutral is right that the middle case bleeds premium, so call it even.

On the expensive hedge, I'd rather collar than halve. The $32 call gives up only a one-week gap above $32. That's above the top of our fair value and still below the $33.47 range high, while halving gives up half our exposure to the whole move. If the print gaps toward $32 and all four tests pass, we buy the call back so the ladder starts from a full base. And if Barchart's bullish flow means calls are bid, that call pays more than the neutral estimated, so price it Monday alongside the spread.

On unfilled limits, I'm with the neutral, and the all-in rule answers the conservative's worry. A Monday-only order turns whether we own anything into a coin flip on a single session. It's also the session the technical report says brings automated death-cross selling. That's the dip we want, and it might come Tuesday. Let the limits work at the 10-day EMA and Bollinger middle until a week before the print. At a $27 fill and a dollar spread, the all-in is $2.00 and the rule says no trade, so the cap polices itself.

Conservative, your strongest point is that grading the Q2 filing a full pass means reading it more kindly than the market did. So look at what the market actually did.

The verdict on the report took one day. On August 13 the stock gapped 7.3 percent on 32 million shares, and OBV lost 73 million in four sessions.
Then it held. It closed at $29.36 on August 25, above the 50-day, and at $28.74 on August 28, above the 200-day.
The next 10 percent came after August 31. The 10-year rose 53 basis points, the Fed hiked, the dollar gained about 3 percent in three weeks, and Barron's tied yields directly to weakness in China internet stocks. Arete's downgrade landed in that stretch too.
That leg came on light volume. It traded 4 to 7 million shares a day, and OBV fell about 58 million over six weeks, less than in the four days around the gap.

You're right that the repricing isn't finished. But the second leg looks like macro plus one analyst, not a second verdict on JD. If Q2 passes all four tests, most of the discount below the post-gap level is China beta, which the hedge covers and which can reverse. What the filing still has to explain is the gap day itself. If we can't find what was sold on August 13, I accept the neutral's rule and drop a tier.

On FY2014, check the table you cited. The opex ratio fell from 16.7 to 15.2 percent in the first year, 1.5 points. FY2018 to FY2019 was 1.7 points in its first year. You're right that 57 percent revenue growth did much of that work, and we're growing at 13. But at today's revenue, 1.5 points is about RMB 20 billion of operating income, roughly seven times last year's total. The stock doesn't need two years of unwinding to reprice. It needs Q3 to point the same way Q2 did, and the filing gate means we only buy if Q2 already does.

And yes, operating leverage cuts both ways. One more point takes operating income to about minus RMB 10 billion. That's why nobody here goes into the print unhedged, and why the gate exists. The option market does charge for big moves, which is exactly why size now comes from the quote. If it charges a lot, we're smaller or out. If it underprices the event, we're bigger. That's taking risk on purpose instead of by default.

I'll sign the rest:

Filing test: the neutral's version. Operating income must be up year on year with revenue still growing, because ending a subsidy war should cost some bought growth. A concrete signal of wider Q3 losses vetoes the trade; boilerplate doesn't.
Weekend reading: add the Golden Week spending data.
Stop: exit on a daily close below $25.71, with one filtered re-entry and the spread held through the three sessions. Every option leg closes with the stock, including any short call.
Macro tripwires: a single tripwire freezes adds. The 10-year above 5.4 and the VIX above 20 in the same week cuts anything unhedged.
Gap test: a 25 percent gap against half a percent of equity, counting existing China internet holdings.
Exclusions: no KWEB short and no call spread.
After the print: the 60/80/full ladder. Presales can veto a step but not earn one. By the time the weekly SuperTrend flips it will sit lower than $31.63, so waiting for it is cheap.

So my final position on JD is Buy. Grade the filings this weekend. Price the $26/$22 spread before any stock order, with an expiry at least a week past the latest plausible Q3 date. Work limits at the 10-day EMA, capped at $27, until a week before the print. Size off the all-in, with 10 percent on a partial pass. No adds before Q3, then the ladder. Every plan in this room now has the same protections. The only thing left between us is whether we take more of a positive-expected-value bet when the market prices it cheaply. Then is exactly when we should. Aggressive Analyst: Aggressive Analyst: I'll start by giving up what I lost last round, because the conservative earned it.

The all-in formula had no stop in it, and that's a real flaw. Under a working limit that follows the 10-day EMA down, my table would have given its biggest tier to a fill sitting less than an ATR above $25.71. That's the share least likely to survive to the print. So size gets set once, from Monday's quote against the $26.75 reference, and a cheaper fill earns nothing extra. I'll take the $26.25 floor, the $27.00 cap, and the neutral's combination order so the stock never trades without its spread.

I'm also dropping 35. The neutral's math shows the edge is real but small. The collar point goes to the conservative too. An expensive spread is the market warning about the tail below $22, and selling a $32 call doesn't touch that tail. So it's half size first, then the call on top of the smaller position.

Conservative, your closing charge was that both our tables only go up. Look at the rung everyone now agrees on at the expensive end. The neutral's no-trade line above $1.25 is exactly my no-trade line at a $2.00 all-in, because at the $26.75 reference, 75 cents plus $1.25 is $2.00. Your table didn't have that rung. It held 12.5 percent at any premium above a dollar, and at $1.50 that position needs about 56 percent odds, above the top of our own range. The rule that refuses a bad bet came from the aggressive side. Being smaller isn't the same as being disciplined. Discipline means declining where the numbers don't carry the trade and taking a bit more where they do.

That leaves one real disagreement: whether a clean Q2 can earn the neutral's 30. Your principle is that size should follow how well we know the odds. I agree, and that principle is the case for the top tier. This weekend's filings are the measurement you said was missing.

Suppose Q2's opex ratio is down a full point year on year. That's around RMB 3 billion of operating income in one quarter, about 13 billion annualized, nearly five times FY2025's entire operating profit. Suppose new-business losses are also falling both year on year and from Q1. Then the 50 to 55 percent stops being a guess about whether spending peaked, because we'll have watched it peak. If that evidence can't move size, the gate can only ever shrink us. That's the one-way table you accused us of, pointed the other way. The neutral is right that tightening the bar to a half point and then cutting a pass from 25 to 20 counts the same caution twice.

Use your own method. Your 35/30/35 split at a dollar comes out near zero, and the neutral's tilt to 40/30/30 gives about 19 cents a share. Now take the case that actually earns 30: a full-point opex drop, the spread at 85 cents or less, and options pricing a smaller move than JD delivers. Tilt it only to 45/30/25 and it's about 54 cents a share, roughly 2 percent of the position, nearly triple. These splits are illustrative, like yours, but the direction holds.

Any fractional sizing rule scales with the edge. Going from 25 to 30 on roughly triple the edge is a 20 percent increase in size. That's a much heavier haircut than the overbet you're warning about.

The cost is small. In a 25 percent gap, the hedged 30 at 85 cents loses about 4.0 percent of a full allocation, against about 3.5 for the hedged 25 at a dollar. That's half a point, in the tail, and the portfolio gap test overrides any tier before it gets there.

There's one more point. The neutral estimated the stop gets touched 45 to 55 percent of the time before the print, so a 25 starter reaches the print at 11 to 14 on average. Your 25 is really a low-teens bet on the only payoff you agree the starter uniquely owns. A 30 is a mid-teens bet. Neither is reckless.

On the cheap spread being a second bet, I concede it. The neutral's implied-versus-realized check answers it and sits inside the 30 gate. If options are pricing roughly what JD actually moves on its prints, the cheap spread earns nothing and we stay at 25. We only take the volatility view after we've tested it.

On the middle case, you treat a fine quarter with the stock near $27 as pure bleed. Follow the ladder through. If the four tests pass and the stock sits at $27, the 60 percent step happens on the print at $27, with information in hand and three dollars below the $30 we'd otherwise pay. The roughly 58 cents of decay buys the cheapest informed entry this trade will offer. That's a setup, not a loss. You're right that the gap itself is the starter's unique payoff, which is exactly why its size comes from the quote.

On China beta, I accept that much of the move since late August came from the long end of the bond market. But count the rules already handling it:

The spread covers it down to $22 through the print.
The joint yield-and-VIX trigger cuts anything unhedged.
The gap test counts every China holding in the book.
After the print, the failed-gap exit and the trail to $26.42 cover it once the hedge rolls off.

Shrinking the tier for it would count the same risk a fifth time. It isn't all one way either. The yuan has held at 6.70 through a 3 percent dollar rally, and this weekend's Golden Week data gives a direct read on the consumer.

On Arete, the neutral put it well: stop inferring Q2 from people who read it, and read it ourselves. If it passes and we can't explain what was sold on August 13, we drop a tier. I've signed that.

I'd still change one rule, because as written it can kill a good trade on noise. You both agreed a single tripwire cancels the unfilled starter. The 10-year is 12 basis points from 5.4 percent with September CPI due mid-month. Brent is about $2 from $105, and WTI went from $84 to $107 to $96 in two months. Either one can trip in a single session.

The starter is now a combination order that never exists without its hedge. Cancelling it on one close turns a rule built to freeze adds into a veto on the whole trade, which all three of us rejected for single triggers. So a single tripwire should pause the working orders, and two consecutive closes beyond the level should cancel them. The joint trigger still cancels immediately. It's the same filter we put on the re-entry with the volume test: respect the signal, screen out the noise.

After the print, I'll sign the 60, 80, full ladder, the conservative's failed-gap exit on every step, and the neutral's trail to a daily close below $26.42 once the hedge expires. I'd add one tool, since we all agreed to revisit it once the event premium comes out.

On a passing print, price a call spread toward $33.50 the day after, once implied vol has collapsed. Let it carry part of the next ladder step, counted at its delta. The upper strike sits where supply turned the stock twice this year, at $33.47 and $33.77, so we'd be selling upside the chart says is hard to reach anyway. If the failed-gap rule fires, we lose the premium rather than sliding dollar for dollar from $30. If implied vol hasn't come in, we use stock. Here the aggressive tool is also the one with the defined loss.

So I'm at Buy, on the neutral's sequence with two changes:

Gather the data. Read the Q1 and Q2 releases and the Golden Week data this weekend. No filings, no trade.
Grade Q2 on the four tests with the half-point bar.
Price the hedge. Confirm the Q3 date or use the latest plausible one, and price the $26/$22 spread with expiry at least a week past it.
Size once from that quote against $26.75.
30 percent if opex fell a full point, the spread is 85 cents or less, and options price a smaller move than JD delivers.
25 percent on a full pass at a dollar or less.
12.5 percent between a dollar and $1.25, covered call allowed.
Nothing above $1.25.
10 percent on a partial pass.
The gap test against your actual China holdings overrides all of it.
Work the entry. Place limits at the 10-day EMA between $26.25 and $27.00 as combination orders. A single tripwire pauses them, and two consecutive closes beyond the level cancel them. This is the first change.
Manage the stop. Exit on a daily close below $25.71, with the filtered re-entry and the spread held through it.
Keep it clean before the print. No adds, no KWEB short, no pre-print call spread.
After the print, run the ladder with its exits, and use a post-crush call spread for part of a step when vol allows. This is the second change.

Conservative, you said the odds are the one thing we can't measure yet. By Monday we'll have measured them. If the filings say the subsidy war has turned, the bigger risk is ending up too small at $26.75.

Conservative Analyst¶

Conservative Analyst: Conservative Analyst: Some of my colleague's case holds up. The operating leverage is real, the balance sheet is real, and buying in tranches is the right instinct. My objection is to the specifics. The edge is thin, the fundamentals behind it are nine months old, and two of the plan's rules increase our risk at the moment the thesis is failing.

I'll start with the stale information, because nobody has raised it. Every fundamental number in this debate comes from the FY2025 annual report. We have nothing for Q1 or Q2 2026. The fundamentals report says plainly that those filings weren't in the data and that nothing shows whether the spending eased or got worse. The market, though, did see something. On August 13 the stock gapped down 7.3% on 32 million shares, five times normal volume, right when JD usually reports its second quarter. The tools can't confirm the cause. Still, a gap like that, followed a few weeks later by Arete cutting to Neutral and lowering its target from $36 to $30, is not how a market reacts to news that the subsidy war is winding down. When my colleague calls FY2025 "the trough," that's an assumption. The most recent evidence we have, the price reaction, suggests the trough may still be ahead. Reading those two quarterly filings costs us a day. Buying before we read them means choosing to trade blind.

The valuation multiples flatter the picture in two ways.

The 14x figure is on EPS that the fundamentals report says was propped up by interest income and investment gains. The operating business earned RMB 2.8 billion on RMB 1.3 trillion of revenue, a 0.21% margin. That cushion is interest on a cash pile now being drawn down by buybacks, capex, subsidies and a $2.5 billion acquisition.
The 6.7x figure is anchored to FY2024, JD's best margin year ever at 3.34%. The precedent my colleague cites, FY2018 to FY2019, recovered operating margin to 1.56%. Applied to FY2025 revenue, that's roughly RMB 20 billion of operating income. That would be a big recovery from 2.8, but it's about half of FY2024. Normalization doesn't mean a return to the peak.

That precedent was also JD pulling back its own spending. This time it's a subsidy fight in food delivery, where JD doesn't control when the spending stops, and the 7Fresh Kitchen launch suggests it's still pushing, not retreating.

I'd also be careful with "nothing is broken in the core." The 13% revenue growth and the RMB 43 billion of extra spending arrived in the same year. We can't break operating expenses down by line, so we don't know how much of that growth was bought. If the subsidies come out, some of the growth probably comes out with them. The record gross margin tells us little if the subsidies are booked below gross profit. And estimated return on equity has fallen to about 8%, below the 11% cost of equity our own fair value uses. Right now the business earns less than its cost of capital.

On cash, "cut the subsidies and the cash comes back" just restates the thesis. Here's what we actually know:

Operating cash flow fell 67%.
The cash balance rose only because JD sold RMB 41.8 billion of investments.
Capital returns exceeded free cash flow by RMB 15.5 billion.
Equity attributable to shareholders shrank 6%, and liabilities rose to 57.7% of assets.

My colleague lists the Ceconomy deal as a catalyst. It's roughly RMB 17 billion going into a low-margin European electronics retailer while the ECB is raising rates. That's about a year and a half of last year's free cash flow. EU approval removes a headline. It doesn't add earnings, and it does add integration risk.

On Arete, a Neutral rating with a $30 target is not a hidden bullish call. It's a 17% target cut, and analysts' targets tend to follow price down. More to the point, our fair value of $29 to $31 is essentially the same number as the analyst who just downgraded. Our "edge" is a downgrade's target.

My colleague's own math makes my point on risk and reward. He says waiting for a close above $27.72 gives up 3.6%, which is a third to a half of the upside to the low end of fair value. So the upside from $26.75 to $29 is about 8.4%, and the stop is 8.8% away. To the low end of fair value, we're risking more than we stand to make. Even with a $30 target, we need to be right a little over 40% of the time to break even. Our estimate is 50 to 55%. That five-to-ten-point edge was estimated without the last two quarters, without valuation data, and before pricing a put spread that has to run through an earnings report. The edge is smaller than the uncertainty in the estimate.

Then there's the part of the plan I'd change no matter what. My colleague says the burden of proof is on the bears to break $25.71. I agree, and so does the technical report: losing $25.71 cancels the reversal case and produces the first lower low against this year's pattern of rising lows. But when the bears clear that bar, the plan doesn't exit. It buys a second tranche with a resting limit order at $24.60 to $25.20, entirely below the level we just said invalidates the setup. We'd double exposure exactly when the structure breaks, and the bottom of that range sits twenty cents above the stop.

The stop itself is a weekly close, not a price. "Just under the March and June lows" is true only of the closing lows. The March intraday low was $23.66. A stock that can trade there midweek, in a market where China headlines can land any day, can take us well past 8.8% before Friday's close lets us out. The "2.2% of a full allocation" figure assumes a clean exit that a weekly-close rule can't promise. And the gap cap assumes a 15% gap. With Beijing back in the headlines, I'd size for something closer to 20 to 25%.

On the technicals, I concede the death cross is mostly arithmetic. But the technical report also says it will probably trigger automated and headline-driven selling around October 12, which is Monday. Why place the starter right before a selling event we can see coming?

The weekly TD 9 is sitting on an unfinished bar. My colleague's reply, that if it fails it fails because the stock rallied, just means it isn't evidence either way. A completed TD buy setup typically signals a bounce of one to four bars. We've already had four up sessions and 4.4%, so we may be buying the tail end of the bounce it predicted.

The rest of the momentum picture is no better:

MACD is still below zero.
RSI hasn't printed above 50 once since late August.
On-balance volume made a new low along with price, and the bounce has come on volume barely above average.
"Tested $27.04 twice without rejection" also means "failed to get through $27.04 twice."

Above that level the resistance stacks up: the daily SuperTrend at $27.44, the upper Bollinger band and 23.6% retracement at $27.58, the swing high at $27.72, and then the death-crossed moving averages at $28.50 to $28.70, where the report itself says to expect sellers. Holders like Tiger Global, with an average cost near $33.70, add supply on any rally. As for the rising lows, three data points don't make a rule. Those earlier rallies happened while the Fed was on hold, and the Fed is now raising rates.

That leads to the macro point my colleague underrates. His argument that core inflation is soft and oil may ease is about the Fed. But the pressure isn't coming from the Fed. The 2-year yield is flat since the hike. The 10-year is up 53 basis points since August to near 5.3%, and the curve is steepening. That's investors demanding more to hold long bonds, and cheaper oil doesn't automatically fix it. Barron's ties that move directly to weakness in Chinese internet stocks.

A VIX at 15 while the bond market does this looks like complacency that tends to end abruptly. When it does, high-beta China ADRs get sold as a basket, which is how retail traders are treating JD right now: tagged alongside BABA, KWEB and YINN. On the Alibaba probe, the same report that says JD has less AI exposure also says JD dipped on the news. And "advances while market declines" is a formulaic recap. The chart shows a 23% drop in two months while global markets sat near highs.

Between now and Q3 we face September CPI, the FOMC at month-end, the midterms with Iran strike risk returning right after, and Singles' Day. Then comes the earnings report, whose date we still haven't confirmed. That's five binary events stacked on a thin edge.

The catalysts are also thinner than they sound. "Bullish options flow" is a headline with no detail. The 57/43 StockTwits split comes from 30 messages over 27 hours, with one account supplying three of the eight bullish tags. Reddit data was disabled, and the report itself grades sentiment as low confidence. That isn't room to run; it's no signal at all. Singles' Day presales could read either way, and Nike cutting back on China online distributors to curb discounting suggests the price war is still live.

I'd decline the call spread. Buying more upside ahead of earnings, without checking JD's implied volatility, adds premium cost and time decay to a trade whose edge the hedge is already eating. The plan already has a way to add exposure: wait for Q3 to pass the three tests.

Finally, the fear of chasing at $30. If Q3 shows the expense ratio falling, new-business losses shrinking and cash flow recovering, fair value rises with it. Buying at $28 or $30 with that information is a better trade than buying at $26.75 without it. Missing the first 10% is the cost of insurance. The opposite mistake, holding half a position into a disappointing report in a weak market, is how you lose 20%.

JD has a precedent for that too. After the FY2021 margin squeeze, operating income recovered over three years to a record in FY2024. The stock still sits with its monthly SuperTrend pointing down at $41.83. A recovery in the business and a recovery in the stock are different bets.

To our neutral colleague, before you make the case that a staged plan is balanced: it looks balanced on paper. It isn't balanced in risk when the second tranche buys below the invalidation level and the stop only triggers on a weekly close.

So here's what I'd support. Keep the direction as a cautious Buy, but change the terms:

Read the filings first. Before any order goes in, pull the Q1 and Q2 2026 quarterly filings and confirm the Q3 date. If first-half operating expenses ran above the FY2025 ratio, stand aside.
Shrink and delay the starter. Cut it to 10 to 15% of a full allocation, placed after today's weekly close and Monday's likely death-cross session.
Tighten the stop. Make it a daily close below $25.71, the level my colleague himself named. That's roughly 4% of risk instead of 9%, with about 1.5 to 1 reward to risk to $28.45 and close to 3 to 1 to $30.
Delete the averaging-down tranche. Remove the $24.60 to $25.20 limit entirely. The only add before Q3 is the confirmation trigger: a close above $27.72 on 8 million or more shares with RSI above 50.
Cap exposure before Q3 at 25% of a full allocation, not 50%.
Keep the hedge, priced first. Keep the put spread, price it before committing, and put it on early. That's the one point where my colleague and I fully agree.
Add macro tripwires. A 10-year yield above 5.4% or Brent back above $105 means no adds and cutting toward zero.
Scale up in steps after Q3. Don't go straight to 100%. Before going beyond half, require price to recover the moving-average cluster near $28.70.
No call spread.

That keeps us in the trade if the subsidy war is truly ending, limits the damage if it isn't, and means the firm only adds exposure as the evidence improves. Conservative Analyst: Conservative Analyst: Most of the risk in the original plan is now gone. The averaging-down limit at $24.60 to $25.20 has been deleted. The weekly-close stop at $24.40 is now a daily close below $25.71. The filings get read before any order goes in, and the call spread is off the table. Those were the most dangerous parts of the trader's plan, and I'm glad to see them go. What's left is the pre-Q3 size, plus a few arguments my aggressive colleague uses to defend it that don't hold up when you check them.

Start with his gap comparison, because his case for 50% rests on it. He compared his hedged 50% against "the conservative's unhedged 25%." That isn't my plan. Point six of my proposal kept the put spread, priced first and put on early, and he quoted it back as the one thing we fully agree on. So compare like with like. Take a 25% starter at $26.75, covered by the same $26/$22 spread at the same $1.00. In his 20% gap to $21.40, the stock loses $5.35 a share, the spread pays $4.00, and the premium cost $1.00. That's a net loss of $2.35, about 8.8% of the position, or 2.2% of a full allocation. His hedged 50% loses 5.2% in the same gap, well over double. At the $33.47 range high, he makes 9.6% of a full allocation and I make 5.3%. That is less than twice the upside for more than twice the downside, and the range high is the best case.

Now look only at the extra tranche he wants, bought at $27.72 or higher on the confirmation close. At $30, the low end of our fair value, it earns about 1.2 points of a full allocation after premium. In the gap, it loses about 3.0. The quarter he's fighting for risks roughly two and a half times what it makes at our own fair value. It also carries a fixed cost: if Q3 is simply fine and the stock sits near $27, the hedge on a 50% position costs about 1.8% of a full allocation. That premium alone is bigger than the entire stop risk on his starter.

His breakeven math has the same problem. He says risking 3.9% to make 8.4% to $29 breaks even at about 32%. That leaves out the $1.00 of premium he has made mandatory, which is 3.7% of the price. Take it out of the reward and the move to $29 is worth about 4.7%. If we're stopped at $25.71, the spread will be near the money and worth something, but probably not all of what we paid. Breakeven to $29 then sits somewhere between the mid-40s and the low 60s. Even to $30 it's roughly a third to a half. We're back where I started: the edge is smaller than the error in our odds.

There's a deeper problem. In a stock with no edge at all, the chance of reaching $29 before closing below $25.71 is about 32%: $1.04 divided by $3.29. That's not a coincidence. In a random walk, the breakeven rate and the odds of hitting the target first are the same number. So every point he claims above 32% has to come from a real directional edge over the next five weeks, before Q3 tells us anything new. The near-term evidence is the weakest part of this case. OBV made a new low with price, all three SuperTrends point down, MACD is below zero, and the death cross is due Monday. With ATR at 0.52, a stop two ATRs away has something like even odds of being touched on a closing basis over five weeks even if the stock has no trend at all. Our 50 to 55% was the probability that the subsidy war winds down. It was never the probability that the stock reaches $29 before it closes below $25.71. He's borrowing the answer to one question for the other.

Next, "the market already paid $33 knowing how bad FY2025 was." JD usually reports full-year results in early March and first-quarter results in mid-May. The March 4 closing low of $24.53 falls in the first window. The May 13 high of $34.30 intraday falls almost exactly in the second. The August 13 gap falls in the Q2 window. The tools can't confirm causes, so treat this as timing only. But if the timing means what it appears to, the market sold the FY2025 results, bought something in Q1, and then sold Q2 on five times normal volume and kept selling for seven more weeks. The market didn't pay $33 in spite of FY2025. It paid $33 for Q1 and took it back on Q2.

That also answers my neutral colleague's view that the August news is "priced in and then some." A one-off repricing gaps and stabilizes. This one gapped, fell another 12%, and made a new OBV low on October 2. That looks like continued selling into a worsening trend, and Q3 could be the next leg of it. That's why the filing veto has to be strict. The neutral's version was right: falling from Q1 to Q2 and falling year on year. My aggressive colleague's final version kept only the sequential part. That's the weaker half, because Q2 includes the 618 festival and sequential comparisons in Chinese retail are muddied by seasonality. Year on year is the cleaner test, and it has to stay in. I'd add one more condition. If the Q2 release that coincided with the August gap guided to continued or heavier spending, we stand aside regardless of the ratios.

On valuation, his recalculation of the FY2019 precedent is fair arithmetic, and I accept that a 1.7-point opex cut gets you to about RMB 25 billion. But FY2019 revenue grew 25%. Part of that opex improvement came from growing into the cost base, and today's growth is 13%. The more recent precedent is FY2021 to FY2022, when revenue grew about 10%, close to today. Then the opex ratio fell only 0.9 points, from 13.1% to 12.2%. Applied to FY2025, that's roughly RMB 15 billion of operating income. So the precedents span about 15 to 25 billion, and my 20 sits in the middle. Both precedents were JD deciding to cut. This time Meituan and Alibaba also get a vote on when the subsidies stop, and the 7Fresh Kitchen launch suggests JD isn't done pushing.

I'd also point out a habit in his argument. When FY2025 looks bad, it's "the trough." When he needs comfort, he reaches for FY2024: 17 to 18% ROE, and Ceconomy measured against a third of FY2024's free cash flow. FY2024's free cash flow no longer exists. Against FY2025's actual RMB 11.2 billion, last year's RMB 26.7 billion of capital returns plus roughly RMB 17 billion for Ceconomy comes to about four times what the business generated.

The claim that cash is "half the market cap" has the same flaw. RMB 137.5 billion of cash sits against RMB 306 billion of current liabilities, much of it owed to suppliers. Part of it sits inside JD Logistics and JD Health, which have about RMB 69 billion of outside equity. And it rose only because RMB 41.8 billion of investments were liquidated. That moved money between pockets; it didn't create any. This is a supplier-funded retailer's float, not a cushion shareholders can count on.

Then the "short-duration" argument. A company with a 0.21% operating margin has nearly all its value in the recovery years, and that's what duration means. The tape has also already answered the question. JD dipped on the Alibaba probe, retail traders tag it alongside BABA, KWEB and YINN, Barron's ties the yield move directly to Chinese internet weakness, and the stock fell 23% while global markets sat near highs. The theory says short duration; the price action says China beta.

That brings me to the KWEB short, and I'd push back on it harder than either of you has. KWEB holds JD itself. It also holds Alibaba and Meituan, and Meituan is JD's direct opponent in food delivery. If the subsidy war ends, which is our entire thesis, Meituan and Alibaba are among the biggest winners. Shorting the basket partly shorts the other beneficiaries of our own catalyst. We also have no beta or correlation estimate to size it, and China policy headlines can gap the whole basket up overnight. A hedge we can't size is just a second position. If someone wants less China beta, the cleaner fix is less gross exposure, and either way any existing China internet holdings should count against the cap.

On Arete, $30 is a twelve-month target. Taken at face value, that's 11 to 12% over a year, and Arete considered that only worth a Neutral. We're trying to earn most of that move in five weeks, net of a dollar of premium, through an earnings report.

On scaling after Q3, his "75% on the print, full size on a weekly close above $28.70" collapses into a single week in practice. If Q3 is good enough to gap toward $30, Friday's close clears $28.70 automatically, and we're at full size on one quarter of data. Q3 covers the summer delivery battle. Q4 contains Singles' Day. One improving quarter in a fight JD doesn't fully control isn't proof the fight is over. I'd use the neutral's four tests, sequential and year on year. Go to 60% on the print, 75% on a weekly close above $28.70, and full size only when the weekly SuperTrend flips or a second quarter confirms. Waiting from $30 to $31.63 on the last quarter of the position costs about a point and a half of a full allocation. That's cheap insurance against a false dawn. On supply, he's right that I shouldn't have cited Tiger Global's cost basis. It came from the same unverified feed I dismissed, and I withdraw it. The argument doesn't need it anyway: the range highs at $33.77 in May and $33.47 in August both turned price down, and that comes straight from the price data.

To my neutral colleague, you caught me on the TD count. Those are weekly bars, not days, and I accept the correction. You were also right that I stacked a tighter stop on top of a smaller size, and that your Monday limits below Thursday's close absorb the death-cross session without a second delay. So I'll move to your 20% starter and your Monday timing. Your 40% hedged cap has the same flaw as the aggressive 50%, just smaller. Hedged 40% loses about 4.2% of a full allocation in that same gap, against 2.2% at 25%. The spread only covers $26 down to $22. Above $26, below $22, and in the premium itself, size still drives the loss. A hedge doesn't make size free; it moves where the risk sits.

I'll take your re-entry rule with two filters. First, apply our own volume standard in both directions. We say a breakout on fewer than 8 million shares is suspect, so a breakdown on more than 8 million isn't a shakeout and shouldn't earn a re-entry. Second, no re-entry within a week of the Q3 date, and none unless the hedge is still on. On the tripwires, I accept that a single trigger should only freeze adds. But if the 10-year closes above 5.4% and the VIX closes above 20 in the same week, that's a regime change rather than noise, and any unhedged portion should be cut.

So I'm still a cautious Buy, on these terms:

Filings. Read the Q1 and Q2 filings this weekend. Proceed only if the opex ratio and new-business losses fell both sequentially and year on year. Stand aside if Q2 guided to more spending.
Starter. Place a 20% starter Monday with limits at $26.66 to $26.77, and buy the put spread the same day with a $1.00 ceiling and an expiry at least a week past a confirmed Q3 date. If it prices above the ceiling, lower the strikes or cut the starter to 15%.
Stop. Exit on a daily close below $25.71, with one filtered re-entry. The averaging-down order stays deleted.
Adding before Q3. Add only on the confirmation close, with a second close required if the move comes on a Ceconomy headline. Cap total exposure at 30%, fully hedged, and trail the stop to a daily close below $26.42.
Gap budget. Size the whole position so that the post-hedge loss in a 25% gap stays within the trader's own 0.5% of portfolio equity rule, counting existing China exposure.
Exclusions. No call spread, and no KWEB short we can't size.
After Q3. Scale up in steps, and reach full size only after the weekly trend actually turns.

My colleague's plan is far safer than where it started. The pre-Q3 size is the one place left where it still takes on more risk than the extra return justifies. Conservative Analyst: I'll start where I was wrong, because two corrections from last round are fair. Neutral, the put spread isn't a sunk dollar during the window before the print. If we're stopped at $25.71 a week from now, the $26 put is in the money with earnings still ahead, and the spread is worth more than we paid. So my mid-40s-to-low-60s breakeven for that window was overstated. It's close to a fair bet, as you said. Your Q2-against-Q2 test is also better than mine, because Q1 2026 against Q1 2025 would fail almost automatically. I accept both.

Aggressive, you've moved a long way. You've dropped the averaging-down order, the weekly stop, the 50 percent cap, the KWEB short and the FY2024 free cash flow. But I think you took the right lesson from the neutral's tranche math and then spent it on the wrong thing.

The neutral showed the confirmation add was a bad bet. The right response is to delete it. You deleted it and moved its budget into the starter, which is a different decision. Take your claim that 35 percent has the best upside per unit of downside of the three plans. That ratio doesn't change with size. A 25 percent starter at the same price, with the same spread, loses about 2.2 percent of a full allocation in a 20 percent gap and makes about 5.3 at the range high. That's the same ratio as your 3.1 and 7.5. The better ratio came entirely from removing the add. Ten extra points of the same bet only changes how much we lose if our 50 to 55 percent is wrong.

Your table also compares your unconditional 35 against our maximums, and the add only exists after a confirmation close. Take the path that worries me most: the stock never closes above $27.72, and then the print disappoints. The neutral's plan holds 25 percent and loses about 2.2. Yours holds 35 and loses 3.1. That's 40 percent more damage in the likeliest bad path, and you described it as a tenth of a point.

Now the claim that the edge is in the print and that we can be fifteen to twenty points too optimistic. Look at what the hedged starter pays after the print. Anywhere between $22 and $26, it loses a flat $1.75 a share, about 6.5 percent, because the spread absorbs everything except the 75 cents above the strike and the premium. The downside is fixed, so the answer depends entirely on how high the good case goes.

At $31, the top of our fair-value range, breakeven is 35 percent.
At $30, about 44 percent. That's the midpoint of our fair value, it's Arete's target, and it's your own phrase from two rounds ago: a good Q3 "could open near $30."
At $29, the low end of fair value, about 58 percent, which is above our own odds.

Neutral, you said it yourself: our fair value is Arete's twelve-month Neutral target, and our edge isn't a mispriced normal value. If so, the base good case is fair value, not the top of the range.

All of that also assumes the spread costs a dollar, and nobody has a quote yet. Every quarter above a dollar adds five or six points to breakeven. At $1.25, with a $30 print, the hedged starter wins $2.00 or loses $2.00, a straight coin flip. The Q3 date isn't confirmed either. If we have to buy a later expiry to be sure the hedge covers it, the price goes up again.

Neutral, you called operating leverage lopsided with more room up than down. It works in both directions. At a 0.21 percent operating margin, one more point on the opex ratio takes operating income from RMB 2.8 billion to roughly minus 10. The last print in this window was followed by a 7.3 percent gap on five times normal volume and a further slide, and the 7Fresh Kitchen launch says JD is still spending.

Aggressive, you say big moves work for us because the spread caps the downside near entry. It only covers $26 down to $22. Below that we're unhedged again. The option market also charges for big expected moves; it doesn't hand them to the long side for free.

On FY2022, you're right and I withdraw it. FY2021 was a gross-margin squeeze, and the opex ratio never left 13.1. But look at the two times JD actually unwound an opex ratio this high:

FY2014: after 16.7 percent, it took two years to reach 14.2, with revenue growing 57 and then 43 percent.
FY2019: the recovery came with 25 percent growth.

Both times JD grew into its cost base. Today it's growing 13 percent, and Meituan and Alibaba also decide when the subsidies stop. That isn't a reason to stay out. It is a reason not to assume one quarter shows the whole recovery.

Then the fallback. You said you won't chase, and you called the confirmation tranche a coin flip that costs a dollar more. Then you rebuilt it at 20 percent, twice the add you deleted, triggered by the stock running away from our limits. With its spread struck a dollar below $27.72, it needs about 44 percent odds if the print takes us to $31, and nearly 60 at $30. That's chasing with a hedge attached. Neutral, the same math applies to your 10 percent add with its own spread. If Monday's limits don't fill, we wait for Q3 and buy with information.

On the filing test, I'll take the Q2-against-Q2 structure. But neutral, two rounds ago you warned that comparing year on year against 2025 is a low bar because 2025 is the subsidy year. Q2 2025 sits inside that year. So a full pass should apply your fourth test now, not only after Q3: if the opex ratio fell but revenue growth fell with it, that's bought growth and not a pass.

I'd also read the call for anything specific about Q3. Boilerplate about investing shouldn't veto the trade. A concrete signal that third-quarter losses would widen should, because that's the quarter we're holding through.

And keep one fact in view, on timing alone. The market read that Q2 release, sold it 7.3 percent on five times volume, and then took off another 12 percent. If we grade it a full pass, we're reading it more kindly than the market did. We may be right, but that earns the base size, not the biggest.

On the window, since I now accept it's close to a fair bet, that settles the size question. The neutral estimates the stop gets touched 45 to 55 percent of the time over the next five weeks. That window holds September CPI, the FOMC, the Ceconomy decision, and the midterms with Iran risk right after. A fair bet held at 35 percent is just more variance than the same bet at 25, with no more expected return. Taking variance without edge is exactly what we're here to avoid.

After Q3, I'll take the neutral's ladder: 60 percent on the print, 80 on two consecutive weekly closes above $28.70, and full size on a weekly SuperTrend flip or Q4 confirmation. You both pointed out that the weekly SuperTrend will sit below $31.63 by late November. That makes waiting for it cheaper than the point and a half I estimated, which removes the aggressive's main reason for skipping it.

On presales, we have no data feed, only headlines that the aggressive himself said can read either way. They can veto a step, but they can't upgrade one from 60 to 75. As for Arete revising up, if that happens we'll see it after the print, which is when the ladder adds anyway.

Two practical points on the hedge. Aggressive, you said the case for concentrating rests on a strike near entry. Then lowering the strikes is never the fix: if the spread prices above the ceiling, we cut the size instead. And if the stop fires on the print, the spread comes off with the stock. We shouldn't leave a short $22 put open after a gap, where an assignment could hand us stock below the line we all agree means we're wrong.

So I'm still a cautious Buy, on these terms:

Grade the filings this weekend. A full pass needs all four of these:
Q2's opex ratio below Q2 2025.
New-business losses below Q2 2025.
New-business losses down from Q1 to Q2.
Revenue growth holding up, with nothing in the commentary pointing to wider losses in Q3.

A full pass gets a 25 percent starter. A partial pass gets 10. Anything less, we stand aside. 2. Confirm the Q3 date and price the $26/$22 spread before any stock order. The expiry should be at least a week past the date, with a one-dollar ceiling. If the date isn't confirmed, buy the expiry that covers the latest plausible date. If that breaks the ceiling, halve the starter. 3. Place the starter Monday at $26.66 to $26.77, with no fallback entry if it doesn't fill. 4. Exit on a daily close below $25.71, with the one filtered re-entry and the spread held through the three sessions. 5. No adds before Q3. The starter is the cap. 6. Size for a 25 percent gap after the hedge within 0.5 percent of equity, counting existing China internet holdings. 7. Macro tripwires. A single tripwire freezes the post-Q3 steps. The joint yield-and-VIX trigger cuts anything unhedged. 8. No call spread and no KWEB short. 9. After Q3, follow the neutral's ladder. Mixed results mean we hold the starter, and failed tests mean we exit.

That gives the aggressive the cheap, hedged entry he says the edge depends on. It gives the neutral the larger starter when the filings earn it. And it keeps the one thing I won't give up: we don't put more money into a print than our unverified odds can carry. Everything beyond the starter waits for Q3, when we'll actually know something. Conservative Analyst: I'll start with what I accept, because the last round moved me. Neutral, you're right that my revenue condition would have failed the outcome we're hoping for. If growth slows from 13 percent to high single digits while operating profit rises, the thesis is working, so I'll take your version. You're also right that a one-day order is too rigid, and that letting Monday's quote set size is better than arguing taste. Aggressive, your all-in arithmetic is correct: entry minus the $26 strike plus the premium, divided by four, gives breakeven against a $30 good case. So is your FY2014 point that the opex ratio fell 1.5 points in the first year. I'll add the Golden Week data to the weekend reading.

But look at which way both your tier tables run. They only go up. Every input that's easy to measure earns more size. The input that actually decides the trade, our 50 to 55 percent, never gets tested. I think that's backwards, for four reasons.

First, aggressive, you said my argument, taken to its end, means holding nothing until the print. It doesn't. My argument is that size should follow how well we know the odds, not just how good they look. Our estimate was made without the Q1 and Q2 filings, without valuation data, and before anyone looked at what the market sold on August 13. You said proportional sizing would put the top tier near 45. That's the overbet anyone sizing on an unverified probability is supposed to avoid. When the odds could be off by ten points, you bet a fraction of what the point estimate says. Twenty-five isn't nothing. It's the size where the print matters to us and an error in our odds doesn't sink us. Size belongs on the ladder after the print, when the odds stop being a guess.

Second, a cheap spread isn't free edge. Your formula holds the $30 good case fixed while the premium falls. But the premium mostly falls because implied volatility is lower. A lower implied vol means the options market expects a smaller move in both directions. If the spread comes in at 84 cents instead of a dollar, the market is saying $23 is less likely, and it's also saying $30 is less likely. Sizing up on that quote adds a second bet, that options are underpricing JD's event, on top of the subsidy bet. Your closing line, take more when the market prices it cheaply, is that second bet stated plainly.

Third, and this is the one I'd ask you both to look at hardest: the all-in formula has no stop in it. It prices the print as if we always get there. Under the working-limit rule, cheaper fills come on down days, because the 10-day EMA follows price lower. Say the stock sags and we fill at $26.20 with a dollar spread. The all-in is $1.20, breakeven is 30 percent, and the aggressive's table gives us its top tier. But we're now 49 cents above a $25.71 closing stop, less than one ATR. In a no-trend model, that's roughly a four-in-five chance of a closing breach before the print. From $26.75 it's about 55 percent. The formula gives us the most size exactly when we're least likely to still hold it at the print.

So size should be set once, from Monday's spread quote against a reference entry of $26.75. A cheaper fill shouldn't earn more size. The working order needs a floor around $26.25, one ATR above the stop. Any single macro tripwire should cancel unfilled orders, because an unfilled starter is an add. And the spread gets bought with each fill. If we buy it Monday ahead of a fill that may never come, we end up owning a bearish position with no stock under it.

Fourth, neutral, you said the middle case and the post-print upside roughly cancel. I don't think they do. Anything the stock does after the print, from $30 toward the range highs, is open to anyone who buys on the ladder after the print, with information. It isn't the starter's edge. The starter's only unique payoff is the print move itself. And our 50 to 55 percent is the chance the subsidy war winds down, not the chance the stock prints $30. Some of those right-thesis outcomes are the one you described: a fine quarter, the stock near $27, and the premium bleeding away.

Take a split like this: a 35 percent chance of $30, 30 percent near $27, and 35 percent at $23. At a dollar of premium, those pay roughly plus $2.25, minus 58 cents, and minus $1.80 a share. The expected value is about zero. At 85 cents it's positive, but only about half a percent of the position. These splits are illustrative, and that's my point. Our whole edge sits in a probability nobody has measured, and it swings heavily with the hedge price. The quote should size us down when it's expensive, not up when it's cheap.

On the expensive case, I'd reject the collar as a substitute for cutting size. A spread above a dollar means the market is pricing a big move. That also makes a gap below $22, where we're unhedged again, more likely. Selling the $32 call lowers what we pay for the hedge, but it doesn't remove a dollar of downside. It keeps full size into the move the market is warning about, and pays for it by giving up the gap the aggressive says the starter exists to own. Sell the call on the smaller position if you like, but not instead of making it smaller.

Aggressive, your reading of the Q2 reaction is careful, and I accept that the second leg came on lighter volume alongside the bond selloff. But two things follow that cut against size. Arete is the one participant in our data known to have read Q2, and afterward it cut from Buy to Neutral and from $36 to $30. That's a fundamental verdict, not macro. And if most of the move since late August is China beta, then much of this position's variance comes from a factor where we have no edge. The 10-year at 5.3 percent and the steepening curve haven't resolved. That discount can reverse, but it can also extend. The hedge expires a week after the print; the yield problem doesn't. More variance from something we can't forecast argues for less size.

On the filing test, I've taken the neutral's revenue condition, but I'd tighten the operating income test. Two rounds ago the neutral warned that comparing against 2025 is a low bar, because 2025 is the subsidy year. "Operating income above Q2 2025" could pass on a trivial improvement from a terrible base. A full pass should require Q2's opex ratio to be at least half a point below a year earlier. That's roughly RMB 1.6 billion a quarter, enough to show spending has turned rather than drifted. And if the Q1 and Q2 filings can't be obtained and graded by Monday, that isn't a partial pass. It's no trade. The fundamentals report said plainly that these tools couldn't get them.

Neutral, you said the real catastrophe control is the portfolio gap test, not five points of starter. I agree that's the control that matters most, but the five points aren't free. With a dollar premium, a 25 percent gap costs about 4.8 percent of a full allocation at 35 percent size, against about 3.5 at 25. That gap also lands on the same day as every other China holding in the book. Run the gap test Monday against the caller's actual holdings, and let it bind before any tier does.

One hole none of us has closed is what happens after the print. The hedge expires a week later, and the ladder takes us to 60 percent with no stated exit. This stock reversed hard from the range highs twice this year, from $34.30 in May and $33.47 in August. As you said, neutral, FY2014 argues for patience after the print, and patience needs exits. So after any post-print step, if the stock closes back below the pre-print close, the gap has failed and we drop back to starter size. Nothing added after the hedge expires is held without a stop.

So I'm still a cautious Buy. I'm adopting the neutral's quote-based mechanism, calibrated so it can lower risk before the print but never add to it.

Read the filings and grade them on the four tests, with the opex ratio down at least half a point year on year. No filings, no trade. Confirm the Q3 date, and price the spread with expiry past the latest plausible date.

Size once from that quote: - 25 percent if the spread costs 85 cents or less. - 20 percent between 85 cents and a dollar. - 12.5 percent above a dollar, with a covered call allowed only at that size. - 10 percent on a partial filing pass.

Twenty-five is the ceiling before the print.

Work the limits at the 10-day EMA, capped at $27 and floored near $26.25. Buy the spread with each fill, and cancel unfilled orders on any tripwire. Exit on a daily close below $25.71, with one filtered re-entry and the spread held through the window, and close every leg together. Stress-test a 25 percent gap against half a percent of equity, counting existing China holdings. No call spread, and no KWEB short. After the print, follow the 60, 80, full ladder, with an exit on every step.

You both built rules where a cheap quote or a cheap fill buys more stock. Measuring the hedge is useful. But the odds are the one thing we can't measure yet, and they're what actually pays us. Conservative Analyst: Conservative Analyst: Both of you landed fair hits, so I'll start with what I'm conceding.

Neutral, you're right that I counted caution twice. I raised the evidence bar to a half point and then cut what passing it earns. So I'm dropping my 20 percent tier: a full pass at the stricter bar, with the spread at a dollar or less, earns 25. Aggressive, you're right that my table had no ceiling at the expensive end. At a $1.50 spread the hedged starter needs about 56 percent odds, which is above our own range, and your $2.00 all-in cutoff is the rule that catches that. So nothing goes on above $1.25. I'll also take the ladder of 60, 80, then full with failed-gap exits, the combination order, and the implied-versus-realized check as a principle.

That leaves the 30 percent tier, three loopholes in rules we've already agreed, a mistake in the post-print trail, and the post-crush call spread. In each of those, risk can come back into the trade without anyone deciding to take it.

Start with the 30. The case for it is that a full-point drop in the Q2 opex ratio turns our 50 to 55 percent from a guess into a measurement. Aggressive, early in this debate you made the opposite point, and you were right. You said the filings are public, the market has had them for weeks, and reading them guards against a mistake. That's still true. A full-point improvement in Q2 isn't something the market missed. The market already had it when it priced JD at $26.91. It raises our confidence that the subsidy war has turned, and it raises the market's expectations for Q3 by the same amount. Our edge at the print is the gap between what JD reports and what the market expects, and a public filing can't widen that gap. So the filing gate is a veto. It protects the 25, but it can't earn the 30.

Follow the best case for the 30 through. If the August 13 gap was the Q2 release, as the timing suggests, then a Q2 with a full point off the opex ratio means the market sold a good report 7.3 percent on 32 million shares. The stronger Q2 looks, the harder August 13 is to explain, and the more weight falls on the rule we all signed: if we can't identify what was being sold, we drop a tier. The scenario that earns the 30 on paper is exactly the one where that rule is most likely to bind.

"Drop a tier" is also ambiguous right now, so I'd make it concrete. An unexplained August 13 means our read is incomplete, and an incomplete read is a partial pass. That caps us at 10.

On "triple the edge," let me separate what we'll measure from what we're assuming. Use simple payoffs, with the spread worthless in the good and middle cases. A 40/30/30 split at a dollar is worth about 15 to 19 cents a share, depending on how you value the spread in the middle case. Drop the spread to 85 cents and keep the split, and it's about 30 cents. Tilt it to your 45/30/25 and it's about 50. So well under half of the improvement comes from the quote we'll see Monday. The rest comes from a five-point tilt in the odds that we're crediting to a public filing.

The implied-versus-realized check was supposed to test whether a cheap quote is really cheap, and I accept it in principle. But the only earnings-day move our data actually measures is August's 7.3 percent. The March and May windows show rallies over weeks, not gaps on the day of the print. One observation can't tell us the options are underpricing JD's event. Doing the check properly means pulling years of print-day moves, and even eight quarters is a noisy sample. If that isn't done by Monday, the 30 tier's third gate hasn't been passed, only left unmeasured, and unmeasured means 25.

Now put it to scale. On your own optimistic numbers, the extra five points add roughly a tenth of a percent of a full allocation in expected profit. Without the assumed tilt, it's about half that. In a 25 percent gap, those same five points cost about two-thirds of a point. I've already conceded that the ratio doesn't change with size. What does change is how much rides on an odds estimate whose only new input is information the market already has. The 30 also lowers the bar on the gap test. At 85 cents it binds for anyone whose full JD allocation is above about 12.5 percent of equity, not 14.

Your point that a 25 starter reaches the print at 11 to 14 on average doesn't help the 30 either. By the same arithmetic a 30 reaches it at 13 to 17, so the proportion is identical. More importantly, losses don't happen on the average path. They happen on the path where we survive the window and the print gaps, and on that path we hold the full 30. That's why the gap test measures it.

On the middle case, the 60 percent step at $27 after a fine print is open to us whether or not we held a starter, because the ladder gives us that entry. The 58 cents of decay doesn't buy it. It's still a cost.

On China beta, you listed four rules already handling it. Every one of them acts after the move or only covers a band. The spread covers $26 to $22 until a week after the print. The stop fires after a close. The joint trigger fires after yields and the VIX have already moved. Size is the only control that acts in advance. I'm not asking to shrink the 25 for this, only not to grow past it.

Now the three loopholes.

First, the expensive end. The neutral's cutoff is $1.25 "net of any covered call." That lets a $1.45 spread qualify for 12.5 percent by selling a 25-cent $32 call. But a $1.45 spread is the market saying a big move is likely, and the call does nothing about the tail below $22. Last round we agreed the call can't substitute for size, and netting it against the cutoff substitutes it by another route. Tiers should be judged on the gross spread at the price we can actually execute, not the mid. The call can lower our cost once we're in a tier, but it can't qualify us for one.

Second, the fill. We agreed size is set once from Monday's quote, so a cheap fill can't earn more. The same logic has to cut the other way. Puts get richer on down days, which is exactly when a working limit fills. If we size at 25 on a 95-cent quote and the combination fills with the spread at $1.10, we're holding a 25 that only qualifies for 12.5. So each combination order should carry the spread ceiling of the tier it was sized at, and size should be the lower of the Monday tier and the fill tier.

Third, the calendar. The Q3 date still isn't confirmed. We said to buy the expiry a week past the latest plausible date. The working orders need the mirror image: they stop a week before the earliest plausible date, not a week before our best guess. Uncertainty about the date should cost us at both ends, not neither.

On tripwires, aggressive, I'll take pause instead of cancel on a single close. The 10-year is twelve basis points from 5.4 percent, Brent is two dollars from $105, and the starter now never exists without its hedge. But your noise filter has to run both ways. If one close beyond the level is noise, one close back inside is noise too. So a paused order resumes only after two consecutive closes back inside. Two closes beyond, or the joint trigger, cancels it.

I'd add that the orders shouldn't be working on the day the September CPI comes out or on the FOMC decision day. Those are the two scheduled sessions most likely to move long yields, and there's no reason to be filling into them. And since we've agreed presales can veto a ladder step, a credible read of deeper Singles' Day discounting before the starter fills should cancel the unfilled orders for the same reason.

Neutral, on the trail once the hedge expires, I agree with your goal but not your level. You said trailing to $26.42 means a winning print can't become a losing position. Count the premium. A starter at $26.75 with a dollar spread, stopped on a close below $26.42, loses about $1.33 a share, roughly five percent of the position, after a print that went our way. If the goal is that a winner stays a winner, the trail has to sit at our all-in cost, about $27.75 on those numbers. If the stock can't hold above what we paid in total after a print that passed all four tests, the print didn't really win.

Aggressive, on the post-crush call spread, I won't reject it outright, because a defined loss after the print is a reasonable tool. But it shouldn't be pre-authorized today for a decision we'll make in six weeks with information we don't have yet. If it's used, three conditions apply:

It replaces the stock for that step and never adds to it.
Its premium is capped at what the stock step would lose on its failed-gap exit. "Counted at its delta" isn't a hard number, because delta moves every day, and the risk system needs a fixed figure.
Its expiry runs past the confirmation the next step waits for, so we aren't paying time decay while we wait on our own rule.

If implied vol hasn't come in, we use stock or nothing.

So here's where I land, still a cautious Buy.

This weekend, read the Q1 and Q2 filings and the Golden Week data. No filings, no trade. Grade Q2 on the four tests with the half-point bar. An unexplained August 13 counts as a partial pass. Confirm the Q3 date or bracket it, and price the $26/$22 spread at its executable price, with expiry a week past the latest plausible date.

Sizing:

A full pass with the spread at a dollar or less earns 25 percent. That's the ceiling before the print.
A spread between a dollar and $1.25 gross earns 12.5, with a covered call allowed on top.
Above $1.25 gross, nothing until after Q3.
A partial pass earns 10, and only at a dollar or less.
The gap test against the caller's actual China holdings overrides every tier.

Entry: work combination orders at the 10-day EMA between $26.25 and $27, each carrying its tier's spread ceiling. They pause on a single tripwire and resume only after two closes back inside. They cancel on two closes beyond or on the joint trigger. They sit idle on CPI and FOMC days and stop a week before the earliest plausible print.

Exit: a daily close below $25.71, with the one filtered re-entry and the spread held through it, and every leg closed together. No adds, no KWEB short, no pre-print calls.

After the print, run the 60, 80, full ladder with failed-gap exits. Trail the starter to its all-in cost once the hedge expires. Any call spread is a capped substitute for stock, never an addition.

If the trader overrides me on the 30, I'd ask for three things at minimum. First, the August 13 gap is explained. Second, the implied-versus-realized check is run on real print history, not one data point. Third, the gap test is passed at the 30 level, not the 25.

The last point is the simplest. On our most optimistic numbers, those five extra points are worth about a tenth of a percent of a full allocation in expectation. If Q3 passes, the ladder takes us to 60 on the print anyway, with real information in hand. Waiting costs us almost nothing. Getting the odds wrong at 30 instead of 25 costs more, and the odds are the one input none of us can measure by Monday.

Neutral Analyst¶

Neutral Analyst: Neutral Analyst: You two agree on more than this debate suggests. You both want to own JD, you both want the put spread on early, and you both accept the close above $27.72 on volume as the confirmation trigger. The real disputes are how much risk the starter carries, where we admit we're wrong, and how large we get before Q3. On most of those, one of you has the right diagnosis and the wrong fix.

Start with valuation. The operating leverage point is the strongest argument either of you has made: one point of opex ratio is worth about RMB 13 billion, against RMB 2.8 billion of operating profit last year. But the 6.7x multiple assumes a return to FY2024, JD's best margin year ever, and the aggressive side's own FY2019 precedent only got margins back to 1.56%. So I ran the conservative's half-recovery case, very roughly and ignoring minority interests. About RMB 20 billion of operating income, taxed normally, added to last year's earnings base gives roughly RMB 21 to 22 per ADS, a bit over $3. Cut the non-operating cushion by a third, since the cash that funds it is being spent, and you get nearer $2.70. That puts the stock at roughly eight to ten times earnings. So the conservative is right that normalization doesn't mean a return to the peak, and the aggressive is right that even a partial recovery leaves the stock cheap. That's why the direction stays Buy. What it doesn't support is the aggressive side's confidence that FY2025 was the trough. Nobody here knows that.

The conservative's best point is that we're working from nine-month-old numbers while the market has already seen two quarters we haven't. The August 13 gap on five times normal volume, right in JD's usual Q2 reporting window, followed by Arete's downgrade, has to be taken seriously. But it doesn't make us late. The stock is now 12% below the post-gap close of $29.30, so whatever that report said has been priced in and then some. I'd also change the conservative's test. "Stand aside if first-half opex ran above the FY2025 ratio" compares half a year against a full-year average. The ratio jumped from 12.5% to 15.8%, so if the spending built up during 2025, the later quarters were already running above 15.8%. A first half at 16% could then be an improvement. The test that matters is direction: are the opex ratio and new-business losses falling from Q1 to Q2 and year on year? If they're still rising, stand aside. If they've peaked, proceed.

The timing argument also goes away once you check the calendar. Today is Friday. We read the filings this weekend and place orders Monday, which is the session the death cross is projected to hit. The conservative's two delays become one weekend. The aggressive side gives up nothing either, because its own entry is limit orders at $26.66 to $26.77, below Thursday's close. If Monday brings automated selling, those limits fill at better prices. If the stock runs instead, the no-chase rule meant they weren't going to fill anyway.

On the stop, you're each pulling the wrong lever. The aggressive side's weekly close below $24.40 sits more than a dollar under the level it called the line in the sand. A weekly rule also means the real exit can be much worse than 8.8%, given the March intraday low of $23.66. The conservative side is right about that. But it then tightens the stop and cuts the size at the same time. Risk is size times distance. A 25% starter with a 4% stop risks about 1% of a full allocation, less than half the aggressive side's 2.2%. Cutting to 10 to 15% on top of that brings the risk to about half a percent, on a position whose main value is keeping us positioned for a rerating after Q3. At that size it isn't worth the attention.

You're also both reusing the 50 to 55% odds as if they don't depend on where the stop sits. The conservative's 3-to-1 reward-to-risk with a stop at $25.71 looks attractive, but that stop is only two ATRs away. This week brings a death cross, CPI, and possibly an EU headline, so the chance of being stopped out on noise is much higher than the thesis odds imply. A tighter stop gives a better payoff and a lower hit rate, and you can't claim both. The wide stop has the opposite problem: risking 8.8% to make 8.4% to the low end of fair value means 50 to 55% barely clears breakeven.

Here's my fix. Make the starter 20%, with a hard exit on a daily close below $25.71, and allow one controlled re-entry. If we're stopped out and the stock closes back above $25.71 within three sessions, without having closed below the June close of $25.19, we rebuild the starter once, with its stop on a daily close below $25.19. JD has a habit of breaking its lows intraday and then recovering: $23.66 intraday against a $24.53 close in March, and $24.55 against $25.19 in June. One re-entry respects the invalidation level without handing the trade to a shakeout. If both stops get hit, the loss is roughly 1.3 to 1.5% of a full allocation, still less than the aggressive plan loses on a single stop.

That rule replaces the resting limit at $24.60 to $25.20, which should go. The conservative side is simply right here. You can't say the bears carry the burden of proof at $25.71 and then double up after they've met it.

On adding before Q3, I'm between you. The confirmation add stays as written. But the cap should depend on the hedge, not on a number picked in advance. If the put spread is on and covers the whole position, go to 40%. If it isn't on, or it was too expensive to buy, stop at 25%. What makes holding a large position into a bad report dangerous is unhedged exposure through a binary event, and the hedge fixes that better than a smaller number does. Once the add fires, move the stop on the whole position to a daily close below $26.42, the October 7 low, which by then will be the higher low. One caveat: if the breakout comes on a Ceconomy approval headline, require a second close above $27.72 before adding. A news spike tells us nothing about subsidies, and the deal itself is RMB 17 billion of capital-allocation risk, not a reason to add.

On the hedge, the VIX at 15 says nothing about JD's own implied volatility, and the conservative is right that we're paying for an earnings event. Set the maximum premium before seeing the quote. Choose an expiry at least a week after the confirmed Q3 date. If the $26/$22 spread costs more than roughly 80 cents to a dollar, that's 3 to 4% of the stock price and about a third of the move to $30. In that case, either lower the strikes or shrink the stock position. For whatever is unhedged, size for a 20% gap. August's gap was 7.3%, but China regulatory headlines have caused worse, and with the Alibaba probe live, that isn't paranoia. I'd skip the call spread. We'd be paying for event volatility twice without knowing the price. Revisit after Q3, when that premium comes out.

On macro, the conservative side has the analysis right. The pressure is in long-dated bonds, the 2-year is flat since the hike, and soft core PCE is a Fed argument, which isn't where the problem is. The "advances while market declines" headlines are undated Zacks boilerplate, and the same feed has a "fell more than broader market" headline. The yuan holding at 6.70 removes a headwind; it isn't a tailwind. But look at where the conservative's tripwires sit. The 10-year is at 5.28%, twelve basis points from 5.4%, after moving 53 basis points in five weeks. Brent is around $103, two dollars from $105, and WTI went from $84 to $107 and back to $96 in two months. Those tripwires will fire on ordinary noise. Use them to freeze adds, and let the price stop and the hedge handle any selling.

Since we don't know the caller's portfolio, there's one point neither of you raised. JD trades as China beta. It dipped on the Alibaba probe, and retail traders lump it in with BABA and KWEB. Any existing China internet exposure should count against the cap. If the main fear is a basket selloff driven by yields, a small short in KWEB or Alibaba against the JD long would separate the subsidy thesis from that beta. It's optional, and it carries Alibaba's own risks, but it targets the problem better than shrinking JD toward nothing.

On the technicals, one correction. The conservative says a weekly TD 9 implies a one-to-four bar bounce and we've already had four up days. Those are weekly bars, not days. This bounce is less than a week old, and the 9 isn't complete until today's close, so if it holds, the window runs into November. The aggressive side shouldn't lean on it either. If today closes at or above $27.06 the 9 fails, and it was never a strong signal. The more reliable reading comes from the rising lows and the 30% compression in ATR: a narrowing range that is likely to break soon, in an unknown direction. That setup calls for a modest position with clear invalidation and a hedge. I'd give sentiment zero weight. Thirty messages over 27 hours, with one account behind three of the bullish tags, is noise.

After Q3, I'd use the conservative's step-up rather than jumping straight to 100%, with one change. All three tests as written are year on year, and comparing against 2025 means comparing against the subsidy year itself, which is a low bar. Require sequential improvement as well. Add a fourth test that answers the conservative's best fundamental point: revenue growth has to hold up as spending falls. If growth collapses along with the subsidies, the growth was bought. If all four pass, go to 60%. Go further only after a weekly close above the $28.50 to $28.70 moving-average cluster, and go to full size when the weekly SuperTrend at $31.63 flips. That's when the aggressive side's range highs at $33.47 to $33.77 become the target. If Q3 fails, we exit.

So my recommendation is still Buy, on these terms:

Read the Q1 and Q2 filings this weekend and judge the trend in spending, not its level.
Place a 20% starter as Monday limits at $26.66 to $26.77, with a daily-close stop at $25.71 and one re-entry.
Delete the averaging-down order.
Go to 40% before Q3 only through the confirmation trigger and only if fully hedged; otherwise stay at 25%.
Buy the put spread early, with a premium ceiling set in advance.
Use the macro levels only to freeze adds.
Count existing China exposure against the cap.
Skip the call spread.
Scale up after Q3 in steps, against tests that are actually hard to pass.

That keeps us positioned if the subsidy war ends, and keeps the cost small and known if it doesn't. Neutral Analyst: We're down to four live disagreements: how big the starter is, how big we get before Q3, how strict the filing test is, and how fast we scale after the print. On most of them, I think you've each been arguing about the wrong part of the trade. Fixing that points to a structure neither of you has proposed.

Start with the breakeven fight, because it's driving the size dispute. Conservative, your random-walk point is correct. In a stock with no edge, the chance of reaching $29 before a close below $25.71 is about 32%, and that is also the breakeven. I checked your stop estimate too, and it holds. With ATR at 0.52 and roughly 24 sessions to a mid-November print, a closing stop two ATRs away gets touched something like 45 to 55% of the time even with no trend. So the aggressive side's 32% breakeven proves nothing, because in a coin-flip stock the hit rate equals breakeven automatically.

But your premium adjustment is wrong in the other direction. The put spread isn't a sunk dollar; its value moves opposite to the stock. If the spread really costs about $1.00, that implies implied volatility in the mid-40s, which we still haven't confirmed. At that level:

If we're stopped at $25.71 in a week or two, the $26 put is in the money with earnings still ahead. The spread is worth roughly $1.30, more than we paid.

If we reach $29 first, the spread is still worth around 40 cents.

Net those out and the hedge shrinks the win and the loss in about the same proportion. Breakeven stays near 31 to 32%, not the mid-40s to low 60s.

So the five weeks before Q3 are close to a fair bet. Holding the starter through them costs trading friction and some hedge decay, not edge. It also means the starter has roughly even odds of being shaken out before the print. "The starter is how we own the gap" only works about half the time, and the re-entry rule matters more than either of you has given it credit for.

The edge is in the Q3 print, so look there. Take a rough good case around $31 and a bad case around $23, after the $1.00 premium:

The starter at $26.75 with the $26/$22 spread makes about 12% in the good case and loses about 6.5% in the bad case. At our 50 to 55% odds, that's clearly positive.

The confirmation tranche at $27.72 or higher, with the same spread, makes about 8% and loses about 10%. That's roughly break-even. It costs a dollar more, and the $26 strike doesn't start paying until that tranche is already down $1.72.

In the most likely bad outcome, a 10 to 15% miss rather than a 20% gap, the add is close to unhedged. So size should go where the entry is cheap and the hedge works best, which is the starter. The add should be small and carry its own spread struck near its own entry.

That's why I'd stop arguing 20 versus 25 on taste and let the filings decide. On the stop, the difference is two-tenths of a point of a full allocation. What should move size is evidence about the subsidy war, because that's what Q3 tests.

On the test itself, conservative, you're right that year-on-year has to stay in, but you're testing the wrong quarter. If the spending built up during 2025, as the full-year numbers suggest, Q1 2026 against Q1 2025 compares against a base from before the war really started. It would fail almost automatically even if spending has peaked. Q2 against Q2 is the clean comparison: same season, the 618 festival in both, and both inside the spending period. That answers your seasonality objection better than dropping the year-on-year test does.

So grade the filings:

If Q2's opex ratio and new-business losses are both below Q2 2025, and new-business losses fell from Q1 to Q2, the starter is 25%.

If only part of that holds, the starter is 15% with no add before Q3.

If none of it holds, we stand aside.

On guidance, JD doesn't guide formally, and every management team says it will keep investing. I'd only veto on an explicit statement that spending will rise, not on boilerplate.

Aggressive, your gap comparison against an unhedged 25% was a strawman, and the conservative was right to call it out. A hedge doesn't make size free. It moves the risk to prices above $26, prices below $22, and the premium. Here's the like-for-like comparison, using a 20% gap for the downside and the range high for the upside, both as a share of a full allocation:

Plan	Loss in a 20% gap	Gain at range high
25% starter + 10% add (mine)	about 3.4%	about 7%
50% (aggressive)	5.2%	9.6%
30% (conservative)	about 3.0%	about 6.0%

Per unit of downside, the version that puts more size in at the cheaper entry is marginally the best of the three. It gets there by buying on information rather than on a breakout.

Conservative, your timing evidence holds up. The March low, the May high and the August gap all fall in JD's usual reporting windows, so the claim that the market paid $33 knowing how bad FY2025 was doesn't survive. I also withdraw "priced in and then some." A gap followed by another 12% drop and a new OBV low on October 2 is not a finished repricing.

But notice what that same evidence says. This stock rallied 38% between the March and May prints and gapped 7% on the August one. Q3 is a large event that can go either way. That argues for hedged, moderate exposure into it, which is what we're building. It doesn't settle the direction for either of you.

On valuation, the two precedents bracket the outcome. The FY2022 cut implies about RMB 15 billion of operating income; the FY2019 cut implies about 25 billion. Even the low end leaves JD around nine to eleven times recovery earnings by my rough method, so it's cheap. But our $29 to $31 fair value is essentially Arete's twelve-month Neutral target. Our edge isn't a mispriced normal value. It's that operating leverage makes a Q3 surprise lopsided, with more room up than down. That's why the structure matters more than the stock pick.

On cash, I'd split the difference. The conservative is right that it isn't a shareholder cushion: there are RMB 306 billion of current liabilities, and outside investors own about RMB 69 billion of equity in subsidiaries like JD Logistics and JD Health. But it is a solvency cushion. It removes the risk that JD gets forced into a bad decision, and it adds no value beyond that. The duration argument goes to the conservative; the price action says JD trades as China beta.

I raised the KWEB short, and I'll drop it. Meituan and Alibaba sit in that basket and would benefit from our own catalyst, and we have no beta to size the hedge. If you can estimate JD's beta to KWEB from price history, a hedge sized to that number is fine. Otherwise, count existing China internet holdings against the cap and stop there.

I'll take both of the conservative's re-entry filters. One practical addition: if we're stopped out, don't sell the put spread at the stop. It's likely worth more than we paid, and it becomes the hedge for the re-entry. Sell it only if there's no re-entry within the three sessions.

The joint trigger, a 10-year yield above 5.4% and a VIX above 20 in the same week, is a sensible refinement, and either one alone still just freezes adds. With the spread on, the "unhedged portion" is mostly losses below $22. In practice, the rule cuts any tranche we couldn't hedge under the price ceiling.

I'll also accept 25% as the gap stress test for anything held through the print. For most books it won't bind. At 35% of a full allocation with the hedge on, a 25% gap costs about 5% of a full allocation. The 0.5%-of-equity rule only bites if a full JD position, counting other China internet holdings, is around a tenth of your equity or more.

After Q3, the conservative is right that "full size on a weekly close above $28.70" collapses into the print week if the stock gaps to $30. The aggressive is right that waiting for $31.63 means buying the last tranche near the range high. But both of you treat that level as fixed. A SuperTrend in a downtrend only moves lower, so by late November the weekly line will sit below $31.63.

So here's my adjustment to the trader's Buy:

First, grade the Q1 and Q2 filings this weekend as above: 25% starter, 15% starter, or stand aside.

Second, place the starter Monday with limits at $26.66 to $26.77. Buy the $26/$22 spread the same day, with expiry at least a week past a confirmed Q3 date and a $1.00 price ceiling. If it costs more, lower the strikes or cut the starter.

Third, exit on a daily close below $25.71. Keep the spread through the three-session window and re-enter once under the filtered rule. The averaging-down order stays deleted.

Fourth, add at most 10% of a full allocation before Q3, and only from a 25% starter. The trigger is the confirmation close, with a second close required if the move comes on a Ceconomy headline. The add carries its own spread struck about a dollar below the add price, under the same ceiling as a share of price. If that spread isn't available, there's no add. That caps us at 35%, and after the add the stop on the whole position trails to a daily close below $26.42.

Fifth, stress-test for a 25% gap against 0.5% of equity, as described above.

Sixth, a single macro tripwire freezes adds; the joint yield-and-VIX trigger cuts anything unhedged.

Seventh, no call spread, and no KWEB short without a measured beta.

Eighth, after Q3, if all four tests pass both sequentially and year-on-year, go to 60% on the print. Go to 80% on two consecutive weekly closes above $28.70, which is what stops the steps collapsing into one week. Go to full size when the weekly SuperTrend flips, wherever it sits by then, or when Q4 confirms. If the results are mixed, drop back to starter size with the daily stop. If they fail, exit.

That keeps the conservative's discipline on how much we hold into a print that can go either way. It gives the aggressive side its larger starter when the filings earn it. And it puts our size where the edge actually is: at the cheaper entry, hedged, waiting for Q3. Neutral Analyst: Neutral Analyst: This debate has done its job. The averaging-down order is gone, the weekly stop is gone, the confirmation add is gone, the KWEB short is gone, and nobody is buying calls. Five things are still open. How big the starter is. Whether there's any entry if Monday's limits don't fill. What to do if the hedge is expensive. How strict the filing test is. How fast we climb after the print. On most of these, each of you has the mechanism right and the conclusion wrong. On two of them, the trader can stop arguing and just measure.

Start with size. Conservative, you're right that upside per unit of downside doesn't change with size. A hedged 25 and a hedged 35 at the same price with the same spread have the same ratio. Aggressive, the better ratio came from deleting the add, not from moving its budget into the starter. In the path where the stock never breaks out and the print disappoints, 35 loses 40 percent more than 25. Calling that a tenth of a point was wrong.

But conservative, your own breakeven table settles size in a way neither of you used. Every number in it depends on the premium. Take the $30 planning case you insisted on, which I accept.

At a dollar, the hedged starter loses a flat $1.75 between $22 and $26, makes $2.25 at $30, and breaks even at about 44 percent. At 85 cents, it breaks even at 40. At 75 cents, about 37 and a half. At $1.25 it's a coin flip, as you said.

Against 50 to 55 percent odds, the margin of edge runs from ten to seventeen points at the cheap end down to nothing at $1.25. Size should follow that margin. So I'd stop arguing 25 versus 35 and let Monday's quote decide:

Full filing pass with the spread at 85 cents or less: 30 percent.
Full pass with the spread between 85 cents and a dollar: 25.
Above a dollar: see the hedge section below.

That's not splitting the difference. The aggressive gets more size only when the measured inputs earn it, and the conservative's 25 is exactly what the assumed dollar earns.

I'd also flag that your two-outcome model is incomplete in both directions. It leaves out the middle case, where the print is fine, the stock sits near $27, and we bleed most of the premium. That's probably the single likeliest outcome, and it favors the conservative. It also treats the print-day close as the exit, when a good print puts the starter into the ladder and holds it toward the range highs. That favors the aggressive. Those two omissions roughly cancel, which is why $30 is the right planning case. Not $31, which flatters the trade, and not $29, which assumes we sell the morning after good news.

Aggressive, one more reason 35 is worth less than it looks. I estimated the $25.71 closing stop gets touched 45 to 55 percent of the time over the next five weeks, even with no trend. So the starter owns the gap only about half the time, re-entry aside. The extra ten points pay their window friction every time but reach the print only half the time. Conservative, the same fact cuts your way less than you think. Under every plan on the table, the worst realistic print outcome is two to four percent of a full allocation. The real catastrophe control is the portfolio-level gap test and counting China exposure, not five points of starter.

On the unfilled-limits case, I'll concede first. Conservative, your math kills my 10 percent add too. Struck a dollar below $27.72, it needs roughly 48 percent odds at $31 and over 60 at $30. Aggressive, your 20 percent fallback is the same tranche at twice the size, so it goes as well.

But a one-day order is too rigid. Let the limits keep working each day at the 10-day EMA or Bollinger middle, with a hard cap of $27.00, until a week before the confirmed print. That keeps any entry within about a dollar of the $26 strike, which is the condition you both now say the edge depends on. It catches the pullback the death cross may well deliver. And it never buys a breakout. If the stock simply leaves, we buy after the print with information.

On an expensive hedge, conservative, you're right that lowering strikes is never the fix. I'm withdrawing my earlier "lower the strikes or cut the starter." The numbers show why. Moving down to a $25/$21 spread adds a dollar of unprotected room between entry and the long strike. To match the $26/$22 at a dollar, it would have to cost under about 45 cents. At the implied vol a dollar spread implies, it's closer to 80.

If the quote comes in over a dollar, there's one thing to try before cutting size. Sell a call around $32 with the same expiry, covered by the stock. At those vols it might bring in 20 to 30 cents, so we're selling the same inflated event premium we're buying. It only gives up a one-week gap above $32, which is beyond our own fair value. If that still doesn't get the net cost under a dollar, halve the starter. Use the latest-plausible expiry if the date isn't confirmed, as the conservative said. And when the stock exits, every option leg exits with it.

On the filing test, conservative, your revenue condition as written would fail the outcome we're hoping for. Ending a subsidy war should cost some subsidized growth, and that's the price of the thesis, not a refutation of it. If growth slows from 13 percent to high single digits while operating profit dollars rise, we've won. So make the fourth test that Q2 operating income is above Q2 2025 and revenue still grew. If revenue actually shrank, that's bought growth and a fail.

On commentary, you two are closer than you think. A concrete statement that Q3 losses will widen is a veto. Boilerplate about continued investment isn't.

Your point that the market sold this release 20 percent is the best reason not to go to 35. If we grade it a full pass and can't find what the market was selling, I'd drop a tier.

Your FY2014 precedent is fair, but it argues for patience after the print, not a smaller starter. FY2014's opex was building a logistics network. FY2025's is subsidies, which can be turned off faster but not unilaterally, since Meituan and Alibaba get a vote. Either way, one quarter won't show the full unwind. A single point off the opex ratio is still worth about RMB 13 billion against 2.8 billion of operating profit, though, so the stock doesn't need the full unwind to rerate.

That's why I'm holding my post-Q3 ladder, and the conservative's adoption of it is right. Aggressive, presales can veto a step, but with no data feed and headlines you yourself called two-sided, they can't upgrade one. Making two weekly closes above $28.70 the trigger for full size rebuilds the one-quarter bet I was trying to prevent. So it's 60 on the print, 80 on two weekly closes above $28.70, and full size on a weekly SuperTrend flip, wherever the line has fallen to, or on Q4 confirmation.

So here's my final position. It's still a Buy.

Grade the Q1 and Q2 filings this weekend. A full pass needs four things:

Q2's opex ratio below Q2 2025.
New-business losses below Q2 2025.
New-business losses down from Q1 to Q2.
Operating income up year on year with revenue still growing.

A concrete signal of wider Q3 losses vetoes the trade.

Confirm the Q3 date and price the $26/$22 spread before any stock order. Size the starter off that quote: 30 percent at 85 cents or less, 25 up to a dollar, and above that a covered $32 call or half size. A partial pass gets 10. Never lower the strikes.

Work the limits at the 10-day EMA, capped at $27, with no breakout entry and no add before Q3.

Exit on a daily close below $25.71, with one filtered re-entry. Hold the spread through the three-session window, and close every leg together if the stop fires around the print.

Stress-test a 25 percent gap against half a percent of equity, counting existing China internet holdings. A single macro tripwire freezes adds. The joint yield-and-VIX trigger cuts anything unhedged.

After the print, follow the 60/80/full ladder. Mixed results mean hold the starter. Failed tests mean exit.

That keeps every protection the conservative fought for. It gives the aggressive his cheap, hedged entry, sized up when the market actually prices the hedge cheaply. And it replaces the last argument about taste with a number we'll have Monday morning. Neutral Analyst: Neutral Analyst: We've converged enough that the remaining fight is about which inputs are allowed to change size, and in which direction. The conservative's last round landed two real hits on the aggressive plan and one on mine. It also counted the same caution twice and left a hole at the expensive end. Let me take those in order.

The strongest point on the table is the conservative's observation that the all-in formula has no stop in it. That settles how fills should be treated. Under a working limit that follows the 10-day EMA down, the cheapest fills arrive on the weakest days, closest to $25.71. A fill at $26.20 sits less than one ATR above the stop and has something like a four-in-five chance of being closed out before the print, yet the aggressive table would give it the top tier. So size gets set once, from Monday's quote against a $26.75 reference, and a cheap fill earns nothing extra.

I'll also take the conservative's other order rules: - a $26.25 floor and a $27.00 cap on the working limit; - cancelling unfilled orders on any single tripwire, because an unfilled starter really is an add; - buying the spread with each fill rather than Monday morning.

Practically, enter the stock and the spread together as one combination order, so we never hold one without the other. Puts get richer on down days. If the spread has moved above its ceiling when the stock reaches our level, that fill simply doesn't happen.

Conservative, you're also right that a cheap spread isn't free edge. A low premium mostly means low implied volatility, so the market expects a smaller move both ways. Sizing up on that adds a volatility bet on top of the subsidy bet. But take the argument all the way and it proves too much: if the market's distribution is the truth, the stock is fairly priced too and there's no trade at all. The useful version is a check we can run Monday. Take the move the options imply across the print, from the at-the-money straddle, and compare it with what JD has actually done on recent reports. August alone was a 7.3 percent gap. If the market is pricing a smaller move than JD has been delivering, the cheap spread is genuinely cheap. If it's pricing about what JD usually does, the cheapness is just the market saying the move will be small, and it earns nothing.

Then there's your claim that both tier tables only go up and that our 50 to 55 percent never gets tested. Mine went both ways, from 30 down to half size, but the point lands on the top tier, so I'll answer it. The odds do get tested, this weekend. That's what the filing gate is. A Q2 that cuts the opex ratio and new-business losses, year on year and sequentially, is direct evidence on exactly what that 50 to 55 percent was guessing at.

You've also tightened that test, requiring the opex ratio to fall at least half a point. Then you cut what a full pass earns at a dollar of premium from 25 to 20. That's the mistake I flagged two rounds ago, when you tightened the stop and cut size together. You can raise the evidence bar, or you can cut what passing it earns, but doing both counts the same caution twice. A full pass at your stricter bar, with the spread at a dollar or less, earns 25.

Your scenario split makes the same point from the other side. You put the good case and the bad case at 35 apiece. That's essentially the bottom of our range with nothing to spare, plus some middle-case bleed, so of course it comes out near zero. As an illustration of what happens if our odds are wrong, it's useful, and it's exactly why "no filings, no trade" is right. But if Q2 passes, the split should tilt. Even a modest tilt to 40 good, 30 middle and 30 bad, at a dollar of premium, comes to about 19 cents a share, roughly 0.7 percent of the position.

I'll be honest about what that means. Even after a clean pass, the starter's edge is real but small. That's the best argument in this room for a moderate size, and it cuts against 35 as much as against 12.5.

Aggressive, that's where your top tier goes too far. You're right that the window costs the 35^th share exactly what it costs the 25^th, so "variance without edge" can't by itself justify going smaller. There's also a point in your favor that neither of you raised. With a 45 to 55 percent chance the stop gets touched before the print, a 25 starter reaches the print as something like 11 to 14 on average unless the re-entry rule rebuilds it. Caution has a cost.

But the edge is under a percent of the position, on a probability nobody has measured. The conservative's fractional-sizing point is the right discipline for that. So the ceiling is 30, not 35, and 30 has to be earned twice: - the filings must clear the bar by a wide margin, call it a full point off the opex ratio year on year; - the spread must be 85 cents or less and pass the implied-versus-realized check.

That way the top tier needs evidence on our odds and evidence that the hedge is cheap, which are the two things each of you said the other was missing.

Now the expensive end, where the conservative's table has a real hole. Conservative, you said yourself that at $1.25 the hedged starter is a straight coin flip against a $30 good case. Yet your table holds 12.5 percent at any price above a dollar, with no ceiling. At $1.50 that position needs about 56 percent odds, above our own range. The aggressive's cutoff is the more disciplined rule here. If the spread costs more than $1.25 net of any covered call, we hold no stock before the print and buy after Q3 with information, which is what you've been defending all along.

Between a dollar and $1.25, though, the conservative wins the collar argument. An expensive spread is the market saying a big move is likely, which puts more weight below $22, where we're unhedged again. Selling a $32 call lowers the premium but doesn't touch that tail, and it gives away the upside gap the starter exists to own. Size is what drives the loss below the short strike, so the fix is size. Cut to 12.5 percent, where you'd both have ended up anyway, with the covered call allowed on that smaller position. I'm withdrawing my earlier "covered call or half." It should be half first, then the call.

On reading the market's reaction to Q2, I'd stop arguing through proxies. The aggressive's breakdown is careful. The gap and the four sessions after it did 73 million of OBV damage, while the next six weeks lost 58 million on light volume, alongside a 53-basis-point bond selloff. The conservative counters that Arete actually read the report and then cut. Both of you are inferring what Q2 said from people who read it, and by Monday we'll have read it ourselves. The one rule worth keeping from that exchange is the one you both accepted: if Q2 grades a pass but we can't identify what the market was selling on August 13, we drop a tier.

The conservative also closed a real hole after the print, and I'd extend it. The failed-gap rule is right: after any ladder step, a close back below the pre-print close cuts us back to the starter. But the starter needs the same care once the spread expires. Otherwise a good print to $30 leaves an unhedged starter with a stop more than four dollars below. So on a passing print, when the hedge rolls off, the starter's stop trails to a daily close below $26.42, the October 7 low we all accepted earlier as the trail level. That way a winning print can't turn into a losing position. On a mixed print, the starter keeps its stop at $25.71.

On the portfolio gap test, conservative, I agree it should bind before any tier. It's the only rule here that knows the caller's book, and the China beta behind most of the move since late August will hit every China holding on the same day. With a dollar spread, a 25 percent gap costs about 3.5 percent of a full allocation at a 25 percent size. So the gap test overrides the tier for anyone whose full JD allocation is above roughly 14 percent of equity. It overrides for smaller allocations too, once you count that same gap hitting other China internet holdings.

One small note on timing: today's close decides whether the weekly TD 9 completes. Nothing in this plan depends on it, and that's how it should be.

So I land at Buy, with this sequence:

Gather the data this weekend. Get the Q1 and Q2 releases and the Golden Week data. No filings, no trade.
Grade the filings. A full pass needs all of these:
the Q2 opex ratio down at least half a point year on year;
new-business losses down year on year and from Q1;
operating income up with revenue still growing;
no concrete signal that Q3 losses will widen.
Price the hedge. Confirm the Q3 date, or use the latest plausible one, and price the $26/$22 spread with expiry at least a week past it.
Set size once from that quote, against a $26.75 reference:
25 percent on a full pass with the spread at a dollar or less;
30 percent only if the opex ratio fell a full point, the spread is 85 cents or less, and the options are pricing a smaller print move than JD has actually delivered;
12.5 percent with the spread between a dollar and $1.25, with a covered $32 call allowed at that size;
nothing until after the print above $1.25 net;
10 percent on a partial pass, and only at a dollar or less;
whatever the tier, the gap test against your actual China exposure overrides it.
Work the entry. Place limits at the 10-day EMA, between $26.25 and $27.00, until a week before the print. Buy the spread with each fill and cancel on any tripwire.
Manage the stop. Exit on a daily close below $25.71, with the one filtered re-entry and the spread held through the three sessions. Close every leg together.
Keep it clean before Q3. No adds, no KWEB short, no call spread.
After the print, follow the 60, 80, full ladder. Apply the failed-gap exit on every step, and trail the starter to $26.42 once the hedge expires.

That gives the conservative a rule set where the quote can cut us to zero and a cheap fill buys nothing extra. It gives the aggressive a larger starter when the evidence actually earns it. And it's honest that this is a small, positive edge that deserves a moderate, hedged position, neither a big one nor a token one. Neutral Analyst: Neutral Analyst: We're nearly done. The remaining disagreements are worth fractions of a percent, so I'll settle them on principle and then point out two holes that all three of us left in the plan, including me.

The 30 percent tier is the only real disagreement left, so I'll start there.

Conservative, your argument that a public filing can't earn more size is the strongest point you've made in this debate. But it proves too much, as your implied-volatility point did. If everything public is already priced, our 50 to 55 percent has no basis either, and you wouldn't hold 25. You do hold 25, so you believe the market is over-discounting a spending cycle JD can reverse. The real question is how we tell that the discount is wrong rather than informed.

You skipped the one piece of public information that speaks directly to expectations, which is the market's own reaction. You said a strong Q2 would raise the market's expectations for Q3. The tape says the reverse happened:

the stock gapped down 7.3 percent on five times normal volume;
it slid another 12 percent;
Arete cut its target from $36 to $30.

Whatever Q2 said, expectations went down after it. Suppose Q2 turns out to be strong and the cause of August 13 doesn't carry into Q3. It could have been a miss against an inflated consensus, a one-day China headline, or a change to the buyback. In that case the bar for the November print sits below what the business is actually doing, and that is exactly where a print edge comes from. If the cause was a forward signal of more spending, our existing veto already handles it.

Aggressive, the same point cuts against you. A full point off the opex ratio tells us spending peaked. It doesn't tell us the market hasn't noticed. The starter gets paid on the gap between the print and expectations, not on the business improving. The opex number alone can't earn the 30.

So the 30 survives, but what earns it is an explanation of August 13. Conservative, your three minimum conditions become its gates, alongside the two we already had. The 30 requires all five:

a full point off the opex ratio;
the spread at 85 cents or less at its executable price;
options pricing a smaller move than JD actually delivers on its prints;
August 13 explained by something that doesn't reach into Q3;
the gap test passed at 30, not 25.

On the implied-versus-realized check, you're right that one data point is useless, but it isn't a research project either. JD has reported for over a decade. Pulling print-day moves for the last eight to twelve reports from price history takes an afternoon. If the implied move isn't clearly below the median of those moves, the gate fails. If nobody runs the check, it also fails.

I'll be honest about the stakes so nobody spends Monday fighting over this. On the aggressive's optimistic split at 85 cents, the hedged starter is worth about 50 cents a share, under 2 percent of the position. Five extra points of a full allocation adds roughly a tenth of a percent in expectation. Because the stop takes the starter out before the print about half the time, the real figure is about half that. Conservative, you set that against two-thirds of a point lost in a 25 percent gap, which compares an average to a worst case. That isn't fair either. The truth is that the tier is nearly worthless in both directions. It should fire only when every input has been measured, which is when being wrong costs least, and with five gates it will rarely fire.

On "drop a tier," I'll take the conservative's concrete version. An unexplained August 13 on an otherwise full pass counts as a partial pass, which means 10 percent at a spread of a dollar or less. Since the 30 now requires the explanation, this rule only ever bites the 25, and 10 versus 12.5 isn't worth arguing.

Aggressive, you complained that a gate which can only veto can only shrink us. Evidence already has a way to add size: the ladder. Evidence before the print protects us, and evidence after the print adds to the position. That's the right division of labor.

On the three loopholes, the conservative is right on all of them.

Gross price, not net. I wrote "net of any covered call," and that let the call back in as a substitute for cutting size. Tiers are judged on the gross executable price, not the midpoint.
Size is the lower of two tiers. It's the lower of Monday's tier and the tier at the moment of the fill. Each combination order carries its tier's spread ceiling, and a fill can step down a tier but never up.
Order and expiry dates. Working orders stop a week before the earliest plausible print date, and the hedge expiry runs a week past the latest plausible date.

The practical consequence is that the working window shrinks to perhaps two to three weeks, minus the idle days. There's now a real chance the starter never fills, which exposes a hole I'll come to.

On tripwires, I accept the conservative's version:

a single tripwire pauses the orders;
they resume only after two closes back inside the level;
they cancel on two closes beyond it, or on the joint trigger;
they sit idle on CPI and FOMC days, which costs almost nothing.

Presales are the exception I'd change. I'd hold them to the same standard as the filing veto. Both of you called presale headlines two-sided, and we have no data feed, so a single headline should pause the orders like any other single tripwire. A concrete announcement from JD, Meituan or Alibaba of bigger Singles' Day subsidies should cancel them, just as a concrete statement of wider Q3 losses vetoes the trade.

On the trail, conservative, you're right that my framing was wrong. I said "a winning print can't become a losing position" without counting the premium. But your fix at $27.75, the all-in cost, inverts the exits.

Walk through it. Q3 passes, the stock gaps to $30, and the ladder takes us to 60 percent. The hedge expires a week later and the stock drifts to $27.60. Your rule sells the starter we bought at $26.75 and keeps the 35 points we bought at $30, because the failed-gap exit sits down at the pre-print close. We'd be selling the cheap shares and keeping the expensive ones. That's what happens when a stop is anchored to cost basis. Once the hedge expires, the premium is sunk. A stop's job is to say where the trade is wrong, not whether we've earned back our insurance bill.

The clean rule is that every step exits when the condition that triggered it fails:

the print step exits on a close below the pre-print close;
the 80 percent step, triggered by two weekly closes above $28.70, reverts on a weekly close back below that cluster;
full size reverts if the weekly SuperTrend flips back down;
the starter keeps its $25.71 stop while hedged, and after a passing print it joins the print step at the pre-print close once the hedge expires.

The exits then fire from the most expensive shares down to the cheapest, which is the right order. On a mixed print, the starter alone keeps its $25.71 stop.

On the post-crush call spread, I'd take the conservative's three conditions as written:

it replaces the stock for that step and never adds to it;
its premium is capped at what the stock step would lose on its failed-gap exit;
its expiry runs past the confirmation the next step waits for.

Aggressive, those conditions are the pre-authorization you asked for: rules now, quantities later. I'd add one more condition: implied volatility must be measurably lower than before the print. Otherwise we use stock.

Now the hole the shrinking window opens up. If the starter never fills, the ladder as written would buy 60 percent in a single order at the gap price, unhedged. That is a bigger, less informed bet than anything we've allowed before the print. With no starter, the print step should be capped at 35, with the two-weekly-close confirmation taking us to 80 as normal. The gap test applies there too.

So I land at Buy. Here's how that changes the trader's original plan:

Stop and adds. The weekly stop at $24.40 becomes a daily close below $25.71, with one filtered re-entry. The averaging-down order at $24.60 to $25.20 is deleted, and so is the breakout add.
Size before the print. Instead of a 50 percent cap, the starter is sized once from Monday's gross executable spread quote against a $26.75 reference:
25 percent on a full filing pass at a dollar or less;
30 only through all five gates;
12.5 between a dollar and $1.25, with a covered call allowed;
nothing above $1.25;
10 on a partial pass or an unexplained August 13.
Gap test. The gap test against the caller's actual China holdings overrides every tier.
Filings. No filings, no trade.
Entry. Combination orders work at the 10-day EMA between $26.25 and $27.00, under the pause, resume and cancel rules and the calendar limits above.
Before the print. No adds, no KWEB short, no calls.
After the print. The four tests are applied both sequentially and year on year:
on a pass, 60 percent on the print (35 if there's no starter), 80 on two weekly closes above $28.70, and full size on a weekly SuperTrend flip or Q4 confirmation;
every step exits when its own trigger fails;
mixed results mean we hold the starter, and failed tests mean we exit.

That's a small, real edge held at a moderate, hedged size, with every rule telling us in advance what we'll do. It doesn't depend on any of us being right about something we can't yet measure.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Overweight

Executive Summary: Overweight JD with a small, hedged position, entered only after the Q1/Q2 2026 filings are read and graded; if they cannot be obtained, do not trade. If the filings fully pass, build a starter of 25% of a standard allocation (10% on a partial pass) as combination orders that buy the stock and a $26/$22 put spread together, working at the 10-day EMA between $26.25 and $27.00, with the put spread expiring at least a week after the latest plausible Q3 date. Exit on a daily close below $25.71 (one filtered re-entry allowed), make no adds before Q3, and size so a 25% gap after the hedge costs no more than 0.5% of portfolio equity, counting other China internet holdings. After a passing Q3, scale to 60%, then 80%, then 100% on confirmation, targeting $30 over 2-4 months; exit if Q3 fails.

Investment Thesis: DIRECTION: The bull case on value is stronger, which is why this is not a Hold or Underweight. FY2025 revenue grew 13.0% to RMB 1,309bn and gross margin hit a record 16.04%. Operating income nonetheless collapsed from RMB 38.7bn to 2.8bn because opex rose from 12.5% to 15.8% of revenue, about RMB 43bn of discretionary spending above the FY2024 run-rate. Each point of opex ratio is worth about RMB 13bn, nearly five times FY2025 operating profit. JD has unwound similar spikes before: opex fell 1.5 points in the first year after FY2014 and 1.7 points in FY2019. The bear's own revised case moved to fairly priced at $26.4-28.8, so even the downside case does not call the stock expensive. Recovery operating income of RMB 15-25bn implies roughly RMB 21-24 of EPS per ADS, about $3.10-3.60 at 6.70 CNY/USD, so $30 is only 8.4-9.7x recovery earnings. Technical exhaustion supports entering now rather than waiting: closing lows are rising (24.53, 25.19, 25.78), MACD made a higher low (-0.66 vs -0.81) while price made a lower low, RSI held about 30 three times, and ATR has compressed 30%. WHY OVERWEIGHT, NOT BUY: The edge is thin and partly unverified, and the conservative analyst won most of the sizing debate. All fundamentals are FY2025; Q1/Q2 2026 data are missing. The Aug 13 gap (-7.3% on 32M shares, in JD's usual Q2 window) was followed by a further 12% slide, a new OBV low on Oct 2, and Arete's cut to Neutral with the target lowered from $36 to $30. FCF fell 79%, and capital returns exceeded FCF by RMB 15.5bn. All three SuperTrends point down, a death cross is due around Oct 12, and the 10-year sits at 5.28%. The random-walk point holds: before the print, reaching $29 before a close below $25.71 is about a 32% event, equal to breakeven. The pre-print window is therefore close to a fair bet, and the stop has a 45-55% chance of being touched on noise. The edge sits in the Q3 print. With a $26.75 entry and a $1.00 spread, the all-in cost is $1.75, so breakeven against a $30 good case is 1.75/4 = 44%, versus our estimated 50-55% odds that the spending war winds down. That edge is real but small, which supports a moderate, hedged starter rather than the trader's 50%. CHANGES FROM THE TRADER'S PLAN: (1) Delete the $24.60-25.20 averaging-down tranche, which bought below the $25.71 invalidation level. (2) Replace the weekly-close stop at $24.40 with a daily close below $25.71. That stop is about 2 ATR away and risks about 1% of a full allocation on a 25% starter. If stopped out, re-enter once if price closes back above $25.71 within 3 sessions without a close below $25.19, using a $25.19 daily stop. Skip the re-entry if the breakdown came on 8M+ shares, if it falls within a week of Q3, or if the hedge is off. Keep the spread through the re-entry window. (3) Delete the breakout add: at $27.72 with the same spread it is roughly breakeven. (4) Cap pre-print exposure at the starter. FILING GATE (this weekend): A full pass requires all four: Q2 opex ratio at least 0.5pt below Q2 2025; new-business losses down year on year and from Q1; operating income up year on year with revenue still growing; and no concrete signal of wider Q3 losses. An unexplained Aug 13 gap counts as a partial pass. SIZING, set once from the gross executable spread price against a $26.75 reference: 25% on a full pass with the spread at $1.00 or less; 12.5% at $1.00-1.25, with a covered $32 call allowed on top; nothing above $1.25; 10% on a partial pass. 30% is allowed only if all five hold: opex down a full point, spread at $0.85 or less, implied move below JD's median print-day move over the last 8-12 reports, Aug 13 explained by something that does not carry into Q3, and the gap test passed at 30%. Size is the lower of the Monday tier and the tier implied at fill. Never lower the strikes to fit a ceiling. The gap test overrides every tier. EXECUTION: Pause orders on a single tripwire (10-year above 5.4% or Brent above $105) and resume after two closes back inside. Cancel on two closes beyond a tripwire, on the joint trigger (10-year above 5.4% and VIX above 20 in the same week, which also cuts anything unhedged), or on a concrete announcement of larger Singles' Day subsidies. Keep orders idle on CPI and FOMC days, and stop working them a week before the earliest plausible print. No KWEB short and no call spread before the print. AFTER Q3: The four tests must pass both sequentially and year on year. On a pass, go to 60% (35% if the starter never filled), to 80% on two weekly closes above $28.70, and to full size on a weekly SuperTrend flip or Q4 confirmation. Each step exits when its own trigger fails: the print step on a close below the pre-print close, the 80% step on a weekly close back below $28.70, and full size on a SuperTrend reversal. After the hedge expires, the starter joins the print-step exit. Mixed results mean hold the starter only. Failed tests (JD Retail margin down, new-business losses not lower, or guidance to sustained or higher food-delivery spending) mean exit everything. A post-crush call spread may replace stock for a step, never add to it, with its premium capped at that step's failed-gap loss. WHAT CHANGES THE CALL: Rising Q2 spending or a concrete Q3 loss warning means stand aside. A daily close below $25.71 without re-entry means flat. A clean Q3 pass upgrades the position toward Buy-sized exposure through the ladder. PRICE TARGET $30: This is the midpoint of the Research Manager's $29-31 fair value at an 11% cost of equity, and it coincides with Arete's $30 target and 8.4-9.7x recovery EPS of $3.10-3.60. It implies 30/26.91 - 1 = +11.5%. Technical waypoints are $28.45-28.72 (MA cluster and 38.2% retracement) and $29.3-29.4 (late-August closes). The range highs of $33.47-33.77 apply only after Q3 confirms. Cross-check: probability-weighting the two scenarios ($33.6 wind-down, $21.5 no wind-down) at 52.5% gives about $27.9 today. That shows how thin the unconditional edge is and why size stays small until Q3.

Current Price: 26.91

Price Target: 30.0

Confidence: Low

Time Horizon: 2-4 months

Trading Analysis Report: JD¶

I. Analyst Team Reports¶

Market Analyst¶

JD (JD.com, Inc.): Technical Report¶

Bottom line¶

Indicators chosen and why¶

1. Price structure and context¶

2. Moving averages¶

3. SuperTrend (trend-following stop on three timeframes)¶

4. Momentum: MACD and RSI¶

5. Volatility: ATR and Bollinger Bands¶

6. Volume: OBV (On-Balance Volume)¶

7. Exhaustion: TD-9 (TD Sequential)¶

8. Key levels¶

9. Scenarios and possible trades¶

10. Risks and caveats¶

Summary table¶

Sentiment Analyst¶

JD Sentiment Report (2026-10-01 to 2026-10-08)¶

1. Source-by-source breakdown¶

2. Cross-source divergences and alignments¶

3. Dominant narrative themes¶

4. Catalysts and risks¶

5. Summary of key sentiment signals¶

News Analyst¶

JD.com (JD) news and macro report, as of 2026-10-08¶

Bottom line¶

1. JD company news¶

a) Ceconomy deal near EU approval¶

b) Analysts, positioning and attention¶

c) Recent relative strength¶

d) Sector and regulatory news¶

2. Macro backdrop (FRED data)¶

a) Both the Fed and the ECB raised rates¶

b) Inflation is the reason¶

c) The selloff has moved to long-dated bonds¶

d) The dollar is up but the yuan is holding¶

e) Oil and geopolitics¶

f) Market sentiment¶

3. How the macro picture affects JD¶

4. Upcoming catalysts¶

5. Takeaways for the trading decision¶

Summary table¶

Fundamentals Analyst¶

JD.com, Inc. (JD): Fundamental Research Report¶

0. What data was available¶

1. Summary¶

2. Long-term revenue and profit history¶

3. Cash flow¶

4. Balance sheet¶

5. Implications for traders¶

6. Key metrics summary¶

II. Research Team Decision¶

Bull Researcher¶

1. The core business is the strongest it has been¶

2. Small cost cuts move profit a lot¶

3. What you're paying (my arithmetic; the vendor withheld valuation data)¶

4. Upcoming catalysts¶

5. The chart shows sellers running out of steam¶

6. Answering the bear's likely objections in advance¶

7. How I'd trade it¶

Bottom line¶

1. What the bear got right¶

2. "About 14% is priced in": right on the math, wrong on the conclusion¶

3. The bear's downside case needs every assumption to go wrong at once¶

4. The Q2 question, using the bear's own method¶

5. The balance-sheet critique is fair, but much smaller than claimed¶

6. Macro, briefly¶

7. The chart: concessions and one correction¶

8. The revised trade¶

Bottom line¶

1. What I concede¶

2. "Name the year": the price doesn't need one¶

3. The right base rate: what JD did after each prior trough¶

4. Scenarios where spending and revenue move together¶

5. Why full credit for cash is the right answer¶

6. Smaller points¶

7. The trade, with a Q3 test the bear can hold me to¶

Bottom line¶

1. Your question, answered¶

`JD` (JD.com, Inc.): Technical Report¶

JD.com (`JD`) news and macro report, as of 2026-10-08¶

JD.com, Inc. (`JD`): Fundamental Research Report¶

2. Your first question: my destination isn't `JD`'s best year¶

3. The gap the price needs, against `JD`'s record¶